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Abstract 
This work aims at studing the role of tachykinin NK-3 receptor (R) and 
kinin B1R in central autonomic regulation of blood pressure (BP) and to 
determine whether the B1R is overexpressed and functional in rat models 
of hypertension by measuring the effect of a B1R agonist on behavioural 
activity. Assumptions: (1) NK-3R located in the ventral tegmental area 
(VTA) modulates the mesolimbic dopaminergic system and has a tonic 
activity in hypertension; (2) B1R is overexpressed in the brain of 
hypertensive rats and has a tonic activity, which contributes to 
hypertension via a dopamine mechanism; (3) the inhibition of NK-3R and 
B1R with selective antagonists, reduces central dopaminergic hyperactivity 
and reverses hypertension. A model of genetic hypertension and a model 
of experimental hypertension were used: spontaneously hypertensive rats 
(SHR, 16 weeks) and Wistar-Kyoto (WKY) rats infused for 14 days with 
angiotensin II (Ang II) (200 ng / kg / min, subcutaneous (s.c.) with Alzet 
mini pump). The age-matched untreated WKY rats served as common 
controls. In the first study (article # 1), the cardiovascular response in SHR 
was evaluated following intracebroventricular (i.c.v.) and/or intra-VTA 
injection  of an agonist (senktide) and antagonists (SB222200 and R-820) of 
NK-3R. These responses have also been characterized using selective 
dopamine antagonists DA-D1R (SCH23390), DA-D2R (raclopride) or non-
selective dopamine DA-D2R (haloperidol). Also the VTA has been 
destroyed by ibotenic acid. The pressor response induced by senktide and 
the anti-hypertensive response induced by SB222200 or R-820 were more 
pronounced by intra-VTA. These responses were prevented by pre-
treatment with raclopride and haloperidol. The lesion of the VTA has 
prevented the pressor response relayed by senktide (i.c.v.) and the anti-
hypertensive effect of R-820 (i.c.v.). In addition, SB222200 (intra-VTA) 
prevented the pressor response of senktide (i.c.v.) and conversely, senktide 
(i.c.v.) prevented the antihypertensive effect of SB222200 (intra-VTA). The 
second study (article # 2) showed that the B1R antagonist (SSR240612) 
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administered by gavage or i.c.v. reverses hypertension in both models. This 
anti-hypertensive effect was prevented by raclopride and haloperidol. In 
contrast, the two B1R antagonists (R-715 and R-954) injected s.c., which do 
not cross the blood-brain barrier reduced weakly blood pressure in 
hypertensive rats. In the third study (article # 3), the i.c.v. injection of a 
selective kinin B1R agonist Sar[DPhe8][des-Arg9]BK caused behavioural 
responses in SHR and Ang II-treated rats and had no effect in control WKY 
rats . The responses elicited by B1R agonist were blocked by an antagonist 
of NK-1 (RP67580), an antagonist of NMDA glutamate receptor (DL-AP5), 
an inhibitor of nitric oxide synthase (NOS) (L -NNA) as well as raclopride 
and SCH23390.The responses were modestly affected by the inhibitor of 
inducible NOS (iNOS). The B1R mRNA (measured by RT-PCR) was 
significantly increased in the hypothalamus, the VTA and the nucleus 
accumbens of hypertensive animals (SHR and treated with Ang II) 
compared with control rats. 
These neuropharmacological studies suggest that: (1) the NK-3R from the 
VTA is involved in the maintenance of hypertension in SHR by increasing 
DA transmission in the midbrain; (2) the B1R in SHR and Ang II-treated 
rats contributes to hypertension via a central mechanism involving DA-
D2R; (3) the central B1R increases locomotor activity and nocifensive 
behaviours via the release of substance P (NK-1), DA and nitric oxide in 
both rat models of hypertension. 
Thus, the brain tachykinin NK-3R and kinin B1R represent potential 
therapeutic targets for the treatment of hypertension. The modulation of 
the mesolimbic/mesocortical dopaminergic pathway by these receptors 
suggests their involvement in other physiological functions (pleasure, 
motor activity, coordination of the response to stress) and pathophysiology 
(anxiety, depression). 
  
Keywords: Tachykinin NK-3R, kinin B1R, dopamine, ventral tegmental 
area, hypertension, behavior. 
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Résumé 
Ce travail vise à étudier le rôle du récepteur NK-3 des tachykinines (NK-
3R) et du récepteur B1 des kinines (B1R) dans la régulation autonomique 
centrale de la pression artérielle et de déterminer si le B1R est surexprimé 
et fonctionnel chez le rat hypertendu en mesurant l’effet d’antagoniste 
B1R  sur l’activité comportementale. Hypothèses: (1) le NK-3R localisé 
dans l’aire tegmentale ventrale (VTA) module l’activité dopaminergique 
du système mésolimbique et possède une activité tonique dans 
l’hypertension; (2) le B1R est surexprimé dans le cerveau du rat 
hypertendu et possède une activité tonique qui contribue à l’hypertension 
via un mécanisme dopaminergique; (3) l’inhibition des NK-3R et B1R avec 
des antagonistes sélectifs réduit l’hyperactivité dopaminergique centrale 
et renverse l’hypertension. Un modèle d’hypertension génétique et un 
modèle d’hypertension expérimentale ont été utilisés: le rat spontanément 
hypertendu (SHR, 16 sem) et le rat Wistar Kyoto (WKY) infusé pendant 14 
jours avec l’angiotensine II (Ang II) (200 ng/kg/min, s.c. avec mini pompe 
Alzet). Le rat WKY non traité du même âge a servi de témoin commun. 
Dans la première étude (article # 1), la réponse cardiovasculaire des SHR a 
été évaluée  à la suite de l’injection i.c.v. et/ou intra-VTA d’un agoniste 
(senktide) et d’antagonistes (SB222200 et R-820) du NK-3R. Ces réponses 
ont aussi été caractérisées en utilisant des antagonistes sélectifs des 
récepteurs DA-D1R (SCH23390), DA-D2R (raclopride) ou non-sélectif DA-
D2R (halopéridol). Aussi le VTA a été détruit par l’acide iboténique. La 
réponse pressive induite par senktide et la réponse anti-hypertensive 
induite par SB222200 ou R-820 étaient plus marquées par la voie intra-
VTA. Ces réponses ont été prévenues par un pré-traitement avec le 
raclopride et l’halopéridol. La lésion du VTA a prévenu la réponse 
pressive relayée par le senktide (i.c.v.) ainsi que l’effet anti-hypertenseur 
du R-820 (i.c.v.). De plus, le SB222200 (intra-VTA) a prévenu la réponse 
pressive du senktide (i.c.v.) et inversement, le senktide (i.c.v.) a prévenu 
l’effet anti-hypertenseur du SB222200 (intra-VTA). La deuxième étude 
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(article # 2) a montré que l’antagoniste du B1R (SSR240612) administré par 
gavage ou i.c.v. renverse l’hypertension artérielle dans les deux modèles. 
Cet effet dépresseur a été prévenu par le raclopride ainsi que 
l’halopéridol. Par contre, le traitement avec deux antagonistes du B1R (R-
715 et R-954)  qui ne traversent pas la barrière hémo-encéphalique a réduit 
faiblement la pression artérielle chez les rats hypertendus. Dans la 
troisième étude (article # 3), l’injection i.c.v. d’un agoniste sélectif du B1R, 
le Sar[DPhe8][des-Arg9]BK a causé des réponses comportementales 
typiques chez le SHR et le rat traité à l’Ang II mais il n’a pas eu d’effet 
chez le rat témoin WKY. Les réponses induites par l’agoniste B1R ont été 
bloquées par un antagoniste du récepteur NK-1(RP67580), un antagoniste 
du récepteur NMDA du glutamate (DL-AP5), un inhibiteur des 
synthétases du monoxyde d’azote (NOS) (L-NNA) ainsi qu’avec le 
raclopride et le SCH23390. Les réponses ont été modestement influencées 
par l’inhibiteur de la NOS inductible (iNOS). L’ARNm du B1R (mesuré 
par RT-PCR) était significativement augmenté dans l’hypothalamus, le 
VTA et le noyau accumbens des animaux hypertendus (SHR et traités à 
l’Ang II) comparativement aux rats témoins.  
 
Ces études neuropharmacologiques suggèrent : (1) que le NK-3R du VTA 
est impliqué dans le maintien de l’hypertension chez le SHR en 
augmentant la transmission DA au niveau du  mésenséphale. (2) Le B1R 
chez le SHR et les rats traités à l’Ang II contribue  à l’hypertension artérielle 
via un mécanisme central impliquant le DA-D2R. (3) le B1R central 
augmente l’activité locomotrice et les comportements défensifs, via la 
relâche de substance P (NK-1), de DA et de NO dans un modèle 
d’hypertension génétique et expérimental chez le rat.  
 
Ainsi, les récepteurs cérébraux NK-3 des tachykinines et B1 des kinines  
représentent des cibles thérapeutiques potentielles pour le traitement de 
l’hypertension artérielle. La modulation de la voie dopaminergique 
mésolimbique/mésocorticale par ces récepteurs suggère une participation 
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dans d’autres fonctions physiologiques (plaisir, activité motrice, 
coordination de la réponse au stress) et en pathophysiologie (anxiété, 
dépression). 
 
Mots clés : Tachykinine NK-3R, kinine B1R, dopamine, aire tegmentale 
ventrale, hypertension, comportement. 
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1. General introduction 
1.0.1 The autonomic nervous system: A strategic role in blood pressure 
regulation 
The autonomic nervous system (ANS) is controlled by central autonomic 
nuclei of the diencephalon (hypothalamus nuclei), forebrain (amygdala), 
midbrain (periaqueductal gray region) and brainstem (nucleus of the 
solitary tract, ambiguous nucleus, and dorsal motor of the vagus, rostral 
and dorsal ventrolateral medulla). These regions of the central nervous 
system (CNS) control pre-ganglionic sympathetic and parasympathetic 
efferent viscerimotor fibers (Benarroch, 1993). This system is very complex 
and provides precise control of cardiovascular function in normal 
physiological situations (standing, intense exercise).  
In addition, the ANS provides a fast and sensitive regulation of arterial 
pressure due to the baroreflex. Through arterial baroreceptors and 
chemoreceptors, the cardiovascular centers situated in the brainstem and 
hypothalamus received constant information on the status of the peripheral 
circulation (de Champlain, 2001).  Several studies supported the major role 
of ANS in controlling cardiac function and peripheral resistance (de 
Champlain et al., 1998). Clinical and experimental studies demonstrated 
that sympathetic activity was increased in hypertensive patients and in 
several models of experimental hypertension  (Julius et al., 1988; de 
Champlain et al., 1998; Laflamme et al., 1998a, b; Grassi, 1998). Moreover, 
decreased parasympathetic tone was observed in several cases of clinical 
and experimental hypertension (Korner, 1989; Korner et al., 1989). 
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1.0.2 Hypertension  
According to 2008 statistics, provided by the Heart and Stroke Foundation 
of Canada, hypertension affects one in five Canadians. Hypertension is a 
risk factor that can triple the chance of developing cardiovascular diseases. 
It is the number one risk factor for stroke and a major risk factor for heart 
disease. However, since there are no symptoms, 42% of Canadians with 
high blood pressure (BP) do not even know that they have it. This is why 
hypertension is known as the silent killer.  
The five major classes of anti-hypertensive agents are: diuretics, beta-
blockers, calcium channel blockers, angiotensin converting enzyme (ACE) 
inhibitors,  and angiotensin AT1 receptor antagonists (Plante, 1999).  
The causes of hypertension are highly diverse and provide an immense 
challenge for fundamental research, because it involves the kidneys, 
vascular, cardiac, nervous and endocrine systems.  
1.0.3 The tachykinins and their receptors: regulation of central 
cardiovascular function in hypertension  
Tachykinins are one of the largest families of neuropeptides. They can be 
found in species from amphibians to mammals. The tachykinin family is 
characterized by a common C-terminal sequence, Phe-X-Gly-Leu-Met-NH2. 
Therefore, the tachykinin N-terminal determines the receptor selectivity, 
while the conserved C-terminal sequence is responsible for the receptor 
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activation (Lucas et al., 1992). This family is named tachykinins, which 
means “fast movement" on the contraction of smooth muscles.    
In mammals, the family members are substance P (SP), neurokinin A 
(NKA), neurokinin B (NKB), neuropeptide K (NPK) and neuropeptide  
(NP ). They are distributed in both the central and peripheral nervous 
systems. These have a wide range of biological effects that follow the 
activation of three types of trans-membrane receptors (R) called NK-1, NK-
2 and NK-3, which are G protein-coupled receptors (GPCRs). Due to their 
vast distribution in the CNS, they play a major role in many essential 
functions such as learning, memory and emotional processes. This also 
includes stereotyped behaviours, anxiety, stress and pain. Thus, the 
tachykinins are known to exert central control over many functions of the 
ANS (Severini et al., 2002).  
The potential role of tachykinins in central cardiovascular regulation has 
been suggested by several studies. Increases in blood pressure and heart 
rate (HR) accompanied by stereotyped behaviours were shown by 
tachykinin agonists injected into the i.c.v. and ventral tegmental area (VTA) 
(Picard et al., 1994; Takano et al., 1990; Cellier et al., 1997; Deschamps and 
Couture 2005). These cardiovascular effects are dependent on the activation 
of the sympathetic nervous system as well as the increased release of 
vasopressin from the neurohypophysis (Unger et al., 1981, Polidori et al., 
1989, Takano et al., 1990). However, the specific neuronal circuits involved 
in cardiovascular and behavioural effects of tachykinins are still largely 
unknown.  
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A strategic central dopaminergic (DA) site is the VTA. It is located at the 
midbrain and composed mainly of dopaminergic neurons forming the area 
A10. Considering its projections to the limbic system and cerebral cortex, 
the VTA is more known for its role in the regulation of behavioural activity 
in response to stress, psychologic diseases, drug addiction and drug 
withdrawal. However, compelling experimental results suggest its 
involvement in cardiovascular control. Some studies suggest that the DA 
system also participates in these events. Indeed, when the three tachykinin 
NK-1R, NK-2R and NK-3R agonists were injected into the VTA of 
normotensive rats, they affected the autonomic control of BP and HR by 
increasing midbrain DA transmission (Deschamps and Couture 2005). 
Substance P (SP) injected into the i.c.v. improved the baroreflex sensitivity, 
while the injection of antibodies against SP (into the i.c.v. or directly into 
the nucleus of the solitary tract  (NTS)) reduced the baroreflex (Chan et al., 
1990; Appenrodt et al., 1993). Moreover, when SP or a selective NK-
1R agonist was injected into the NTS, it induced hypotension and 
bradycardia. Electrical or chemical stimulation of the VTA with the 
injection of SP analogue DiMe-C7 produced an increase in BP and 
locomotor activity. The increases in locomotor activity induced by intra-
VTA DiMe-C7 were blocked by the DA-D1R and DA-D2R antagonists, 
SCH23390 and haloperidol, respectively (Kubos et al., 1987; Cornish et al., 
1994; Placenza et al., 2004). When the NK-3R agonist senktide was injected 
into the VTA, it caused several behaviours such as yawning and chewing 
known to be evoked by DA (Stoessl et al., 1991). Furthermore, the 
6 
 
  
activation of NK-3R by endogenous tachykinins in the substantia nigra 
(SN), an important DA center, stimulated the cardiac function. The NK-3R 
antagonist (SB222200) significantly reduced mean arterial pressure (MAP) 
for more than three hours when injected into the SN in spontaneously 
hypertensive rats (SHR) (Lessard et al., 2001, 2003, 2004). However, the 
function of NK-3R in the CNS during pathophysiological situations 
remains poorly understood. 
 
1.0.4 The kinins and their receptors: regulation of central cardiovascular 
function in hypertension  
Kinins are a small family of peptides (9 to 11 amino acids), including 
bradykinin (BK), kallidin (KD; Lys-BK) and T-kinin (Ile-Ser-BK) (Gabra et 
al., 2003). The most studied members of this family are BK and KD. Their 
active metabolites are produced by the enzymatic action of kininase I (des-
Arg9-BK, des-Arg10-KD). These peptides produced their biological effects 
via the activation of two types of GPCRs, named B1 and B2. The B2R is 
activated by BK, KD and T-kinin (rats only) while the B1R is activated by 
des-Arg9-BK and des-Arg10-KD (Leeb-Lundberg, 2001). As opposed to B2R, 
which is expressed in most tissues, the B1R is usually absent in healthy 
tissues. The B1R is inducible and its expression is increased in the presence 
of cytokines, bacterial lipopolysaccharides (LPS) and after tissue injury 
(Marceau et al., 1998b). 
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Kinins have been identified in the CNS and sufficient evidence suggests 
that kinins play a role as neuromodulators in central cardiovascular 
regulation, pain and inflammation (Couture and Lindsey, 2000; Couture et 
al., 2001). In freely behaving normotensive rats, BK caused a pressor 
response when it was injected into the i.c.v. or directly into the NTS and 
paratrigeminal nucleus (Pa5) (Corrêa and Graeff, 1974; Fior et al., 1993; 
Lindsey et al., 1997; Couture and Lindsey 2000).  
The thoracic spinal cord is another site of central cardiovascular regulation. 
Previous studies from our laboratory have shown that BK injected 
intrathecally (i.t.) increased BP via the activation of the sympatho-adrenal 
system and B2R (Lopes et al., 1992; Lopes et al., 1993). This was 
substantiated by autoradiographic studies, which revealed the presence of 
B2R binding sites in the spinal cord (Lopes et al., 1995; Couture and 
Lindsey, 2000). 
Emanueli et al. (1999) reported that B1R agonists injected into the i.c.v. in 
SHR and Wistar Kyoto rats (WKY) caused increases in BP, while the B1R 
antagonist R-715 caused a small decrease of BP in SHR. The latter findings 
were not reproduced with the identical B1R agonists and antagonists in 
SHR (Cloutier et al., 2004). Thus, the role of central kinin B1R in 
hypertensive rats is still controversial.  
 
1.1 Tachykinins 
The name tachykinin resulted from the pharmacological similarity of these 
peptides to bradykinin. The tachykinins, while having generally the same 
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pharmacological profile, induced a fast contraction of the tissue (Khawaja 
and Rogres, 1996).  
Tachykinins are present in several peripheral tissues where they perform 
many functions on the cardiovascular, respiratory and gastro-intestinal 
systems. Their effects include vasodilatation, increased vascular 
permeability, bronchoconstriction and contraction of smooth muscle cells. 
Neurogenic inflammation involved in diseases such as asthma is induced 
following the release of tachykinins from peripheral sensory C-fibers 
(Harrison and Geppetti, 2001). 
The discovery of SP, by von Euler and Gaddum in 1931, introduced a new 
era of peptides in neuroscience. This previously unidentified substance 
was found in alcoholic extracts of the equine brain and horse intestine. It 
was isolated and characterized as an eleven amino acid peptide, which had 
a potent stimulant action on the jejunum and also caused hypotension 
(Severini et al., 2002). 
Later, neuromedin K and neuromedin L were isolated from the porcine 
spinal cord (Kangawa et al., 1983; Minamino et al., 1984) and neurokinin  
and neurokinin  from guinea-pig ileum and rat duodenum (Kimura et al., 
1984). Substance K, neurokinin , and neuromedin L were re-named 
neurokinin A (NKA), while neurokinin  and neuromedin K were called 
neurokinin B (NKB) (Maggi, 2000).  
Two other mammalian tachykinins, neuropeptide K and neuropeptide , 
were isolated from porcine brain (Tatemoto et al., 1985) and the rabbit 
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intestine (Kage et al., 1988), respectively. These last two tachykinins were 
the products of the same gene (preprotachykinin A), which encodes SP and 
NKA. They were identified as the N-terminal elongated forms of NKA 
(Table 1). 
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1.1.2 Tachykinins: biosynthesis and distribution    
Tachykinins were encoded by two genes that, according to the Human 
Genome Organization Gene Nomenclature Committee, are termed TAC1 
(SP, NKA) and TAC3 (NKB), which replace the previously used terms PPT-
A and PPT-B (Patacchini et al., 2004).  
The precursor RNA from TAC1 was alternatively processed to yield four 
different mRNAs (α, β, γ and δ) (Figure 1). SP was encoded by all four 
mRNAs. NKA was encoded by β- and γ-PPT, neuropeptide K by β-PPT, 
and neuropeptide-γ by γ-PPT. The TAC3 gene encoded the precursor for 
NKB, which derived from α- and β-mRNAs (Severini et al., 2002). Recently, 
TAC4, a third tachykinin gene preprotachykinin-c (PPT-C) has been 
discovered in lymphoid B hematopoietic cells of mouse bone marrow 
(Zhang et al., 2000).  TAC4 encoded hemokinin-1 and endokinin (Page, 
2004). The expression of TAC1 and TAC3 genes which vary between 
tissues and species determined the distribution of the classical tachykinins 
(Page, 2005). Although the β-TAC1 mRNA was the predominant type 
expressed in the human basal ganglia, α-TAC1 mRNA was abundant in the 
mammalian brain (Bannon et al., 1992). The β- and γ- TAC1 mRNAs were 
found mainly in peripheral tissues (Nakanishi, 1987).  
The most studied member among the tachykinins is unquestionably SP. 
The distribution of SP is greatly expressed in CNS areas that are involved 
in the regulation of pain transmission, affective behaviour and stress (De 
Felipe et al., 1998; Kramer et al., 1998). 
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Figure 1. Schematic representation of the TAC1, TAC3, and TAC4 genes 
expression and their mRNA messengers. Adapted from Guard and Watson, 
1991.  
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SP is present in the limbic system, including the hypothalamus and the 
amygdala, areas associated with emotional behaviour (Stahl, 1999). In the 
mesolimbic brain areas, SP is believed to be involved in reward, opioids 
withdrawal (Murtra et al., 2000) and memory-promoting effects (Huston 
and Hasenohrl, 1995).  Immunoreactive-SP nerve fibers were found in the 
rat cortex and hippocampus, and were lightly distributed all over the 
layers of the neocortex. Studies revealed that the localization of these cells 
was a subset of the glutamic acid decarboxylase containing neurons 
supposedly γ-aminobutyric (GABA)-ergic neurons (Penny et al., 1986). In 
some neurons of the raphe nuclei of the rat medulla, SP co-existed with 
serotonin and GABA (Chan-Palay, 1978; Magoul et al., 1986).  
SP has been found in dorsal root ganglia and sensory neurons as well as in 
the most autonomic ganglia and intrinsic enteric neurons in the peripheral 
nervous system (Hokfelt et al., 1977). The highest concentrations of 
immunoreactive-SP fibers were found in the SN and dorsal horn of the 
spinal cord and in nerve terminals of the hypothalamus in rats (Figure 2) 
(Kanazawa and Jessell, 1976; Douglas et al., 1982; Ljungdahl et al., 1978). 
Substantial, but lower levels were present in other regions including 
amygdala, caudate putamen, and globus pallidus (Kertes et al., 2009). The 
distribution of immunoreactive-SP neurons and fibers in the human brain   
showed considerable similarity to the rat brain, including dense 
distribution of immunoreactive-SP in the SN, the caudate putamen, and the  
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Figure 2: Distribution of immunoreactive-SP in the rat hypothalamus 
(bregma: -1.8 mm (Paxinos and Watson, 1998). Scale of density: green, 
high; blue, moderate and plum, low.  CA3, CA3 region of the 
hippocampus; CP, caudate nucleus and putamen of the striatum, GP, 
globus pallidus; HL, lateral hypothalamus; PV, paraventricular nucleus 
of the hypothalamus; PO, piriform cortex; SO, supraoptic nucleus of the 
hypothalamus. Adapted from Shults et al., 1984. 
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brain stem (Chahl, 2006). However, the human cortex and hippocampus 
contained more abundant SP cells and fibers than rat brain (Hokfelt et al., 
1976; Mai et al., 1986; Del Fiacco et al., 1987). The other classical tachykinins 
were generally found in lower concentrations than SP in the CNS. Most 
studies on the distribution of tachykinins have used antisera directed 
towards the C-terminal region of the peptides which differentiate weakly 
between the family members. The recent discovery of hemokinin-1 and 
endokinin and their cross-reactivity with anti-SP antibodies were 
questioning several of the older studies on the peripheral and central 
distribution of the classical tachykinins (Page, 2004). Recent studies using 
molecular biological techniques have confirmed that TAC1 and TAC3 
mRNAs were strongly expressed in the brain (Pinto et al., 2004) and 
peripheral tissues, as described in previous studies. Since the classical 
tachykinins were synthesized in the cell soma and transported to the nerve 
terminals (Krause et al., 1987), precursor mRNAs were present in the cell 
soma, whereas the peptides were predominantly present in the nerve 
terminals. Thus, immunocytochemical methods will detect tachykinins in 
tissues that do not necessarily contain the mRNAs.  
SP has been shown to preferentially activate mesocortical DA neurons in a 
similar way (Tamiya et al., 1990). SP injected directly into the VTA 
increased the levels of DA, its metabolites or both, in the prefrontal cortex 
and the nucleus accumbens, suggesting that SP increased the release of DA 
from mesocortical and mesolimbic DA neurons (Deutch et al., 1985; Cador 
et al., 1989; Barnes et al., 1990; Elliott et al., 1992). 
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SP has been shown to preferentially activate mesocortical DA neurons in a 
similar manner to acute stressors such as mild foot shock or restraint 
(Elliott et al., 1986b). Furthermore, evidence suggested that the increased 
turnover of DA in the prefrontal cortex and the nucleus accumbens in 
response to stress may have been mediated by SP. Increases in DA 
metabolism in the prefrontal cortex in response to foot shock stress was 
blocked by an SP antibody in the VTA (Bannon et al., 1983). These findings 
suggested that SP not only activated mesocorticolimbic DA neurons, but 
the activation of these DA neurons in response to stress may have been 
mediated by the endogenous SP system. The activation of VTA DA 
neurons has been implicated in the mediation of relapse, mainly in drug-
induced (McFarland and Kalivas, 2001), and perhaps foot shock-induced 
relapse as well (Capriles et al., 2003).  
 
1.2 The NKA and NKB 
Immunohistochemical studies and in situ hybridization showed a high 
distribution of NKA, NKB and their mRNA in each major subdivision of 
the brain (Minamino et al., 1984; Nagashima et al., 1989; Nawa et al., 1984b), 
including the hypothalamus (Tateishi et al., 1989; Larsen, 1992; 
Merchenthaler et al., 1992), midbrain (Arai and Emson, 1986) cerebral 
cortex and medulla (Minamino et al., 1984).  NKA and SP were both 
localized to the same region. This was consistent with the fact that these 
two neuropeptides were synthesized from the same precursor (Ribeiro-da-
Silva et al., 2000).  
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In humans and monkeys, the mRNA gene expression of the TAC1 
responsible for the synthesis of SP and NKA was detected in the striatum, 
hypothalamus, periaqueductal gray region and the amygdala (Arai and 
Emson, 1986; Larsen et al., 1992; Sergeyev et al., 1999). 
Immunocytochemical studies revealed high density of NKB, in contrast to 
a low density of SP, in the olfactory bulb, cerebral cortex and hippocampus 
in rats (Lucas et al., 1992). Although the raphe nucleus possesses a high 
density of SP, NKB was not detected (Warden and Young, 1988). In 
addition to these regions, NKB was found in the striatum and several 
nuclei of the hypothalamus, including the lateral and paraventricular 
nucleus (Merchenthaler et al., 1992).   
The gene expression of c-fos was upregulated in rat brain areas activated 
by tachykinins (Spitznagel et al., 2001). Increased numbers of c-fos positive 
neurons were detected in the septum, amygdala, paraventricular nucleus, 
supraoptic nucleus, lateral hypothalamus, thalamus, VTA, and SN 
following i.c.v. injection in rats of NKB or senktide, a NK-3R agonist (Smith 
and Flynn, 2000). Using the same approach in rat, i.c.v. injected SP showed 
small expression of c-fos in the paraventricular and mediodorsal nuclei of 
the hypothalamus, the parabrachial nucleus and the medial thalamus. C-
fos expression was reduced significantly in the presence of tachykinin NK-
1R antagonist, RP67580 (Spitznagel et al., 2001). It is tempting to suggest 
that SP and NKB may activate distinct neural pathways, and consequently, 
that they are involved in different physiological functions. Further studies 
are necessary to confirm this hypothesis. 
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1.3 Tachykinin receptors 
The existence of multiple receptors for tachykinins emerged with the work 
of Erspamer et al. (1981) showing considerable differences between the 
pharmacological profiles of tachykinins. The distribution of tachykinin 
receptors has been examined after identification and molecular cloning of 
the three tachykinin receptors (Yokota et al., 1989; Hershey and Krause, 
1990; Nakanishi, 1991).  
The three tachykinin receptors (NK-1, NK-2 and NK-3) have a very high 
homology between them (from 53.7 to 66.3%) in the seven transmembrane 
domains cytoplasmic or intracellular regions (Shigemoto et al., 1990). Lee et 
al. (1982) were the first to suggest the existence of several types of receptors 
for tachykinins.  
The criteria originally used to distinguish the three receptors were; (1) the 
order of affinity of mammalian and non-mammalian tachykinins; (2) the 
activity induced by different fragments of tachykinins and, (3) the 
development of selective agonists (Maggi, 1995). Thanks to the first 
generation of SP antagonists and subsequently, to the discovery of NKA 
and NKB, the existence of three distinct receptors was suggested and later 
confirmed by molecular cloning. These receptors belonged to the “class A” 
family of seven-transmembranes G-protein-coupled receptors. It was not 
until 1986, at an international symposium held in Montreal on tachykinins, 
until the official nomenclature became neurokinin-1 (NK-1), neurokinin-2 
(NK-2) and neurokinin-3 (NK-3) (Henry et al., 1987). 
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All endogenous tachykinins can act as full agonists at the three receptors, 
yet SP and hemokinin-1 are preferential agonists at NK-1 receptors (R), 
whereas NKA (NKA) and NKB (NKB) are preferential agonists at NK-2R 
and NK-3R, respectively (Regoli et al., 1994; Patacchini et al., 2004). 
 
1.4 Tachykinins: agonists and antagonists   
1.4.1 NK-1R 
The first tachykinin receptor to be cloned was the NK-1R from the brain 
and the submandibular gland of the rat (Yokota et al., 1989; Hershey and 
Krause, 1990). It was identified in neurons and glial cells in the rat CNS 
(Buck et al., 1986), and in human amygdala and forebrain (Weidenhofer et 
al., 2006; Draganic et al., 2007) (Figure 3).  
NK-1R was highly expressed in the hypothalamus, pituitary gland and 
amygdala, which are the brain regions that are critical for the regulation of 
affective behaviour and neurochemical responses to stress (Kramer et al., 
1998).   
Furthermore, the neural pathways that respond to stress, noxious or 
aversive stimulation were associated with the amygdala (Kramer et al., 
1998). 
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The important role of NK-1R in neurogenic inflammation has been 
confirmed by studies using NK-1R knockout (KO) mice (Cao and Rodgers, 
1998).  The observation that tachykinin expression in both sensory neurons 
and hematopoietic cells is needed for the development of inflammation 
following antigen-antibody complex formation, at least in the airways, has 
been highlighted by the availability of the SP/NKA KO-mice (Chavolla-
Calderon et al., 2003). 
Preclinical research has implicated NK-1R in several pathological 
disorders, including emesis, asthma, psychiatric and gastrointestinal 
disorders, pain, migraine, inflammation and urinary bladder disorders 
(Lindstrom et al., 2007).  
The oxidations of methionine at the C-terminal as well as the N-
methylation of residue Gly9 of SP have greatly improved the selectivity of 
the natural peptide to NK-1R (Mussapi et al., 1993). The Sar9, Met (O2)11 -
SP was a relatively stable agonist with a high affinity and selectivity for the 
NK-1R (Regoli et al., 1988). The existence of a subtype of NK-1R has been 
suggested in several studies; at least some agonists such as septide can 
bind to dissimilar sites of the SP receptor. It was proposed that these 
binding sites were located on different conformers at the NK-1R 
(Beaujouan et al., 2000). Agonists that have a pharmacological profile 
similar to SP were therefore, called "classical" while the agonists, which 
showed a similar profile to septide were called "septide-like agonists” 
(Maggi, 1995) (Table II). The first selective peptide antagonist for NK-1R 
was L-668169 developed in the late 1980s. However, like many others that 
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followed, this antagonist had low affinity and selectivity and displayed 
side effects (Maggi, 1995). 
Other peptide antagonists (FK888 and Cam-2445) have subsequently been 
developed with higher affinity and selectivity (Fujii et al., 1992; Chan et al., 
1996) (Table III). To increase the resistance of the antagonists to tissue 
peptidases, CP-96345, the first non-peptide antagonist, was developed 
(Snider et al., 1991). Conversely, it had a very low affinity for the NK-1R in 
mouse and rat and induced several side effects, among others, on the 
cardiovascular system and neural transmission by interacting with ionic 
channels (Wang and Hakanson, 1992). 
 
RP67580, widely used in rats and mice to evaluate the physiological roles 
of NK-1R, has also some side effects including blocking calcium channels 
(Rupniak et al., 1993).  In order to reduce nonspecific effects while 
maintaining a high affinity and selectivity, other non-peptide antagonists 
were developed such as LY303870, a potent antagonist (Iyengar et al., 1997) 
(Table III).  
The possibility that NK-1R antagonists could be valuable as antipsychotic 
drugs was addressed based on evidence that SP modulates the activity of 
the mesolimbic DA system, which is the site of action of antipsychotic 
drugs. Consistent with this interpretation, the locomotor hyperactivity and 
changes in accumbens cell firing induced by intra-VTA infusion of SP were 
blocked by the DA-receptor antagonist haloperidol, an antipsychotic drug 
(Elliott et al., 1991). However, the lack of effect for the NK-1R antagonists in 
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these studies suggested that the effects of SP in rat VTA was mediated by 
the stimulation of NK-3R, rather than NK-1R, as suggested by anatomical 
(Saffroy et al., 1988), electrophysiological (Seabrook et al., 1995) and 
behavioural studies (Stoessl et al., 1991). Additionally, an exploratory trial 
with MK-869, which is a non-peptide antagonist with a high affinity and 
selectivity for the human NK-1R, showed a lack of efficacy in schizophrenic 
patients (Kramer et al., 1998; Rupniak et al., 1999).  
To date, little is known about the way antagonists interact with NK-1R and 
even less is known about the mechanisms that govern the duration of their 
effects in vivo. The in vivo efficacy of an antagonist and its duration of 
action can sometimes be difficult to predict based only on potency values 
obtained by in vitro assays (Copeland et al., 2006) 
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Table II. Tachykinin NK-1R-selective agonists 
      
Classical agonists  "Septide-like agonists" 
      
[Pro⁹]SP   [Glp⁶, Pro⁹]SP (septide) 
[Pro⁹]SP sulfone  SPOMe 
[Sar⁹]SP sulfone [Apa⁹¯¹⁰]SP 
Physalaemin [Pro⁹¯¹⁰]SP 
[Gly⁹Ψ(CH₂CH₂)-
Leu¹⁰]SP [Glu(OBz)¹¹]SP 
    γ-aminovalery [pro⁹, NMeLeu¹⁰]SP(7-11) 
    (GR73,632) 
    [Gly⁹Ψ(CH₂CH₂)-Gly¹⁰]SP 
    γ-aminovalery [Pro⁹, NMeLeu¹⁰]SP(7-11) 
      
      
    Adapted from Maggi, 1995. 
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1.4.2 NK-2R 
The NK-2R was cloned from the bovine stomach and rat brain (Masu et al., 
1987; Sasai and Nakanishi, 1989). It had 48% homology with the NK-1R 
(Yokota et al., 1989). The distribution of NK-2R has been studied mainly in 
the periphery, where high densities of binding sites were found (Mantyh et 
al., 1989; Tsuchida et al., 1990). These receptors have been localized on 
astroglial cells in rat spinal cord using electron microscopy (Zerari et al., 
1998). However, the NK-2R were also located in myenteric of neurons 
descending colon of rats (Mantyh et al., 1989). The presence of NK-2R in the 
CNS has long been disputed; even autoradiography could not 
unequivocally prove their existence (Bergstrom et al., 1987; Saffroy et al., 
1988; Mantyh et al., 1989; Nakanishi, 1991). Conversely, other studies have 
reported the existence of NK-2R at low concentrations in the striatum, 
hippocampus, hypothalamus, cerebral cortex and SN of rats and humans, 
by measuring mRNA by in situ hybridization or RT-PCR (Whitty et al., 
1995; Bensaid et al., 2001). Moreover, autoradiography studies using as 
radioligand [3H]-SR48968 (a selective non-peptide antagonist NK-2R) 
showed the presence of NK-2R in discrete brain areas, including frontal 
cortex, hippocampus, amygdala, striatum, hypothalamus, thalamus and 
SN in rats (Saffroy et al., 2001, 2003). Several NK-2R agonists were 
developed based on observations that the fragment NKA (4-10) was more 
active and selective than NKA for the NK-2R (Drapeau et al., 1987). The 
selectivity of NKA (4-10) was improved by replacing the residue Met11 by 
Nle, ( Nle10 -NKA (4-10)) or by replacing the residue Gly8 by the β-Ala 
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residue which yielded the selective agonist β-Ala8 -NKA (4-10) (Rovero et 
al., 1989). The agonists Lys5, MeLeu9, Nle10 -NKA (4-10) and Lys3, Gly8-R-
γ-lactam-Leu9 -NKA (3-10) (GR-64349) also have a high affinity and 
selectivity for NK-2R (Chassaing et al., 1991, Hagan et al., 1991).     
The cyclic hexapeptide L-659877 was one of the first antagonists with high 
affinity and selectivity for the NK-2R. MEN10627 was synthesized in order 
to optimize the properties of L-659877.  Polycyclic hexapeptides were more 
stable and retained the active conformation. MEN10627 was a competitive 
and reversible antagonist with potency comparable to SR48968 (Maggi et 
al., 1994). SR48968 was the first non-peptide antagonist developed to have a 
very high affinity and selectivity for the NK-2R. SR48968 was also a 
competitive antagonist also known for its long duration in vivo (Advenier 
et al., 1992; Emonds-Alt et al., 1992). GR-159897 was another good non-
peptide NK-2R antagonist (Beresford et al., 1995) (Table IV). 
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1.4.3 NK-3R 
The NK-3R was cloned shortly after the NK-1R and NK-2R (Shigemoto et 
al., 1990). NKB is the endogenous ligand that has the greatest affinity for 
the NK-3R. The rank order of affinity of tachykinins for the NK-3R were 
NKB>>NKA>SP (Smith and Dawson, 2008).  
Studies of function and localization have demonstrated the presence of 
NK-3R in mammalian central, peripheral and enteric nervous systems 
where its activation influences the release of a variety of neurotransmitters 
(for review, see Maggi, 1995). NK-3R were expressed in almost the entire 
CNS and spinal cord in rats (Almeida et al., 2004). 
NK-3R was located in the medial prefrontal cortex (mPFC), thalamus, and 
amygdala. It was present in the midbrain DA nuclei (VTA) and SN, locus 
coeruleus, and septal and basal nuclei, which suggested its role in 
modulating central monoaminergic systems (Langlois et al., 2001). NK-3R 
was also present in dopamine (DA), and non-DA neurons of the VTA 
(Chen et al., 1998; Lessard et al., 2007).  
NK-3R were located in mesolimbic and mesocortical pathways of VTA, 
which were known to be related to behaviours and cognitive functions, as 
well as to the pathophysiology of schizophrenia (Spooren et al., 2005; 
Lessard et al., 2009). This is suggested, in part, by the clinical efficacy of two 
non-peptide NK-3R antagonists (osanetant and talnetant) on the positive 
symptoms of schizophrenia (Meltzer, 2004; Spooren et al., 2005). This idea 
was also consistent with the hyperactivity of mesolimbic DA neurons in 
schizophrenia and the NK-3R was also distributed in other brain areas 
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(Table V). Activation of NK-3R located on the cell body of presynaptic 
neurons may have enhanced DA, acetylcholine (ACh), norepinephrine 
(NE) and GABA efflux at the nerve terminals (Marco et al., 1998; Jung and 
Bennett, 1996; Preston et al., 2000). These data suggested that NK-3R may 
be a target for treatment of psychiatric disorders (for review see Spooren et 
al., 2005). 
Several peptide and non-peptide NK-3R agonists and antagonists have 
been developed. Selectivity and affinity for NK-3R were noticeably 
increased once the agonist MePhe7 -NKB (4-10) replaced Val7 with MePhe 
in the fragment NKB (4-10) (Drapeau et al., 1987). Another agonist that also 
had a good affinity for the NK-3R were the Pro7 -NKB. However, senktide 
[(succinyl-[Asp9, MePhe8])-SP(6–11)] was considered the best NK-3R 
agonist due to its high affinity and selectivity. Indeed, to activate NK-1R or 
NK-2R, the concentration of senktide had to be at least 60,000 times 
stronger than that required to activate the NK-3R (Wormser et al., 1986). R-
486 and R-487 belonged to the first generation of antagonists selective for 
NK-3R, yet they maintained agonist activity to NK-1R and NK-2R 
(Drapeau et al., 1990) (Table VI). Being more selective, R-820 was a semi-
peptide antagonist that had a good affinity in rats (Regoli et al., 1994). The 
first human non-peptide selective NK-3R antagonist was SR142801 
(Emonds-Alt et al., 1995; Oury-Donat et al., 1995). However, in rat SR142801 
and its (R)-enantiomer (SR 142806) act as agonists at spinal and supra-
spinal levels (Cellier et al., 1997; Couture et al., 2000). SB222200 had a very 
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high affinity and selectivity for NK-3R in rat and mouse, and it crosses the 
blood-brain barrier (BBB) (Sarau et al., 2000).   
32 
 
  
 
Table V. Tachykinin NK-3R in rat brain 
Brain structure                   Relative expression 
Cerebral cortex
Cingulate cortex +++
Frontoparietal ++(+)
Entorhinal cortex +
Piriform cortex +
Amygdala
Basal nucleus ++(+)
Central nucleus ++
Lateral nucleus +(+)
Hippocampus
CA1–CA3 +(+)
Dentate gyrus ++
Subiculum ++(+)
Mesencephalon
Ventral tegmental area +++
Substantia nigra +++
pars compacta
Dorsal raphe nucleus +(+)
Metencephalon
Locus coeruleus +(+)
 
 
 
The relative expression of tachykinin NK-3R in different rat brain areas. 
Achieving: +, low expression; ++, moderate expression; +++, high 
expression. Adapted from Spooren et al., 2005. 
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Nevertheless, its low solubility limited its use (Sarau et al., 2000). More 
recently, SB235375, a water soluble non-peptide antagonist, was developed; 
it showed good affinity and selectivity, particularly to NK-3R in the guinea 
pig (Hay et al., 2002). Talnetant (SB223412) was a member of a new class of 
potent, competitive and selective non-peptide NK-3R antagonists that were 
based on the 2-phenylquinoline backbone (Table VI).  
 
1.5 Molecular biology of tachykinin receptors 
 
The tachykinin NK-1R, NK-2R and NK-3R have been cloned in several 
animal species and humans. In rats, the three receptors were respectively 
constituted of 407, 390 and 452 amino acids (Gerard et al., 1993). However, 
all the three receptors possess potential N-glycosylation sites at the 
extracellular amino-terminal and many serine and threonine residues, 
which are likely phosphorylation sites at the cytoplasmic carboxyl-
terminal. Consequently, all the three tachykinin receptors belong to the 
GPCRs family and have seven transmembrane domains (Nakanishi, 1991).  
The amino acid sequences in transmembrane domains and adjacent 
cytoplasmic portions showed similarity of 54-66% between the NK-1R, NK-
2R and NK-3R (Shigemoto et al., 1990). In addition, all three receptors 
contain a histidine residue on the transmembrane segments V and VI, 
which were characteristic of tachykinin receptors. The third cytoplasmic 
loop as well as parts for the C-terminal was highly conserved between NK-
1R and NK-3R, which was not the case for the NK-2R (Ohkubo and 
Nakanishi, 1991). 
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The homology between tachykinin receptors in rats, mice, guinea pigs and 
humans showed that only 10% of amino acids allowed differentiating the 
NK-1R between these species. In fact, only 23 amino acids were different 
between the NK-1R in humans and rats, and only nine amino acids were 
different between rats and mice. 
In rats and mice, unlike humans and guinea pigs, a fourth potential 
glycosylation site at the position 190 in the second extracellular loop 
between M4 and M5 has been identified in the sequence of the receptor. 
This could explain the pharmacological differences observed between 
species. For the NK-2R, a homology of 85% was observed between the 
species mentioned above. The NK-3R, NK-1R and NK-2R differed by an 
extension of 40-50 amino acids in the sequence in rats and humans. 
However, as the NK-1R and NK-2R, these receptors were highly conserved 
between rats and humans with a difference of only 12% of amino acids (for 
review, see Gerard et al., 1993).  
 
1.6 Intracellular signaling pathways  
The G-protein includes three different sub-units, named α, β and γ, which 
are bound to a guanosine diphosphate molecule (GDP). The GDP-bound 
heterotrimeric state is a stable entity. After ligand-receptor interaction, 
conformational changes within the receptor cause the G-protein to 
exchange GDP for GTP (guanosine triphosphate). The GTP activates the G-
protein, causing dissociation of α-sub-unit, which binds to and activates 
the intracellular effector. The α-sub-unit hydrolyses GTP to GDP, and then 
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successfully re-associates with the β- and γ-sub-units. Stimulation of 
tachykinin receptors initiates the  cascade of phosphoinositol in many 
tissues, including the salivary gland and brain in rats and tracheal smooth 
muscle in guinea pigs (Mantyh et al., 1984; Hunter et al., 1985; Grandordy et 
al., 1988) leading to the production of inositol 1,4,5- trisphosphate (IP3) and 
diacylglycerol (DAG). IP3 releases intracellular calcium acting on specific 
receptors in the sarcoplasmic reticulum. DAG increases intracellular 
calcium by opening voltage-gated Ca2+ channels via protein kinase C 
(PKC) (Gallacher et al., 1990). Although PLC was considered to be the 
principal intracellular effector for tachykinin receptors, in certain cells, 
tachykinin receptor activation might be coupled to adenylyl cyclase 
activation (probably via Gs) in cultured neuroblastoma cells and thyroid 
gland in dogs, or to adenylyl cyclase inhibition (probably via Gi) in rat 
salivary gland (Narumi and Maki, 1978; Yamashita et al., 1983; Laniyonu et 
al., 1988). Thus depending on the cell type, tachykinins elicit their effects by 
activating multiple effectors via different G-proteins. 
Some studies have shown that the activation of NK-2R and NK-1R by SP 
and NKA is mediated by the release of arachidonic acid (AA) and the 
production of prostaglandin E2 (Catalioto et al., 1998).  
The activation of NK-1R may modulate ion channels. For example, NK-1R 
stimulation could induce the opening of chloride channels in smooth 
muscle cells of rabbit colon or inhibit K+ channel inward and L-type 
calcium channels in submandibular ganglion neurons in hamsters 
(Nakajima et al., 1988).  
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The substitution of the amino acid sequence located at the third loop of 
intracellular NK-1R by an equivalent sequence from the NK-2R did not 
change the affinity of SP to its receptor, but avoided the generation of 
second messengers IP3 and cAMP. This suggested that the third 
intracellular loop of NK-1R is particularly important for the activation of 
intracellular second messengers (Blount and Krause, 1993).  
 
1.7 Tachykinins in cardiovascular regulation  
The possible site of action for the cardiovascular response associated with 
the defense reaction in rats is the hypothalamus (Culman and Unger, 1995). 
The paraventricular, ventromedial and dorsomedial hypothalamic regions 
are parts of the CNS rich in SP (Brownstein et al., 1976). The hypothalamus 
is an area that is particularly important in the autonomic control of the 
cardiovascular system. Moreover, SP that is injected into the anterior and 
ventromedial hypothalamus induced a defense reaction response that is 
very similar to that observed following its i.c.v. injection (Itoi et al., 1991, 
1994). Tachykinins and their receptors are also found in other CNS parts 
recognized in cardiovascular regulation. SP and their binding sites are 
present in the medulla oblongata (Douglas et al., 1982; Nevin et al., 1994) 
and in the NTS (Helke et al., 1980). Data also suggested a role for SP in 
regulating the baroreflex (Helke et al., 2004). I.c.v. injection of SP or 
phosphoramidon, an inhibitor of endopeptidases, improved the sensitivity 
of the baroreflex, while antibodies against SP injected in the cerebral 
ventricles or directly into the NTS reduced baroreceptor reflex (Chan et al., 
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1990; Appenrodt et al., 1993). Moreover, SP or NK-1R agonist injected into 
the NTS induced bradycardia and hypotension (Kubo and Kihara, 1987; 
Feldman, 1995). 
Tachykinin NK-1R, NK-2R and NK-3R agonists injected into the i.c.v. 
increased BP and HR together with stereotyped behaviours in rats (Itoi et 
al., 1992; Picard et al., 1994; Cellier et al., 1997). Cardiovascular effects to 
i.c.v. injected NK-3R agonists depended on the activation of the 
sympathetic nervous system, and also on the release of vasopressin from 
the hypothalamus, since the increase of BP induced by NK-3R activation 
was blocked by vasopressin V1 antagonist (Unger et al., 1981, 1988; Polidori 
et al., 1989; Takano et al., 1990; Cellier et al., 1997). In SHR, the content of 
NKB in the supraoptic nucleus of the hypothalamus and in the NTS was 
higher than in normotensive rats (Nagashima et al., 1989). Furthermore, the 
tonic activation of NK-3R by endogenous tachykinins in the SN of SHR 
contributed to maintain high BP, since the intra-nigral administration of a 
NK-3R antagonist significantly decreased MAP (Lessard et al., 2003). 
Moreover, tachykinin agonists injected into the SN, an important DA 
pathway, induced tachycardia that was blocked by selective tachykinin 
antagonists (Lessard and Couture, 2001). However, the neuronal pathways 
involved in cardiovascular and behavioural effects induced by tachykinins 
following i.c.v. administration are still not fully known.  
NK-1R binding sites in the spinal intermediolateral horn were located on 
dendrites and cell bodies of sympathetic pre-ganglionic neurons (Charlton 
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and Helke, 1987). The intrathecal (i.t.) injection of agonists in T8-T10 of 
freely moving rats was used to evaluate the effect of tachykinins on these 
neurons. The i.t. injection of SP and NK-1R agonists induced increases in 
BP and HR and these cardiovascular effects were accompanied by the 
release of norepinephrine and epinephrine (Hassessian et al., 1990; Couture 
et al., 1995).  
The role of NK-2R and NK-3R in cardiovascular regulation at the level of 
the spinal cord is uncertain. However, NK-2R were located on astrocytes at 
the edge of the dorsal and ventral horns and around the central canal, 
while NK-3R immunoreactivity were situated in superficial layers (laminae 
I and II) of the dorsal horn and laminae X in rat spinal cord, suggesting that 
some effects of tachykinins on somatosensation may be mediated by NK-
3R, and that NKB may modulate primary afferent, sensory information, 
both post-and pre-synaptically (Zerari et al., 1998; Seybold et al., 1997; 
Couture et al., 2000).  Furthermore, in 2006, Cloutier et al. provided the first 
functional and autoradiographic evidence that NK-1R and NK-3R are up-
regulated in the spinal cord of SHR. The study showed hypersensitivity of 
the pressor and tachycardiac responses induced by i.t. injection of NK-1R 
and NK-3R agonists in SHR. This suggested that the spinal tachykininergic 
system contributes to the hyper-sympathetic activity in SHR. 
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1.8 Tachykinins in spinal nociception  
NK-1R and NK-2R agonists injected i.t. decreased the reaction time to a 
painful thermal stimulus in rats and, therefore, induces hyperalgesia 
(Laneuville et al., 1988; Picard et al., 1993; Severini et al., 2002). The role of 
NK-3R in the process of pain was less clear. Indeed, some studies reported 
that activation of NK-3R could have induced hyperalgesia through the 
release of nitric oxide (NO) (Linden et al., 1999), particularly during 
peripheral inflammation (Ackley et al., 2001), while other studies reported 
analgesia via the local release of opiates following intrathecal injection of 
NK-3R agonists (Laneuville et al., 1988; Couture et al., 2000). 
 
1.9 Tachykinins in behavioural activity  
Tachykinin receptors localized in brain regions were implicated in affective 
behaviour and in the adaptation responses to stress in rats and mice (Ebner 
and Singewald, 2006; Yan et al., 2009). Central injection of tachykinins 
induced behavioural activity in rats. Injection into the cerebral ventricles of 
NK-1R and NK-2R agonists increased locomotion, grooming and sniffing, 
while the injection of NK-3R agonists induced mostly wet-dog shake 
behaviour (Tschöpe et al., 1992; Itoi et al., 1992; Picard et al., 1994; Cellier et 
al., 1997, 1999).  
Behaviours induced by tachykinins such as grooming and locomotion were 
also observed in affective disorders such as addiction and opiate 
withdrawal, depression, anxiety, and stress in guinea pigs and rats. In fact, 
SP is the main tachykinin involved in these disorders (Kramer et al., 1998; 
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Murtra et al., 2000; Gavioli et al., 2002). The induction of acute stress in rats 
affected the concentration of SP and the density of NK-1R in several 
regions of CNS including the limbic system (Takayama et al., 1986; Siegel et 
al., 1987; Rosén et al., 1992). NKA, the endogenous ligand for NK-2R, 
coexisted with SP within the same neuronal population and was co-
released with the latter peptide under stressful stimulus (Griebel et al., 
2001; Steinberg et al., 2001). 
SP injected in the i.c.v. of conscious rats caused a typical defense reaction 
consisting of a behavioural response associated with activation of the 
cardiovascular system. This reaction was characterized by an increase in 
locomotion, grooming, scratching and biting at the skin. These behaviours 
were accompanied by an increase of sympatho-adrenal activity, BP, HR, 
renal and mesenteric vasoconstriction and vasodilatation of skeletal muscle 
in the hind limbs (Unger et al., 1988; Culman and Unger, 1995). 
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2. The ventral tegmental area 
2.1 Location in the CNS  
The ventral tegmental area (VTA) in the ventral midbrain constituted a 
significant portion of the extrapyramidal system of the basal ganglia that 
was medial to the SN and ventral to the red nucleus (Fields et al., 2007) 
(Figure 4). The VTA and SN pars compacta were the sole sources of striatal 
and limbic forebrain DA. These pathways made projections into the 
nucleus accumbens of the striatum in the pre-frontal cortex and the limbic 
system,  including the septum and amygdala (Otsuka and Yoshioka, 1993). 
In rats, the VTA was divided mainly in two parts: a region called the dorsal 
nucleus pigmented para-pharyngeal, and the caudal ventrolateral region 
called the nucleus para-nigral (Halliday and Tork, 1986; Fallon and 
Loughlin, 1995). From a morphological point of view, the VTA was 
characterized by a majority of fusiform neurons, small to medium size and 
rather oriented on a horizontal plane (Swanson, 1982). 
2.2 Roles of the VTA 
The VTA originating in the midbrain is connected to the limbic system and 
cortex which are two systems typically involved in emotions, motivation 
and motor functions.  Moreover, the VTA has a large number of afferent 
and efferent projections and is also the center of the network of the neural 
pathways involved in several major functions of the CNS.  
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Figure 4. Location of the VTA in the rat brain. 
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2.2.1 Neuronal efferent and afferent of the VTA 
2.2.1.1 Major efferents 
The VTA system with its mesocorticolimbic projections can be broadly 
divided in two projections: mesolimbic and mesocortical projections 
(Figure 5). The mesolimbic projections include efferents to the nucleus 
accumbens (ventral striatum), olfactory tubercles, the central nucleus, 
medial and lateral amygdala, the septal region that includes the basal 
nucleus of the stria terminalis and lateral septum, the hippocampus, the 
middle part of the thalamus (lateral and medial habenula) and supraoptic 
nucleus of the hypothalamus. Mesocortical projections include efferents to 
the prefrontal cortex, entorhinal, cingulate and occipital (Figure 5). In 
addition, the VTA has projections to the periaqueductal gray, the 
parabrachial nucleus, the locus coeruleus and the dorsal and medial raphe 
nucleus, which showed implications in the control of the autonomic 
nervous system (Swanson, 1982; Oades and Halliday, 1987; Pierce and 
Kumaresan, 2006).  
Three less important pathways also exist: the mesostriatal, the 
mesodiencephalic, and the mesorhombencephalic pathways. Below is a 
brief summary of where each pathway originates and terminates:  
 Mesostriatal: originates in the SN and VTA; innervates the 
anteromedial striatum. 
 Mesodienchaphalic: originates in the SN and VTA; innervates 
several thalamic and hypothalamic nuclei. 
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 Mesorhombencephalic: originates in the SN and VTA; innervates the 
monoaminergic nuclei, superior colliculus and periaqueductal gray. 
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2.2.1.2 Major afferents 
The VTA received many afferents from different regions of the CNS 
(Phillipson, 1979; Geisler and Zahm, 2005) including afferents from: the 
amygdala (Wallace et al., 1992), the nucleus accumbens (Heimer et al., 
1991), the prefrontal cortex (Sesack and Pickel, 1992), the dorsal raphe 
nucleus (Gervais and Rouillard, 2000), the medial habenular nucleus 
(Cuello et al., 1978) and the lateral preoptic area and medial hypothalamus 
(Swanson, 1982). The chemical nature of these afferents was diverse. For 
example, a projection of the "shell" of the nucleus accumbens core 
paranigral VTA involved enkephalinergic and GABAergic fibers (Kalivas et 
al., 1993). The afferents of the prefrontal cortex synapses were on the 
dendrites of DA neurons and GABAergic neurons (Carr and Sesack, 2000). 
In addition, the afferents of the glutamatergic pedunculopontine nucleus 
was shown to make synaptic contacts with the midbrain DA neurons in 
squirrels and monkeys (Smith et al., 1996). The afferents of the serotonergic 
dorsal raphe nucleus may have synapses on DA and non-DA neurons 
(Herve et al., 1987; Van Bockstaele et al., 1994). 
 
2.3 Main receptors and neurotransmitters found in the VTA  
The VTA area was composed mainly (80%) of DA neurons. This group of 
neurons forms the A10 area. Neurons with hydroxylase-labeled tyrosine 
are found in all VTA (Swanson, 1982; van de Buuse and Catanzariti, 2000). 
Autoradiography studies have reported that D2R located in the dorsal part 
of the VTA are localized on the soma and dendrites of DA neurons, and 
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thus play a role as auto-receptors (Bouthenet et al., 1987; Sales et al., 1989; 
Chen and Pan, 2000). However, there was also D2R at presynaptic 
terminals on neuronal afferent (Pickel et al., 2002). Moreover, the D1R was 
presented in the VTA (Dubois et al., 1986). These receptors were located on 
terminals of GABAergic and glutamatergic afferents innervating the VTA 
(Smith et al., 1996; Steffensen et al., 1998; Ranaldi and Wise, 2001). Thus, 
unlike the D2R, the D1R may modulate indirectly DA neurons, and rather 
by controlling the release of neurotransmitters in afferents innervating the 
VTA. Electrophysiological and immunocytochemistry studies showed the 
presence of non-DA neurons containing GABA in the VTA (Steffensen et 
al., 1998; Carr and Sesack, 2000). A certain portion of these cells was made 
of local inter-neurons providing inhibitor "inputs" to DA neurons (O'Brien 
and White, 1987; Johnson and North, 1992b; Steffensen et al., 1998).  
Neuroanatomical and functional studies suggested the presence of GABAA 
and GABAB receptors in the VTA, which were densely distributed in the 
paranigral region (Churchill et al., 1992; Rodriguez et al., 2000). Moreover, it 
was also reported the existence of a large network of GABAergic neurons 
in the VTA that are interconnected via gap junctions, which have 
projections to the nucleus accumbens and prefrontal cortex (Van Bockstaele 
and Pickel, 1995; Carr and Sesack, 2000). This network allows for electrical 
conduction, which is considerably faster than the chemical conduction of 
signals between synapses (Olson and Nestler, 2007). Among other 
neurotransmitters and receptors, immunofluorescence studies identified a 
subpopulation of DA neurons containing neurotensin (NT) and 
49 
 
  
cholecystokinin in the VTA (Seroogy et al., 1987, 1988). The receptors for 
NT are presynaptic and somatodendritic on DA neurons (Legault et al., 
2002). Several studies also suggested the presence of nicotinic, serotonin (5-
HT2), NMDA, and metabotropic glutamate receptors on DA neurons, and 
Mu opioid receptors on GABAergic interneurons in the VTA (Doherty and 
Pickel, 2000; Klink et al., 2001; Zheng and Johnson, 2003; Swanson and 
Kalivas, 2000; Bergevin et al., 2002). 
 
2.4 Location and function of tachykinins in the VTA 
The injection of SP, NKA and the analogue of SP DiMe-C7 into the VTA in 
rat caused an increase in episodes of physical shock, exploration and 
locomotion (Elliott and Iversen, 1986). The VTA releases SP and it was 
reported that its levels decline after electric shock in rats. However, the 
NKA levels are not altered by this manipulation (Bannon et al., 1986). It is 
interesting to note that stress conditions activate the DA pathway A10 
whose origin lies in the VTA without affecting the pathway A9, which 
originates in the SN (Bannon et al., 1983, 1986). The tachykinins in the VTA 
modulate the activity of DA A10 since DA levels in the nucleus accumbens 
and the prefrontal cortex were increased after senktide injected into the 
VTA in guinea pig (Marco et al., 1998). These effects were completely 
inhibited by the addition of a selective antagonist of NK-3R, SR142801 
(Marco et al., 1998). Moreover, addition of senktide or NKB on rat VTA 
slices caused a local DA increase (Seabrook et al., 1995). Endogenous 
tachykinins released in the VTA activate both the tachykinin NK-1R and 
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NK-3R. Several studies by autoradiography, immunohistochemistry and 
electron-microscopy showed the presence of NK-3R in the VTA (Smith and 
Flynn, 2000; Langlois et al., 2001; Lessard et al., 2003, 2007).  
Several behaviours were induced following injection of NK-1R, NK-2R and 
NK-3R agonists in specific nuclei of the CNS such as the SN, VTA and 
median raphe nucleus. Behaviours induced by NK-1R agonist [Sar9, Met 
(O2)11]SP, NK-2R [β-Ala8]NKA (4–10) and NK-3R agonist senktide 
depended on central dopaminergic activation in the SN and VTA (Stoessl et 
al., 1991; Elliott et al., 1992; Mason and Elliott, 1992; Overton et al., 1992; 
Lessard et al., 2003; Deschamps and Couture 2005). This was consistent 
with the presence of endogenous tachykinins and NK-3R in the VTA 
(Langlois et al., 2001). The increase in locomotor activity induced by NK-1R 
agonists in the VTA was increased by the peripheral administration of D-
amphetamine, a drug known to stimulate the release of DA and inhibiting 
its reuptake (Eison et al., 1982).  In contrast, this behaviour was inhibited by 
haloperidol, a non-selective DA antagonist with high affinity for the D2R 
(Miyamoto et al., 2005) and for sigma 1 and sigma 2 receptors (Hashimoto 
and Ishiwata, 2006). Haloperidol exerts lower affinity for DA-D1R, D3R or 
D4R, serotonin 2A receptor, and α1 adrenergic receptor (Miyamoto et al., 
2005). The locomotor activity induced by NK-1R agonist in the VTA was 
also blocked by a lesion in the A10 DA neurons (Takano et al., 1985; Elliott 
et al., 1992). The wet-dog shakes induced by the activation of NK-3R were 
however dependent on endogenous serotonin. Indeed, wet-dog shakes 
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induced by senktide injected i.c.v. in rats were blocked by antagonists of 
serotonin 5-HT2 and 5-HT1c/2. Another argument suggesting the 
involvement of endogenous serotonin was the cause of intensification of 
behaviour in the presence of an inhibitor of serotonin reuptake (Stoessl et 
al., 1988, 1990). 
 
3. Centrally acting anti-hypertensive agents  
Most of the traditional drugs used to reduce elevated blood pressure 
interact with various elements of the sympathetic nervous system (SNS): in 
fact, almost every component of this system can be modulated by drugs 
(Noll et al., 1998). In addition, diuretics and various types of vasodilators 
have been introduced into anti-hypertensive therapy, and the renin-
angiotensin-aldosterone system has been recognized as an important target 
of anti-hypertensive therapeutics. Ganglionic blocking agents, 
postganglionic blocking agents (guanethidine), and reserpine owed their 
anti-hypertensive potency to their interaction with particular structures of 
the SNS (Plummer and Yonkman 1960). Despite their anti-hypertensive 
efficacy, they are no longer acceptable for chronic treatment due to their 
multiple and severe side effects. The same holds for "directly" acting 
vasodilators such as hydralazine and minoxidil, which cannot be used in 
monotherapy. At present, vasodilation is preferably induced by newer 
drugs, such as calcium antagonists, ACE-inhibitors or selective α1-
adrenoceptor antagonists (van Zwieten, 2002). 
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Central sympatholytic cardiovascular agents reduce the sympathetic nerve 
output and are more effective than β-blockers. A "centrally acting" 
sympatholytic cardiovascular agent is one that when administered by a 
conventional route, oral or i.v., is capable of crossing the blood-brain 
barrier and can produce effects in the CNS. Suitable central acting agents 
like adrenergic stimulants include methyldopa, clonidine, and guanfacine. 
It is also known that certain local anesthetics such as lidocaine, 
bupivacaine, and ropivacaine when administered directly to a sympathetic 
nerve, produce a local effect on the neurons that function in a 
sympatholytic manner (Hildebrand et al., 2005).  
The sympatholytic cardiovascular agent is preferably delivered into the 
CNS which provides access at the sub-arachnoid space of the thoracic 
spinal cord between the first and fifth thoracic vertebrae; the sympathetic 
preganglionic cell bodies located in the intermediolateral cell column of the 
spinal cord; the preganglionic sympathetic neurons which provide 
innervation to the heart; and the preganglionic sympathetic neurons which 
provide innervation to the kidneys to prevent stimulation of the renin-
angiotensin system (Hildebrand et al., 2005).  
Clonidine and methyldopa were the examples of central acting α2-
adrenoceptor agonists (Amery et al., 1970). Several studies have, however, 
reported the involvement of central imidazoline receptors in the central 
anti-hypertensive effect of these drugs (van Zwieten, 1995). Due to their 
adverse reactions, these effective anti-hypertensive drugs had lost their 
importance. Several of these adverse reactions, in particular sedation and 
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the occurrence of a dry mouth, were mediated by central α2-adrenoceptors 
(Kaufman, 1989). Rilmenidine and moxonidine were examples of drugs, 
which activated the central imidazoline receptors and consequently, 
reduced hypertension. Their effect on α2-adrenoceptors was weak and 
these compounds have been claimed to cause less sedation than clonidine 
and methyldopa (Bock et al., 1999). This gives a possibility to develop 
centrally acting anti-hypertensive drugs which cause less sedation than the 
classical drugs (Bricca et al., 1989; Chrisp and Faulds, 1992). 
3.1 Clonidine 
Clonidine is a α2-adrenergic receptor agonist, which selectively stimulates 
postsynaptic α-adrenergic receptors in the depressor site of the vasomotor 
center of the medulla oblongata in the region of the NTS and locus 
coeruleus (Kosman, 1975; Svensson et al., 1975). The activation of these 
central α-adrenergic receptors reduced the efferent sympathetic neuronal 
vasoconstrictor tone to the heart, kidneys, and peripheral vasculature 
causing vasodilatation and lowering blood pressure (Hausler, 1982; 
Rockhold and Caldwell, 1980). Multiple sites within the CNS were 
sensitive to clonidine (Hausler, 1982). The rostral ventrolateral medulla 
(RVLM), an area of the medullary reticular formation that contains neurons 
projecting to the spinal cord (Reis et al., 1988), is the termination site of 
afferent baroreceptor neurons responsible for the control of blood pressure, 
which is an important target for clonidine-induced hypotension 
(Schreihofer and Guyenet, 2000). Clonidine can also reduce stimulation-
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evoked release of noradrenaline from various isolated tissues through an 
action at prejunctional inhibitory α2-adrenoceptors (Starke et al., 1977). 
3.2 Guanabenz 
 
Guanabenz produced its hypotensive effect, at least in part, by means of a 
CNS clonidine-like sympatho-inhibition. However, the precise extent of 
central sympatho-inhibitory action has not been established. For example, 
guanabenz possesses pharmacological actions similar to both clonidine and 
guanethidine and consequently also reduced blood pressure and heart rate 
by peripheral pre- and postsynaptic anti-adrenergic effects (Koss, 1983). 
3.3 Moxonidine  
Moxonidine is a selective agonist acting at imidazoline I1 receptors with 
only minor activity at α2-adrenoceptors. It exerts its anti-hypertensive 
effect by an action in the CNS reducing peripheral sympathetic activity and 
decreasing peripheral vascular resistance. The site of action of moxonidine 
in the CNS is thought to be the RVLM (Haxhiu et al., 1994).  
3.4 Methyldopa  
Methyldopa is an analog of DOPA (3,4-hydroxyphenylanine) and a pro-
drug which must be converted to an active metabolite in order to exert its 
effects in the CNS. The decrease in blood pressure caused by methyldopa 
was discovered in hypertensive human over five decades ago (Oates et al., 
1960; Mah et al., 2009). In the 1970’s and 80’s methyldopa was considered to 
be an effective anti-hypertensive agent especially in the elderly and 
patients with renal insufficiency, and pregnant women. Methyldopa exerts 
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a hypotensive effect by interfering with the synthesis and action of 
noradrenaline. It inhibits the conversion of dopa into dopamine by 
competing with the enzyme dopa decarboxylase and thus reduces the 
amount of noradrenaline formed from dopamine (Vaidya et al., 1970).  
Later on, methyldopa was recommended as adjunct therapy after diuretics 
(Goodman and Gilman, 1996). It has since been associated with a wide 
spectrum of adverse events including CNS depressant effects such as 
drowsiness, fatigue, lethargy, depression, decreased libido, dry mouth, 
hepatitis, myocarditis, and haemolytic anaemia (Hoffman, 2006; Mah et al., 
2009).  
 
4. Dopamine 
DA is one of the main catecholamines in mammals. It plays an important 
role as a brain neurotransmitter and is well known for its contribution to 
the development of pathologies, mainly in arterial hypertension (Contreras 
et al., 2002). Moreover, a vast variety of psychological functions, such as 
motor behaviour, cognition, emotion, food intake were related to DA. 
Parkinson's disease, schizophrenia, drug addition, attention deficit 
hyperactivity disorder (ADHD) and depression, which are severely 
disabling neurological diseases, are also associated with dysfunctions in 
the DA system (Liss and Roeper, 2008; Altar et al., 2009). Within the CNS, 
DA binds to specific membrane receptors presented by neurons, and it 
played the key role in the control of locomotion, learning, working 
memory, cognition, and emotion (Missale et al., 1998). 
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The first evidence for the existence of DA receptors in the CNS came in 
1972 from biochemical studies showing that DA could stimulate adenylyl 
cyclase (AC). This observation came the suggestion to call the receptors: D1 
which stimulated AC, and D2 the one that was not coupled to this effect 
(Kebabian and Calne, 1979).  
Analysis of the primary structure of the cloned DA receptors revealed that 
they were members of the seven transmembrane domain GPCR family and 
shared most of their structural characteristics. Members of this family 
displayed considerable amino acid sequence conservation within seven 
transmembrane domains (for review, see Missale et al., 1998).  
4.1 Dopamine receptors 
Pharmacological, biochemical, anatomical, and physiological studies have 
indicated that the D1, D2, D3, D4 and D5 are receptor subtypes for DA 
(Creese et al., 1982; Stoof et al., 1984; Lebel et al., 2007). Physiological 
functions of the brain DA system were well recognized. However, DA 
biosynthesis did not only occur in neurons, but also in peripheral tissues. 
Moreover, studies in situ hybridization revealed high concentrations of 
D2R mRNA in the neostriatum, olfactory tubercle, SN, VTA and nucleus 
accumbens (Meador-Woodruff et al., 1991, 1992).  The striatum contains DA 
terminals, which received information from the VTA; 80% of the cells in 
this structure were medium spiny neurons (MSN) (Coskran et al., 2006; 
Seeger et al., 2003) containing DA-D1R or DAR receptors. The D3R 
expression was similar to D2R, although with much lower levels in several 
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brain areas. D3R was found in limbic areas such as nucleus accumbens, the 
islands of Calleja and dentate gyrus of the hippocampus (Suzuki et al., 
1998; Bouthenet et al., 1991). 
The D4R had more restricted distribution in the rat brain with a little 
expression in the nucleus accumbens and caudate putamen, although D4R 
was expressed in this rank order: hippocampus > caudate putamen > 
olfactory tubercle = SN > nucleus accumbens core > cerebral cortex > 
cerebellum (Lahti et al., 1995; Jackson et al., 1994; Defagot and Antonelli, 
1997).  
Studies in situ hybridization mRNA were performed to determine the 
distribution of D5R in rats. However, only two structures were identified 
as containig D5R mRNA: the hippocampus, and the perifascicular nucleus 
of the thalamus. This mRNA could not be visualized in the more 
traditional brain regions related with DA cell bodies or projection fields, 
proposing a different function in the brain for D5R (Meador-Woodruff et 
al., 1992). 
Most antipsychotics (psychiatric medications primarily used to manage 
psychosis, including delusions or hallucinations) were developed as D2R 
antagonists. They were likely to bind to the D2R with higher affinity than 
to the D3R and D4R. Conversely, a few antipsychotics have been 
established to show selectivity for the D3R or D4R. Through these, some 
aspects of the functions of the D3R and D4R may be revealed. Clozapine, 
an atypical antipsychotic whose actions are not accompanied by adverse 
motor side effects, shows a higher selectivity for the D4R than for any other 
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D2R-like. Later, it was shown that clozapine effect on D1R and D2R, may 
have been responsible for its exclusive efficacy in schizophrenia patients 
(Weiner et al., 1991; Tauscher et al., 2004) (For DAR distribution in the CNS 
see Figure 6).  
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Several DA antagonists have been discovered such as SCH23390 [R-(+)-8-
chloro-2,3,4,5-tetrahydro-3- methyl-5-phenyl-1H-3-benzazepine-7-ol), 
which is a selective DA-D1R antagonist, and raclopride (3,5-dichloro-N-
[[(2S)-1-ethyl-2-pyrrolidinyl]methyl]-2- hydroxy-6-methoxybenzamide), 
which is a selective DA-D2R antagonist. Both antagonists had 
pharmacologic effects which were similar to standard antipsychotics (Iorio 
et al., 1983; Hall et al., 1989).  
 
4.2 Dopamine: molecular signaling pathways 
Five subtypes of mammalian DAR were grouped into two classes, with the 
D1-like receptor, composed of the D1R and D5R subtypes, and the D2-like 
receptor, composed of the D2R, D3R, and D4R subtypes. There was also 
some evidence suggesting the existence of possible DA-D6R and D7R, but 
such receptors have not been conclusively identified (Contreras et al., 2002).  
All of the DAR are G protein-coupled receptors (GPCRs), whose signaling 
is primarily mediated by interaction with an activation of heterotrimeric 
GTP-binding proteins (G proteins). Members of this superfamily were 
called 7-transmembrane receptors, since they traverse the cell membrane 
seven times (Neves et al., 2002). 
The activation of D1R-like is coupled to the G-protein Gαs, which 
subsequently activates adenylyl cyclase, raising the intracellular 
concentration of the second messenger cyclic adenosine monophophate 
(cAMP). Activation of D2R-like family is coupled to the G-protein Gαi, 
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which directly inhibits the formation of cAMP by inhibiting the enzyme 
adenylate cyclase (Neves et al., 2002) (Figure 7). 
 In the brain, cAMP levels have been implicated in genetic transcription 
processes (Lalli and Sassone-Corsi, 1996), ionic channel activation, DA 
neuron survival (Yamashita et al., 1997), synaptic plasticity (Zhong and 
Wu, 1991), neurotransmitter release (Bouron and Reuter, 1999), locomotion, 
sensory perception and in memory and learning processes (Frey et al., 1993; 
Tully et al., 2003). In striatal cells, the increase in cAMP levels leads to 
activation of protein kinase A (PKA), which plays a role in reward 
mechanisms of drug consumption, locomotion activation and anxiety (Kim 
et al., 2008). Striatal cells, integrators of DA signaling from VTA, SN, 
cortical and thalamic afferent messages, were capable of regulating motor, 
sensory or cognitive action patterns. Thus, the control of the cAMP/PKA 
pathway was very strict and its impairment could be responsible for the 
development of psychotic processes, neurological alterations such as 
Parkinson's and Alzheimer's diseases and anxiety-related disorders. 
Adenylyl cyclase activities and expression have been identified in striatum 
(AC1, AC5, AC8, and AC9), where AC5 is the most abundant in that brain 
region (Glatt and Snyder, 1993; Matsuoka et al., 1997).  
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Figure 7. Signal transduction of D1R-like and D2R-like receptors. AC, 
adenylate cyclase; PLC, phospholipase C. Adapted from Missale et al., 1998. 
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4.3 Dopamine in cardiovascular regulation 
The brain dopaminergic system (mainly the nigrostriatal pathway) which 
connects the SN with the striatum, is one of the four major DA pathways in 
the brain. It is particularly involved in the production of movement, as part 
of a system called the basal ganglia. There are several pharmacological 
studies in vivo supporting an involvement of this central DA system in 
cardiovascular regulation (van den Buuse, 1986; van den Buuse and 
Catanzariti, 2000). 
Chemical or electrolytic lesions of the nigrostriatal DA system in SHR 
during the prehypertensive stage attenuate the development of 
hypertension (van den Buuse et al., 1986, Linthorst et al., 1994). Moreover, 
elevated tyrosine hydroxylase activity and higher dihydroxyphenylacetic 
acid (DOPAC) concentrations have been reported in the striatum of SHR. 
These results suggested that the nigrostriatal DA system in SHR was 
hyperactive and this hyperactivity caused the development of 
hypertension (Nagaoka and Lovenberg, 1994; Linthorst et al., 1994). 
In recent years, along with other observations in rat models of 
hypertension, SHR, DOCA-salt, and in patients with an impaired central 
DA system, the VTA was given a role in central cardiovascular regulation. 
This mesolimbic DA system plays a role in the regulation of diurnal blood 
pressure and heart rate in rats. Normally, during sleep, blood pressure 
decreases. However, a lesion of the mesolimbic DA system due to 6- 
hydroxydopamine (6-OHDA) injected into the VTA inhibited the decrease 
in blood pressure in rats during their resting period (Sakata et al., 2002).  
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I.c.v. injections of 6-OHDA in young SHR inhibited the subsequent 
development of hypertension (van den Buuse et al., 1986). This suggested 
that the central DA system was implicated in the etiology of hypertension 
in these rats. In addition, an increase in DA-D1R and D2R was observed in 
young SHR and an increase of DA-D1R in the nucleus accumbens in adult 
SHR (Kirouac and Ganguly, 1993). The mRNA for the D2R were also 
increased in the nucleus accumbens and olfactory tubercles in young SHR, 
two major afferents to the VTA (Vaughan et al., 1999). Autoradiography 
studies in young DOCA-salt rats have demonstrated an increase of D2R in 
the striatum and olfactory tubercles (Le Fur et al., 1981). It seems therefore 
that the increased expression of DA receptors is not specific to SHR.  
In normotensive rats, the activation of the baroreflex by electrical 
stimulation of aortic depressor nerve and by intravenous injection of 
phenylephrine altered the firing rate of DA neurons in the VTA (Kirouac 
and Ciriello, 1997). Neurons in the VTA were also sensitive to changes in 
blood pressure. Furthermore, studies reported that electrical stimulation of 
the VTA in anesthetized rats, as well as chemical stimulation with a stable 
analog of SP DiMe-C7 in conscious rats, increased blood pressure and this 
effect was blocked by the i.v. injection of DA-D1R, DA-D2R antagonists 
and vasopressin V1 antagonist (Cornish and van den Buuse, 1994, 1995). 
Furthermore, the DA agonist quinpirole injected intravenous (i.v.) induced 
a significant centrally-mediated increase in blood pressure in conscious rats 
(van den Buuse et al., 1996) and electrical stimulation of central DA 
pathways also increased blood pressure (Cornish and van den Buuse, 
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1994). In addition, studies with chemical stimulation of the VTA enhanced 
cellular activity, which caused an increase in the expression of c-fos in the 
mesolimbic and mesocortical DA system (Swanson, 1982). Another study 
also with chemical stimulation of the VTA showed the c-fos expression, 
which was markedly increased in the supraoptic nucleus, but not 
paraventricular nucleus of the hypothalamus which are two regions that 
play a major role in vasopressin production.  
 
5. The kallikrein-kinin system 
 
5.1 Brief history 
About 80 years ago, the researchers Emil Karl Frey, Heinrich Kraut and 
Eugene Werle, from the Max Planck Institute in Munich tried to identify 
the enzyme responsible for the release of kinins.  While attempting to 
identify a substance that may be responsible for the anuria in patients, Frey 
(1926) observed that intravenous injection of human urine in dogs caused a 
drop in blood pressure (BP). French physiologists Abelous and Bardia 
(1909) had previously observed this phenomenon. Kraut et al. (1930) 
isolated that substance, which was found in several organs and mainly in 
the pancreas. This substance was named kallikrein (from the Greek 
kallikreas meaning pancreas), which on a preparation of the guinea-pig 
ileum, produced a smooth muscle contraction only in the presence of 
serum (Werle et al., 1937). The kallikrein was in German called 
“Darmkontrahierender Stoff” (substance that contracts the intestine) or DK 
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substance; the DK is now named kallidin. In 1948, led by Maurício Rocha e 
Silva, three Brazilian physiologists and pharmacologists working at 
the Instituto Biológico in São Paulo, Brazil discovered bradykinin (BK) in 
attempting to determine the mechanisms involved in the septic shock 
produced by venom extracted from Bothrops jararaca (Brazilian lancehead 
snake) (Rocha e Silva et al., 1949). As the extract contained kallikrein, the 
venom alone had no effect on the smooth muscle of the guinea pig ileum, 
but it produced its contraction in the presence of blood. In comparison to 
histamine and acetylcholine, the snake venom induced in intestinal smooth 
muscle a slow contraction. Rocha e Silva et al. named this substance 
“bradykinin”, a name from the suffix kinin (for movement) and the prefix 
brady (for slow) in Greek.  Like kallidin (KD), BK also caused hypotension 
when injected in dogs. Within a short period of time, BK was isolated and 
purified. This process confirmed that it was a peptide (Andrade and Rocha 
e Silva, 1956, Elliot et al., 1960). At the same time, the structure of KD was 
identified by the team of Werle (1961), and it was realized that KD was an 
extension of BK (Lys-BK). The similarity of their structure and their 
biological effects demonstrated that they belong to the same family. Thus, 
the two major kinins were found and their precursors were identified as 
the high molecular weight kininogen (HMWK) and low molecular weight 
kininogen (LMWK) by Habermann (1963). There is also T-kinin, which is 
found only in rats (Okamoto and Greenbaum, 1983 a, b). All these peptides 
were produced during tissue injury or during an infection, and they acted 
locally at the site of inflammation. The development of selective agonists 
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and antagonists has suggested the existence of two types of kinin receptors, 
called B1 and B2 (Regoli and Barabé, 1980). This classification was 
subsequently confirmed by cDNA cloning of B2R in rat by McEachern et al. 
(1991) and B1R in human by Hess et al. (1994).  
In 1960, Rocha e Silva et al.  identified BK as a potent vasodilator and 
observed that BK could increase BP at high doses. This led researchers to 
propose a central action for BK. Shortly after, it has been demonstrated in a 
model of cross circulation in dogs that kinins may act on the cardiovascular 
system by a central mechanism (Benetato et al., 1964). Several studies in 
molecular biology and neuroanatomy followed, and helped identification 
and isolation of all components of the kallikrein-kinin system in most parts 
of the CNS. However, the physiological and pathological role of these 
peptides in the CNS remains largely unknown.   
BK produces the four cardinal signs of inflammation: vasodilatation, 
increased vascular permeability, heat and pain. Moreover, kinins directly 
interact with the immune system, by stimulating the sensory C-fibers, 
along with the release of potent proinflammatory mediators, including 
prostanoids, tachykinins, cytokines, free radicals and nitric oxide (NO) 
(Calixto et al., 2000; Couture et al., 2001). Extensive research was 
undertaken, which revealed a role for kinins in inflammation. On the other 
hand, kininase II, the main catabolic enzyme of kinins was found to be 
identical to ACE (Erdos and Yang, 1970). This discovery opened an 
important avenue of research for the pharmaceutical industry in the field 
of hypertension with the development of ACE inhibitors. Lately, kinins 
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have mainly been known for their involvement in vascular and 
inflammatory processes. 
 
5.2 Kininogens  
 
In humans, there are two types of kininogens synthesized mainly by the 
liver cells.  The HMWK is a glycoprotein (α-globulin) circulating in plasma 
at concentrations of 70 to 90g/ml with a molecular weight of 88-120 kDa 
(Adam et al., 1985). LMWK, a precursor of KD is a glycoprotein (β-
globulin) circulating in plasma at concentrations of 170-220g/ml with a 
molecular weight of 50-68 kDa (Dulinski et al., 2003). They are permanently 
present in the plasma or bound to the endothelial cells membranes and in 
the immune system such as platelets and neutrophils (Bhoola et al., 1992).  
The third type is called T-kininogen (68 kDa) and is present only in rats. 
Two isoforms exist: TI and TII, with 96% homology between them 
(Okamoto and Grennbaum, 1983). The T-kininogen is distributed in 
different regions of the CNS, including the brainstem, the cortex, the 
mesencephalon and cerebellum (Marks et al., 1988); the concentration is the 
highest in newborn rat and decreases gradually with growth (Damas et al., 
1992). 
LMWK and HMWK are derived from alternative splicing of a single gene 
called gene K located on chromosome 3q26, while the T gene is responsible 
for the formation of T-kininogen. Genomic analysis of these two genes 
shows a similarity of approximately 90%, suggesting that they originate 
from a common ancestral gene (Nakanishi, 1987; Cole and Schreiber, 1992). 
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5.3 Formation of kinins by kallikreins 
Kinins are generated by serine proteases named kallikreins. There are two 
major biochemical cascades leading to the release of kinins, in tissues and 
in blood. The tissue, cascade is initiated when kallikreins (25 to 45 kD) 
(Bhoola et al., 1992) cleave the bond Met379-Lys380and Arg389-Ser390 of 
LMWK to liberate kallidin (Fogaça et al., 2004). In rats, there are 13 different 
tissue kallikreins (Gerald et al. 1986; Wines et al., 1989, 1991). In blood, the 
cascade is initiated when the factor XII of coagulation (Hageman factor) 
becomes activated after contact with negatively charged surfaces such as 
damaged membranes or endotoxin. It interacts with the pre-complex which 
is pre-kallikrein and HMWK in the plasma. This interaction catalyzes the 
conversion of the pre-kallikrein into kallikrein and releases BK from 
HMWK (Figure 8). This kallikrein-kinin system participates actively in 
plasma coagulation and fibrinolysis protecting the endothelium (Linz et al., 
1995; Kaplan et al., 1997). It is also involved in maintaining the vascular 
tone and the inflammatory process (Bhoola et al., 1992). The tissue 
kallikrein is synthesized in its inactive form, pro-kallikrein, and 
transformed by several types of proteases. Unlike the plasma kallikrein, 
which is secreted by the liver, tissue kallikrein is synthesized in several 
tissues including pancreas, kidney, sweat glands, sub-maxillary glands and 
the epithelium of the cerebral ventricles ependyma (Bhoola et al., 1992).  
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5.4 Kallikreins distribution 
The presence of kallikrein in the brain was determined by 
radioimmunological techniques and in situ hybridization approaches 
(Chao and Chao, 1987). Kallikrein seems to be distributed in several 
regions of the rat CNS including cortex, brainstem and cerebellum. 
However, the highest concentration was found in the hypothalamus, 
pituitary and pineal gland. By immunohistochemistry, Kallikrein was 
observed in different regions of the brainstem including the oculomotor, 
red and reticular nuclei (Kizuki et al., 1994). Immunocytochemically studies 
showed the presence of kallikrein in neuroglia, in neuron cell bodies of the 
supraoptic and paraventricular nucleus and of the ventromedial and 
posterior hypothalamus (Simson et al., 1985; Snyman et al., 1994).  
Furthermore, in prenatal and adult rats, kallikrein was found mainly 
inneuronal nuclei at the developing stage (Iwadate et al., 2000). Kallikrein 
activity was also detected in human cerebrospinal fluid (CSF) (Scicli et al., 
1984).  The administration of melittin (a compound, found in the bee 
venom, which activates membrane kallikrein) into the cerebral lateral 
ventricles (Nishimura et al., 1980) increases the rate of immunoreactive 
kinins in the CSF. This is associated with an increase of BP in dogs (Thomas 
et al., 1984). The treatment with melittin i.t. increases the density of BK-LI 
in the rat spinal cord, supporting the presence of kallikrein (Lopes and 
Couture, 1997).  
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5.5 Kininases 
A variety of kininases were identified in the brain, such as 
aminopeptidases and enkephalinase (Camargo et al., 1972; Schwartz et al., 
1981) and two additional endopeptidases: kininase A 
(metalloendopeptidase) and B (peptidyl dipeptidase) (Camargo et al., 1973). 
In 1989, Orawski and Simmons showed that the degradation of BK in the 
brain synaptic membranes was due to the activity of three enzymes: 1) a 
form of the metalloendopeptidase which hydrolyses Phe5-Ser6, 2) a 
carboxypeptidase B which cuts the fragment Phe8-Arg9, and 3) peptidyl 
dipeptidase, which cleaves the fragment Pro7-Phe8, suggesting that BK has 
access to the synaptic membranes in the brain.  
Kininase I is also known as carboxypeptidase N (CPN in plasma) and 
carboxypeptidase M (CPM on the plasma membrane of vascular cells). By 
removing the arginine in the C-terminal end of BK and KD, these enzymes 
yield des-Arg9-BK and des-Arg10-KD, which are biologically active 
peptides acting preferentially through the activation of the B1R. 
Studies on the kininase distribution showed a very strong activity in the 
cerebellum and the striatum in comparison to other rat brain regions. For 
example, activity of the cerebellum and the striatum was about two times 
higher than in the cerebral cortex. The level of activity in regions of the 
mesencephalon, hippocampus, medulla oblongata and hypothalamus were 
not significantly different, and the spinal cord had less activity (Roth et al., 
1969; Cushman and Cheung, 1971; Yang and Neff, 1972; Kariya et al., 1981; 
Elrod et al., 1986). 
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Kininase II, better known as the angiotensin converting enzyme-1 (ACE) is 
a metalloprotease zinc glycoprotein which degrades BK into fragments 
BK(1-7), and BK(1-5) (Erdos, 1990) (Figure 9). ACE is found mainly at the 
surface of endothelial cells and in body fluids, such as semen, blood, urine, 
lymph and CSF (Bhoola et al., 1992). In humans, two types of kininase II are 
found: 1) a protein of 150-180 kDa, present in most tissues, which is 
responsible for the degradation of two-thirds of the serum BK (Decarie et 
al., 1996); and 2) a protein of 100-110 kDa which contributes to male fertility 
(Williams et al., 1992; Fuchs et al., 2005).   
There are also aminopeptidases acting at the N-terminal ends of T-kinin 
and KD, and capable of transforming them into BK but these enzymes have 
no known role in the inactivation of kinins.  The NEP is also found in the 
brain where it is known as enkephalinase (Erdos and Skidgel, 1989; 
Skidgel, 1992) (Figure 9). 
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6. Kinin receptors 
 
Analysis of kinin receptors has been progressing slowly, since in most 
biological preparations, kinins produce their actions indirectly via the 
release of factors derived from the endothelium or other cells.  The rabbit 
aorta was the only preparation of smooth muscle to show a direct effect of 
BK (Garrett and Brown., 1972). However, BK caused an effect in 40% of the 
aortas, and the sensitivity was low in comparison to other biological 
preparations. The sensitivity to BK was strongly increased by the 
elimination of arginine in its C-terminal end (des-Arg9-BK) (Regoli et al., 
1977). This octapeptide was almost inactive on preparations such as guinea 
pig ileum, rat uterus, and spleen tissue frequently used to evaluate the 
activity of BK.  The first BK antagonist ([Leu8]des-Arg9-BK) blocked the 
response of des-Arg9-BK and BK in the rabbit aorta but had no effect in 
other preparations. The existence of two types of receptors for BK was then 
proposed, based on the order of potency of agonists and the apparent 
affinity of competitive antagonists (Regoli et al., 1977). That study provided 
the first pharmacological tools to characterize the two types of receptors 
and a large number of B1R and B2R agonists and antagonists were 
synthesized. The primary structure of BK is in Figure 9. 
6.1 B1 receptors 
Receptor induction is one of the cellular mechanisms displayed in response 
to stress. This process has been widely described for tyrosine kinase 
receptors, but has only rarely been described for G protein-coupled 
receptors (GPCR). The B1R is one of the members of GPCR, which can be 
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induced by a specific stimulus (Donaldson et al., 1997). An increase of the 
temporal response to BK was described for the first time in a preparation of 
the dog saphenous vein in which BK produced vasoconstriction (Goldberg 
et al., 1976).  
Later, Regoli et al. (1977) first suggested the existence of B1R and B2R; they 
noticed that the sensitivity to des-Arg9-BK but not BK increased with the 
incubation time in the rabbit aorta.  The same phenomenon was later 
observed in other vascular and non-vascular preparations (Regoli et al., 
1978; Marceau et al., 1980; Couture et al., 1981). Moreover, this phenomenon 
occurred in most in vitro preparations obtained from rabbit, rat or pig 
(Marceau, 1995) and also in human colon and ileum (Couture et al., 1981; 
Zuzack et al., 1996). Specifically, the tissues are insensitive to B1R agonist in 
the early hours of incubation, but gradually become more sensitive after a 
few hours of isolation in vitro. This phenomenon can be blocked by 
actinomycin D (an inhibitor of RNA synthesis), by cycloheximide (an 
inhibitor of protein synthesis), by tunicamycin (an inhibitor of N-
glycosylation), by brefeldin A (an inhibitor of protein translocation), and 
glucocorticoids such as dexamethasone (Regoli et al., 1978; Marceau et al., 
1980; Whalley et al., 1983; Deblois et al., 1988; Audet et al., 1994; Campos 
and Calixto, 1994; Marceau, 1995; Haddad et al., 2000).  
The induction of the B1R involves increased expression of mRNA, protein 
translocation of the endoplasmic reticulum to the Golgi complex, an 
increased of transcription rate, a slower degradation or increased stability 
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of the mRNA, or both (Marceau, 1995; Haddad et al., 2000; Sardi et al., 
2000). 
The induction of B1R in vivo was first demonstrated in a model of cystitis in 
rats and subsequently on BP in rabbits treated with a sublethal dose of 
lipopolysaccharide (LPS) (Marceau et al., 1984). The stimulation of B1R 
caused paw edema in the rat, after systemic treatment with LPS or 
treatment with a weakened strain of bacteria (Mycobacterium bovis bacillus 
Calmette-Guerin), local injection of proinflammatory cytokines or after 
surgical removal of the adrenal gland (Campos et al., 1995; Campos et al., 
1997; Campos et al., 1998; Cabrini et al., 2001). The induction of B1R by heat 
stress in the rat aorta was also reported (Lagneux and Ribout, 1997; 
Lagneux et al., 1998). Finally, the involvement of the B1R in the hypotensive 
effect of des-Arg9-BK or des-Arg10-KD after systemic treatment with LPS 
was observed in pig and monkey (Siebeck et al., 1998; deBlois and Horlick, 
2001). 
The B1R plays an important role in chronic pain. The induction of B1R in 
vivo has been reported in inflammation and hyperalgesia models, after UV 
irradiation and intra-articular injection of Freund's adjuvant and cytokines 
in rats (Perkins et al., 1993,1995; Davis and Perkins, 1994; Khasar et al., 
1995). The MAP kinase p38 is involved in the induction of functional B1R 
in a model of inflammatory hyperalgesia produced by intraplantar 
injection of IL-1 in rats (Ganju et al., 2001).  B1R KO mice showed a 
decreased in thermal hyperalgesia and mechanical allodynia induced by 
injection of Freund's adjuvant (Ferreira et al., 2001). The non-peptide B1R 
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antagonist SSR240612 is anti-nociceptive in models of inflammatory and 
neuropathic pain induced by sciatic nerve ligation, UV irradiation, and 
injection of capsaicin (Gougat et al., 2004). Autoradiography studies 
showed increases of B1R binding sites in the spinal cord and increased 
mRNA (in situ hybridization) in the thoracic spinal cord  in streptozotocin 
(STZ) diabetic rats (Ongali et al., 2004). B1R is likewise overexpressed in 
several brain areas, such as the hippocampus, amygdala, and throughout 
the cortex (Campos et al., 2005). Selective B1R antagonists (R-715 and R-
954) blocked thermal hyperalgesia in animal models of type 1 diabetes 
(STZ rats and BioBreeding/ diabetic-prone rats) (Gabra et al., 2003, 2005a). 
Furthermore, the level of B1R mRNA was increased in endothelial cells 
incubated with high concentrations of glucose (Rodriguez et al., 2006). A 
study by autoradiography in chronic glucose-fed rats (models of type 2 
diabetes and insulin resistance) showed an increase in B1R binding in the 
spinal cord (El Midaoui et al., 2005) and peripheral tissues (Lungu et al., 
2007).  In glucose-fed rats, SSR240612 improved allodynia through a direct 
inhibition of B1R (Dias et al., 2007).   
6.1.2 Mechanism of the B1R induction 
Various studies have demonstrated that the induction of B1R is controlled 
by the generation of some specific cytokines produced during tissue injury 
or stress (Marceau and Bachvarov, 1998a).  
B1R is induced and overexpressed in the presence of cytokinins TNF-α, IL-
1β, IL-6, and IL-4 (Marceau et al., 1998; deBlois and Horlick, 2001; Sardi et 
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al., 2002). The synthesis of IL-1β is induced by inflammatory mediators that 
are stimulated by bacterial endotoxins or viral agents (Stylianou and 
Saklatvala, 1998). 
Receptor-adaptor interactions lead to the recruitment and activation of 
kinases of the IL-1R-associated kinase (IRAK) family, which regulate 
positively or negatively, a complex signaling cascade leading to the 
activation of nuclear factor kappa-light-chain-enhancer of activated B cells 
(NF-κB) and mitogen-activated protein kinases (MAPK), and to the 
production of defense molecules such as inflammatory cytokines (Meylan 
and Tschöpep, 2008). In addition, the intracellular signal triggered by IL-1β 
stimulation can lead to several proteins of the family of MAP kinases such 
as p38, p42, p44, NIK, and SAPK INK (Saklatvala et al., 1999).  
Subsequently, these proteins can activate a group of kinases called IKK1 
and IKK2, which are responsible for controlling the expression of genes 
regulated by the NF-κB. In addition, the response via IL-1β may involve 
the production of cAMP and activation of CREB or the activation of the 
transcription factor (AP-1) via PKC stimulation (Barnes, 1998; Meylan and 
Tschöpe, 2008). All these pathways lead to inducible gene coding for the 
B1R. Binding sites for these transcription factors (AP-1, CREB and NF-κB) 
are in the promoter region of the gene coding for B1R (Ni et al., 1998b; Yang 
et al., 1998). It was shown that mutations in the binding site for NK-κB 
prevented the induction of B1R by LPS, IL-1β and TNF-α in human 
vascular smooth muscle cells (Ni et al., 1998a). The involvement of NF-κB 
in the induction of functional B1R was shown in the rabbit aorta after 
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treatment with LPS (Medeiros et al., 2001). A treatment with pyrrolidine 
dithiocarbamate (PDTC, inhibitors of NF-κB) inhibited the contractile 
response to des-Arg9-BK in the rabbit aorta. The same observations were 
reported in the rabbit aorta incubated with IL-1β (Sabourin et al., 2002). 
These authors showed that the inhibition of NF-κB reduces the expression 
of mRNA encoding the B1R using fresh or cultured rabbit aortic smooth 
muscle cells. 
Several other cytokines, such as TNFα, IL-2 and IL-8, and some growth 
factors, are also capable of inducing the upregulation of B1R (Marceau et 
al., 1998b; Campos et al., 1999). However, this effect is likely to be 
secondary to the production of IL-1β (Marceau et al., 1998b). Some studies 
suggest that the B1R could also be induced by its own agonist in human 
lung fibroblasts (IMR 90) (Schanstra et al., 1998; Phagoo et al., 1999). 
6.1.3 B1R agonists 
Des-Arg10-KD and des-Arg9-BK, the two natural agonists for the B1R, were 
studied in several systems: contractile (rabbit jugular vein and rat portal 
vein) and relaxing (dog renal artery devoid of endothelium). All results 
obtained with these studies reveal that the activity of des-Arg10-KD is 
higher than that of des-Arg9-BK in human, rabbit and pig (Regoli et al., 
2001). This may be explained by a co-evolution of the respective genes 
encoding B1R and kininogens to keep optimal physiological function 
following the activation of B1R (Marceau et al., 1998b; Regoli et al., 2001). 
This theory is supported by the fact that the sequence of BK in rat and 
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mouse kininogen is preceded by an arginine, while the human kininogen 
contains the sequence of Lys-BK (Furuto-Kato and al., 1985, Hess et al., 
1996). The synthetic B1R agonist, Sar[DPhe8][des-Arg9]BK, has high affinity 
and selectivity for B1R (Drapeau et al., 1991) and it is more potent than des-
Arg9-BK, but less than Lys-des-Arg9-BK (Levesque et al., 1995). Moreover, 
the presence of B1R in human brain endothelial cells (HBECs) was 
upregulated on the surface of the HBECs by molecules released during 
inflammatory response. The signaling via this receptor can regulate blood-
brain barrier (BBB) permeability (Prat et al., 2000) and to show its 
involvement in the cardiovascular effect produced by i.c.v. injection of 
kinins in SHR and WKY (Emanueli et al., 1999). These agonists are 
therefore a good instrument to demonstrate the presence of functional B1R.  
6.1.4 B1R antagonists  
The first B1R antagonist, [Leu8]-des-Arg9-BK, was developed by Regoli’s 
team (1977).  Lys-[Leu8]- des-Arg9-BK and [Leu8]-des-Arg9-BK have been 
the two most used B1R antagonists to study the contribution of B1R in 
several experimental models and diseases such as hypertension, type 1 
diabetes, sepsis and inflammation (Marceau et al., 1998b). Due to their 
rapid metabolism these antagonists have some limitations, since they 
maintain a residual agonist activity in some species.  Regoli’s team also 
developed the B1R antagonist R-715 (Gobeil et al., 1996b). This antagonist 
showed no partial agonism and is a competitive antagonist in human, 
rabbit and mouse (Regoli et al., 1998). R-715 has enabled to suggest the 
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involvement of B1R in the CNS of SHR (Emanueli et al., 1999) and in two 
rat models of epilepsy (Bregola et al., 1999) (Table VII). 
LF220542, a non-peptide B1R antagonist, showed high affinity in human 
and mouse. Moreover, the blockade of the B1R with LF220542 caused 
significant anti-nociceptive and anti-hyperalgesic actions in acute, visceral, 
inflammatory and experimental neuropathic pain. This data supports the 
effects seen by Porreca et al. in B1R KO mice, showing the selectivity of 
LF220542 for B1R and the potential development of antagonists for pain 
treatment (Porreca et al., 2006) (Table VII).  
The non-peptide B1R antagonist SSR240612 was developed by Sanofi-
Aventis and is active orally (Gougat et al., 2004). The intraperitoneal 
administration of SSR240612 in a dose-dependent way reduced the paw 
edema caused by des-Arg9-BK in mice treated with IL-1β. Moreover, oral 
administration of SSR240612 decreased paw edema induced by des-Arg9-
BK in mice pretreated with IL-1β and ear edema caused by capsaicin 
application. In 2006, Costa et al. showed that SSR240612 given by gavage 
reduced the total cell and neutrophil counts in the pleurisy model induced 
by carrageenan in mice. This was the first non-peptide B1R antagonist with 
confirmed in vivo efficacy when administrated by gavage. In addition, 
SSR240612 prevented intestinal tissue damage and neutrophil 
accumulation after splanchnic artery   occlusion–reperfusion injury.   This 
result suggests that SSR240612 has relevant anti-inflammatory actions 
(Campos et al., 2006). 
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Dias et al.  (2007) showed that B1R is implicated in tactile and cold 
allodynia in glucose-fed rats, an experimental model of insulin resistance. 
SSR240612 administrated by gavage reversed in a dose-dependent way 
tactile and cold allodynia. Hence, non-peptide B1R antagonists such as 
SSR240612 with oral bioavailability may represent new therapeutic tools 
for the treatment of neuropathic pain. 
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6.2 B2 receptors  
The B2R are expressed in many tissues such as: endothelial cells, 
fibroblasts, neurons, and smooth muscle (Bhoola et al., 1992). This 
receptor is also responsible for: neurogenic inflammation, 
vasodilation, and increased vascular permeability. Furthermore, the 
activation of the B2R indirectly leads to an increase of cAMP / cGMP via 
the release of prostacyclin and NO, which causes vasodilation  
(Gabra et al., 2003). BK causes neurogenic inflammation by activating 
sensory C-fibers, which release SP and calcitonin gene related peptide 
(CGRP). This also leads to the release of prostaglandins, mediators of mast 
cells (histamine and serotonin), and cytokines (Dray, 1997, Couture et al., 
2001). 
  
6.2.1 B2R agonists 
BK remains the most used agonist despite the fact that there are some 
synthetic agonists for the B2R. [Tyr(Me)8]-BK and [Hyp3, Tyr(Me)8]-BK are 
B2R agonists generally more active than BK in preparations containing B2R 
(Regoli et al., 1977; Gaudreau et al., 1981a; Gaudreau et al., 1981b; Rhaleb et 
al., 1991; Regoli et al., 1991). Despite their greater affinity, these peptides 
have been little used because they are not commercially available. In 
addition, the fact that kinins produce four cardinal signs of inflammation: 
rubor (redness); calor (heat), tumor (swelling) and dolor (pain), the lack of 
interest in producing stronger B2R agonists were reported. However, the 
action of BK on the permeability of the BBB has raised clinical interest. 
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Indeed, BK increases the permeability of the BBB and might allow certain 
compounds such as anticancer agents to better penetrate the brain. For 
example, labradimil (Cereport®, formally known as RMP-7) has been 
developed as a B2R agonist with greater resistance to metabolism than BK 
(Straub et al., 1994; Emerich et al., 2001). This agonist was effective in 
increasing the chemotherapeutic agents’ concentration inside brain tumors 
(Emerich et al., 2001). The nonpeptide B2R agonist, FR190997, behaves as a 
full agonist on human, as partial agonist on rabbit, and as pure antagonist 
on pig B2R (Gobeil et al., 1999b; Regoli et al., 2001). 
6.2.2 B2R antagonists  
There are three generations of B2R antagonists. The first was initiated by 
Vavrek and Stewart, 1985, who made the following changes in the 
structure of BK: they replaced the proline in position 7 by one D-aromatic 
acid, D-phenylalanine (D-Phe) that produced [D-Phe7]-BK. Although this 
antagonist has low affinity, the substitution of phenylalanines 5 and 8 by β-
(2-thienyl)alanine(Thi) forming the [Thi5,8,D-Phe7]-BK or the substitution of 
a trans-4-hydroxyproline (Hyp) at position 2 or 3 forming [Hyp3, Thi5,8, D-
Phe7]-BK improved the affinity (Rhaleb et al., 1991). 
Furthermore, the basic residues D-arginine or lysine at the N-terminal, 
increase the metabolism resistance. However, these compounds were 
quickly found to be unsuitable for the pharmacological characterization of 
kinin receptors for the following reasons: they acted as partial agonists in 
some tissue preparations and they have relatively weak antagonist activity 
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(pA2 of 5.9 to 6.2), and low selectivity for B2R. They also caused the release 
of histamine both in vitro and in vivo (particularly those with a Lys or Arg 
in the N-terminal) (Devillier et al., 1988; Lawrence et al., 1989; Rhaleb et al., 
1991; Regoli et al., 1993).  In 1991, Regoli et al. produced another series of 
analogues [D-Phe7]-BK by substituting a leucine in position 8. The most 
interesting compounds are D-Arg-[Hyp3, D-Phe7, Leu8]-BK and Ac-D-Arg-
[Hyp3, D-Phe7, Leu8]-BK. They have a greater affinity for the B2R 
(including the rabbit B2R), little or no residual agonist activity and a 
relatively low pA2 (pA2 is the dose of antagonist that requires a 2-fold 
increase in agonist concentration) for the B1R. 
The second generation of B2R antagonist is characterized by the 
development of Hoe 140 (D-Arg-[Hyp3, Thi5, D-Tic7, Oic8]-BK) by the 
company Hoechst and is also known under the brand name of 
Icatibant® (Hock et al., 1991). This B2R antagonist has high affinity and 
selectivity for B2R. In fact, its pA2 is the 8-fold or higher in most species 
studied (Regoli, 2000), including rat (Meini et al., 2000). Furthermore, the 
Hoe 140 has a long duration (>60 minutes) due to its protection against 
metabolism and its long interaction with B2R. Moreover, the novelty with 
Hoe 140 was the addition of two artificial amino acids at positions 7 and 8 
(DTic: 1,2,3,4 acid, tetrahydroisoquinoline-3-carboxylic acid; OIC acid [3aS, 
7AS]-octahydroindole -2 - carboxylic acid), which improved affinity and 
resistance (Hock et al., 1991; Gobeil et al., 1996a). Hoe 140 is a B2R 
antagonist competitive just in human, not in rabbit and pig (Regoli et al., 
1998).  
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The structure of Hoe 140 enables its use as radioligand ([125I] HPP-Hoe 140 
and [125I]para-iodophenyl Hoe 140 ([125I] PIP-Hoe 140). These ligands have 
been used successfully to reveal by autoradiography the presence of B2R in 
central and peripheral tissues of guinea pig, sheep and rat (Murone et al., 
1996, Murone et al., 1997; Cloutier et al., 2002; Ongali et al., 2006), in the 
vagus nerve in rat and human (Krstew et al., 1998), in the human 
brainstem, and in mouse cancer cells (Wu et al., 2002). 
Finally, the third generation of B2R antagonists are non-peptide molecules 
designed for oral administration in the treatment of chronic inflammatory 
diseases. The first prototype, WIN64338, synthesized by the 
pharmaceutical company Sterling Winthrop (Salvino et al., 1993), had a 
promising future with its strong affinity for B2R in the guinea pig ileum. 
However, this component is not specific since it has a strong affinity for 
muscarinic receptors (Sawutz et al., 1994). Moreover, in comparison to Hoe 
140, which has a very high affinity in several species, WIN64338 has a 
variable affinity between species and is almost inactive in human (Regoli et 
al., 1996, 1998). 
Shortly after, FR173657 was proposed by Fujisawa Pharmaceutical 
Company (Inamura et al., 1997). It represents the first orally active B2R 
antagonist in several species. FR173657 inhibits the hypotension and 
plasma protein extravasation induced by BK and the nociceptive 
behavioural response following intraplantar injection of BK in rats 
(Griesbacher and Legat, 1997; Griesbacher et al., 1998). The vascular effects 
of kinins are also inhibited by this antagonist in experimental models of 
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pleurisy (Majima et al., 1997), pancreatitis and cystitis (Griesbacher et al., 
2000) and allergy in guinea pig (Mori and Imamura, 1998). Therefore, 
FR173657 represents an excellent pharmacological tool. Based on its 
structure, the pharmaceutical company Fournier developed the non-
peptide antagonist LF16-0687 which seems very promising from results 
obtained in various animal models of brain injury (Rachinsky et al., 2001; 
Plesnila et al., 2001) (Table VIII). 
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6.2.3 B2R expression  
B2R is traditionally known to have a constitutive expression in a wide 
variety of tissues including endothelial cells, fibroblasts, neurons, epithelial 
cells, skeletal muscle and smooth muscles cells (Dendorfer et al., 1999; 
Couture and Lindsey, 2000). The physiological responses induced by 
activation of B2R are subjected to tachyphylaxis due to the temporary 
desensitization of B2R, which involves phosphorylation followed by 
receptor internalization (Dengler et al., 1990; Munoz et al., 1992, 1993; 
Phagoo et al., 1999; Faussner et al., 1999; Marceau et al., 2001). Moreover, it 
has been suggested that ACE inhibitors enhance B2R activation of 
endogenous kinins not only by preventing degradation, but by preventing 
also B2R internalization and desensitization (Munoz and Leeb-Lundberg, 
1992; Minshall et al., 1997a, b; Marcic et al., 1999). In 2000, Marcic and Erdös 
suggested that ACE inhibitors do not act directly on B2R, but on a cross-
talk mechanism between ACE and B2R.  
B2R expression is increased in human synovial cells by IL-1β (Barton et al., 
1992), in smooth muscle cells by cAMP (Dixon, 1994) or by PDGF (Platelet-
derived Growth Factor ) (Dixon et al., 1996), and in the dorsal horn ganglia 
by NGF (Nerve Growth Factor) and GDNF (Glial-Derived Neurotrophic 
Factor), via TrkA (tyrosine kinase receptor A) (Lee et al., 2002). B2R 
expression is also increased in smooth muscle cells of the human bronchi 
(Schmidlin et al., 1998) and in vascular smooth muscle cells by high 
concentrations of glucose via PKC (Christopher et al., 2002), in human 
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fibroblasts WI-38 by IL-10 (Phagoo et al., 2000), in human embryonic lung 
fibroblasts (HEL 299) by TNF-α and IL-1 via p38 MAPK (Haddad et al., 
2000), myocardial ischemia (Tschöpe et al., 2000). 
6.3 Cloning of kinin receptors 
Deoxyribonucleic acid (cDNA) cloning and genes encoding of the kinins 
receptors confirmed the pharmacological classification but did not validate 
the existence of B3, B4 and B5 types.  
6.3.1 B1R cloning  
B1R was cloned and its sequence was established in human (Menke et al., 
1994; Yang and Polgar, 1996, Chai et al., 1996), in mouse (Pesquero et 
al., 1996), in rat (Jones et al., 1999), in rabbit (MacNeil et al., 1995) and in dog 
(Hess et al., 2001). However, the potency of agonists differs between 
species. While des-Arg9-BK has more affinity in rodents and in dogs, B1R 
in human and in rabbits have a preference for analogues with a group Lys 
in the N-terminal position (Lys-des-Arg9-BK). There are three potential 
sites of N-glycosylation and for phosphorylation by PKA and PKC. The 
gene encoding B1R in humans and in rats were analyzed, and it was found 
the TATA box sequence and a large number of binding sites for 
transcription factors related to inflammation such as AP-1, NF-κB and 
CREB (Bachvarov et al. 1996; Ni et al., 1998a, b; Jones et al., 1999). 
In all species studied, the B1R presented between 30% and 36% homology 
with the B2R receptor. The studies on the structure and genomic 
organization showed that the respective genes to these two receptors are 
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constituted of 3 exons separated by two introns and that they are localized 
very close to each other on the same human chromosome 14q32 
(Kammerer et al., 1995; Bachvarov et al., 1996; Yang and Polgar, 1996).  
6.3.2 B2R cloning 
The cDNAs encoding the B2R were cloned in rat (McEachern et al., 1991; 
Pesquero et al., 1994, Wang et al., 1994), in human (Hess et al., 1994a,b; 
Park et al., 1994, Kammerer et al., 1995), in mouse (McIntyre et al., 1993; 
Hess et al., 1992, 1994; Ma et al., 1994b), in guinea pig (Farmer et al., 1998), in 
rabbit (Bachvarov et al., 1995) and in dog (Hess et al., 2001). 
For all species studied, the sequences have a homology of 80% or more. 
The order of potency of agonists and antagonists was the same but with 
differences in affinities between species. The analysis showed sequences of 
potential N-glycosylation and phosphorylation sites by PKC and PKA in 
all of these species. The genomic analysis suggested a single copy of the 
gene coding for the B2R in humans (Ma et al., 1994a). The consensus 
sequence TATA box has been identified as potential sites for binding the 
elements of response to cAMP (CREB) and IL-6 on the gene encoding the 
B2R in human, rat and mouse (Wang et al., 1994, Ma et al., 1994a, b, 
Pesquero et al., 1996). 
6.3.3 Intracellular signaling pathways  
BK activates the "classical" signaling pathways which belong to the GPCR 
family by recruiting proteins Gαi and Gαq. The B2R also signals through 
Gαγ (Jones et al., 1995) and Got (Ewald et al., 1989). Depending on the cell 
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type, BK stimulates a variety of intracellular signaling mechanisms. These 
include direct or indirect accumulations of cyclic AMP and cyclic GMP, 
and the activation of phospholipase A2, C and D (Figure 10). B2R activation 
by BK promotes a rapid release of IP3 and DAG, presumably by activating 
a specific PLC (Yano et al., 1985). IP3 and DAG release, in turn, leads to the 
liberation of Ca2+ from intracellular stores and the activation of PKC 
(Figure 10).  
The activation of "alternative" new pathways apparently independent of G-
protein was shown for the B2R (Bascands et al., 2003). A direct interaction 
was showed between the B2R and enzymes such as phospholipase Cγ, 
neuronal NO synthase (nNOS), endothelial NO synthase (eNOS) and 
tyrosine phosphatase SHP2 (AbdAlla et al., 2005). The interaction of 
B2R with eNOS allows the recruitment of protein kinase Akt 
phosphorylation and thus controls eNOS and NO production. The 
interaction between the B2R and tyrosine phosphatase SHP2 is involved in 
the antiproliferative effect of BK (Duchene et al., 2002), it involves a 
sequence ITIM (immunoreceptor tyrosine-based inhibitory pattern). The 
mutation of the Tyr residue of the ITIM deletes interaction and the 
inhibition of the proliferation by BK. Equally unusual for a GPCR is the 
formation of a heterodimer, bringing the B2R and the AT1 receptor of 
angiotensin II. The formation of this heterodimer makes the complex 
resistant to oxygen radicals and alters endocytosis. A consequence would 
be the AT1 receptor hypersensitivity for angiotensin II (Hansen et al., 2009).
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A study using Chinese Hamster Ovary cells transfected with the human 
B1R gene showed that [3H]des-Arg10-LBK binding to the human B1R leads 
to the generation of inositol phosphate (IP) and transient increases in 
intracellular calcium, demonstrating that the receptor was coupled to PLC 
activation. This is consistent with studies also demonstrating B1R-
mediated activation of PLC in cells from other species and confirms that 
B1R is coupled to this signaling pathway (Austin et al., 1997) (Figure 10). 
Several studies revealed that the B1R and B2R are linked to the activation 
of tyrosine kinases, phosphatases and the MAP kinase (mitogen-activated 
protein kinase) (Liebmann and Böhmer, 2000; Liebmann, 2001). For 
instance, the inhibitory effect of BK on cell proliferation which is mediated 
by B2R is associated with an increase in tyrosine phosphatase activity and a 
decrease in tyrosine phosphorylation (Alric et al., 2000).  
The activation of B1R and B2R may also cause subsequent activation of the 
phosphatidylinositol 3-kinase and sphingosine kinase (Liebmann and 
Böhmer, 2000; Liebmann, 2001; Blaukat and Dikic, 2001). 
The difference between the two mechanisms of transduction of kinin 
receptors lies in their way of increasing intracellular calcium. B2R 
activation preferentially mobilizes the intracellular calcium, while the 
activation of the B1R seems to be associated with an influx of calcium 
(Bascands et al., 1996). The temporal pattern of intracellular events in cells 
that express both types of receptors is also interesting. The increase in 
intracellular Ca2+ produced by stimulation of the B1R is more persistent 
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and less subject to desensitization in endothelial cells in rats (Mathis et 
al., 1996). In the same way, activation of PLC is more persistent with the 
stimulation of the B1R (Austin et al., 1997).    
 
 
7. Cardiovascular effects of kinins  
Kinins in the periphery are vasoactive peptides that cause vasodilation and 
a decrease in BP (Bhoola et al., 1992). Many studies have identified several 
sites of action for kinins in the CNS having an effect on the cardiovascular 
system: the lateral area of the septum (Corrêa and Graeff, 1976), the 
hypothalamic nuclei (Diz and Jacobowitz, 1984; Diz, 1985), the ventral 
portion of the III ventricle (Lewis and Phillips, 1984), the periventricular 
areas of the dorsal medulla oblongata, the NTS, the paratrigeminal nucleus 
(Pa5), the area postrema, the dorsal motor nucleus of vagus, the trigeminal 
nucleus (SP5) (Lindsey et al., 1988, 1997; de Sousa Buck et al., 2002; Privitera 
et al., 2003) and the spinal cord (Lopes and Couture, 1992; Cloutier et al., 
2002, Cloutier et al., 2004). The injection of BK in these structures increased 
BP by increasing the activity of the sympathetic nervous system. Moreover, 
the i.t. injection of BK, KD and T-kinin to the ninth thoracic segment in 
unanesthesized rats increased BP and decreased HR via B2R (Lopes and 
Couture, 1992) (Figure 11). Antagonists selective for B2R showed a specific 
and reversible blockade of the pressor effects produced by administration 
of BK in the lateral septal area (Corrêa and Graeff, 1976), the IV ventricle 
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and the Pa5 (Lindsey et al., 1989; Martins et al., 1991) and the spinal cord 
(Lopes and Couture, 1992).  
In 2004, Cloutier et al. showed the cardiovascular effects of BK injected into 
the i.c.v. in SHR and WKY. These effects confirmed previous studies 
suggesting that central administration of BK and related peptides causes 
cardiovascular changes through the activation of B2R in both, hypertensive 
and normotensive and rats (for review, see Couture and Lindsey, 2000). 
This effect also was blocked by the selective B2R antagonist Hoe-140. 
However, the central administration of the Hoe-140 did not caused changes 
on cardiovascular effects in SHR and WKY. Moreover, the pressor effects 
caused by BK were partly mediated by the activation of the sympathetic 
nervous system (Bunag and Takahashi, 1981; Takahashi and Bunag, 1981; 
Qadri et al., 1999), and it is possible that BK-induced pressor responses 
originate at least partly from an exaggerated sympathetic tone in SHR. 
Changes in kininase II activity cannot provide an explanation for the 
hypersensitivity to BK since it was found higher in the CSF of adult SHR, 
suggesting a higher metabolic activity for kinins (Israel and Saavedra, 
1987). 
The involvement of B1R in hypertension is controversial. In SHR, i.c.v. 
injection of Sar[DPhe8][des-Arg9]BK, a B1R agonist, increased BP while the 
B1R antagonist, R-715, decreased BP (Emanueli et al., 1999). However, the 
same pharmacological approach did not confirm the involvement of B1R in 
the central control of BP in SHR (Cloutier et al., 2004). 
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8. Kinin receptors in the CNS 
Several techniques have been used to localize kinin receptors in the CNS 
including autoradiography on tissue sections, detection of mRNA by in situ 
hybridization and immunocytochemistry. The first evidence of the 
presence of B2R in the CNS was reported in 1981, by Innis et al. who 
observed saturably high affinity binding sites for [3H]-BK on brain 
membrane preparations from rat, guinea pig and bovine cerebellum.  
Binding sites with high affinity for B2R were detected using [125I]-Tyr8-BK 
in many systems: on nerve cells from brain of newborn rats (Lewis et al., 
1985), cultured astrocytes from the cortex, brainstem, spinal cord of fetal 
rats and cerebellum of newborn rats (Cholewinski et al., 1991), 
homogenates of the bovine hippocampus (Kozlowski et al., 1988) and 
guinea pig brain (Fujiwara et al., 1988).  
Kinin receptor binding sites were also observed using [3H]-BK on the 
endings of sensory C-fibers in the spinal gelatinous substance and the 
trigeminal nucleus (Steranka et al., 1988). The ligand [3H]-BK showed a 
high density of binding in the medulla oblongata and spinal cord, a 
moderate density in the cerebral cortex, and a low density in the 
hippocampus as well as in other brain regions of guinea pigs (Fujiwara et 
al., 1989). Sharif and Whiting (1991) confirmed the identification of B2R and 
its regional distribution in the CNS. With the ligand [125I]-Tyr8-BK, 
Privitera et al. (1992) showed by autoradiography the presence of BK 
receptors in the region of the medulla oblongata, specifically the nucleus of 
the solitary tract  (NTS), the area postrema, the dorsal motor nucleus of the 
101 
 
  
vagus nerve (X) and the spinal trigeminal nucleus. Their study confirmed 
the regional distribution observed by Fujiwara et al. (1989) for the medulla 
and the protuberance, but they failed to detect specific binding on BK in 
other brain regions (cerebellum and cerebral cortex).  
The anatomical distribution and pharmacological characterization of B2R 
in the different laminae of the spinal cord were studied in rat and guinea 
pig. Although the number of B2R binding sites was higher in guinea pig in 
comparison to rat, the segmental and laminae distributions were similar in 
both species (Lopes et al., 1993; 1995).  
Treatment with capsaicin (a neurotoxin for sensory C-fibers) in the 
newborn rat caused a significant decrease in the density of binding sites for 
[125I]-Tyr8-BK in laminae I and II of the spinal cord. This suggests a 
presynaptic location on primary sensory afferents and presumably on 
sensory neuron terminals of small diameter (C and Aδ) in the superficial 
laminae of the dorsal horn (Lopes et al., 1995). These authors also showed 
that treatment with intrathecal injection of 6-hydroxydopamine (6-OHDA), 
a neurotoxin for noradrenergic fibers, caused a significant decrease of BK 
binding sites. This observation also suggests the presence of B2R on 
noradrenergic bulbospinal neurons. Finally, a small but significant density 
of binding sites for [125I]-Tyr8-BK was detected in the intermediolateral 
nucleus, the cell bodies and dendrites of pre-ganglionic sympathetic fibers 
(Lopes et al., 1995). In all these studies, the pharmacological 
characterization of binding sites with different kinin agonists and 
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antagonists of B1R and B2R revealed the presence of only B2R in rodents 
under normal physiological conditions. 
Immunocytochemical studies have shown the presence of B2R in rat cortex 
and cerebellum. Immunoreactivity for the B2R was present in all layers, 
especially on the soma of pyramidal cells and Purkinje cells in the 
cerebellum (Chen, 2000). The immunoreactivity for B2R in the spinal cord 
was described in a review (Couture and Lindsey, 2000) and confirmed the 
pattern observed by autoradiography in rat (Lopes et al., 1995) and guinea 
pig (Lopes et al., 1993a). In humans, immunoreactivity for B2R was 
observed in neurons of the hypothalamus, thalamus, caudate nucleus, 
cerebral cortex and brainstem  (Bhoola, 1996; Raidoo et al., 1996; Raidoo et 
al., 1997).  
B1R immunoreactivity was observed in the laminae I and II of 
normotensive Wistar rats without apparent pathology (Wotherspoon and 
Winter, 2000). Using retrograde labeling, B1R was identified by 
immunocytochemistry in nerve endings of type C- and Aδ-fibers in sciatic 
nerves (Ma and Tian, 2001). However, these receptors are not functional. 
Kinin B1R is known to participate in neuropathic pain mechanisms 
(Quintao et al., 2008). Thus, increased levels of B1R mRNA or protein have 
been detected in the dorsal root ganglion and spinal cord after sciatic nerve 
constriction injury in rodents (Rashid et al., 2004; Petcu et al., 2008). 
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9. Kinins in the CNS 
The localization of endogenous kinins in the CNS was difficult to 
determine because of their rapid metabolism, the presence of several 
peptidases and contamination from blood vessels. BK immunoreactivity 
(BK-LI) was observed particularly in the hypothalamus, periaqueductal 
gray nucleus, perirhinal cortex, cingulate gyrus, ventral portion of caudate-
putamen and lateral septal area (Corrêa et al., 1979). Unfortunately, these 
studies did not provide data on possible cross-reactivity with kininogens. 
Using high-performance liquid chromatography (HPLC) and the technique 
of radio-immunological tests, BK was detected in the whole brain (0.6 
pmol/g) and found at various concentrations in specific regions:  
hypothalamus > spinal cord = brainstem and the medulla > corpus 
striatum > hippocampus > cerebellum > cerebral cortex = midbrain (Perry 
and Snyder, 1984; Kariya et al., 1985).  
 
10.  Action of kinins on body temperature 
The central action of BK on body temperature comes from the relationship 
with prostaglandins. In fact, BK can release prostaglandins (McGiff et al., 
1976) and it is known that prostaglandins injected i.c.v. cause an increase in 
body temperature in cat (Milton and Wendlandt, 1970) and rabbit (Stitt, 
1973). BK injected i.c.v. caused a dose-dependent increase in body 
temperature in rabbits and this effect was partially inhibited by 
paracetamol and indomethacin (inhibitors of prostaglandin synthesis) 
(Almeida e Silva and Pela, 1978). A decade later, (Rao and Bhattacharya, 
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1988) showed the same effect after i.c.v. injections of BK in rats and its 
inhibition by indomethacin. These authors also suggested the involvement 
of serotonin in the mechanisms underlying the onset of hyperthermia after 
central injection of BK. The physiological importance of these data is 
supported by the involvement of endogenous kinins in the hyperthermia 
induced by either central or systemic administration of LPS in rats (Walker 
et al., 1996a,b; Coelho et al., 1997). B2R and prostaglandins were involved in 
the early event of hyperthermia (Walker et al., 1996a, b). Both B1R and B2R 
also participated in the induction and maintenance of fever induced by 
systemic injection of LPS (Coelho et al., 1997). Destruction of the 
parvocellular region of the paraventricular nucleus of the hypothalamus 
with ibotenic acid significantly reduced fever induced by BK or by 
systemic injection of LPS, suggesting that this region is the site of action 
(Caldeira et al., 1998) of BK.  
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11. Objectives 
11.1 First Objective  
To investigate whether the tachykinin NK-3R in the VTA contributes to the 
maintenance of high arterial blood pressure through the mesocorticolimbic 
DA system in freely behaving SHR. This was accomplished by determining 
the cardiovascular response to selective NK-3R agonist and antagonists 
injected either into the i.c.v. or VTA before and after inhibition of DA-D1R 
and D2R or after destruction of the VTA with ibotenic acid. This work 
constitutes the first article given in Chapter III: 
Blockade of tachykinin NK-3 receptor reverses hypertension through a 
dopaminergic mechanism in the ventral tegmental area of spontaneously 
hypertensive rats. British Journal of Pharmacology Aug 26th 2010 by De 
Brito Gariepy H. and Couture R. PMID: 20804497. 
 
11.2 Second Objective  
To investigate whether the anti-hypertensive effect of the kinin B1R 
antagonist (SSR240612) observed in glucose-fed rats (Dias et al., 2007) can 
be reproduced in two rat models of hypertension: SHR and Ang II-treated 
rats. In order to find out if the anti-hypertensive effect is either centrally or 
peripherally mediated, SSR240612 was administered by gavage and i.c.v., 
and two kinin B1R antagonists (R-715 and R-954), which do not cross the 
BBB, were injected subcutaneously. As the second goal, we decided to 
assess the contribution of central DA in the effects of SSR240612.  
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This is a pharmacological approach using conscious unrestrained rats. This 
study constitutes the second article given in Chapter III: 
Contribution of the central dopaminergic system in the anti-hypertensive 
effect of kinin B1 receptor antagonists in two rat models of hypertension. 
Neuropeptides 44(2):191-198, by De Brito Gariepy H, Carayon P, Ferrari B, 
Couture R (2010). 
 
11.3 Third Objective  
This study was undertaken to determine whether the overexpressed B1R is 
functional in the CNS of hypertensive rats. Brain B1R was stimulated by 
i.c.v. injection of the selective kinin B1R agonist Sar[DPhe8][des-Arg9]BK 
and the effect on behavioural activity was measured in SHR and Ang II-
treated rats. The mechamism was studied with a pharmacological 
approach using selective receptor antagonists or enzymatic inhibitors for 
SP, glutamate, nitric oxide (NO), DA-D1R and D2R. A molecular approach 
was used to measure the expression of B1R at mRNA level in selected brain 
regions related to behaviour and the mesolimbic dopaminergic system in 
SHR and Ang II-treated rats. This study constitutes the third article given 
in Chapter III: 
Mechanism underlying behavioural activity induced by activation of brain 
kinin B1 receptor in hypertensive rats, by De Brito Gariepy H, Talbot S, 
Couture R (2010) (submitted to British Journal of Pharmacology). 
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12. Articles 
12.1 Article #1 
Contributions: 
H. De Brito Gariepy, contributed by performing all the experiments, 
created the graphics, figures, and wrote the manuscript. R. Couture 
contributed in the redaction and correction of the manuscript. 
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Summary   
Background and purpose. Intracerebroventricularly (i.c.v.) injected 
tachykinin NK3 receptor (R) antagonists normalized mean arterial blood 
pressure (MAP) in spontaneously hypertensive rats (SHR). This study was 
pursued to define the role played by NK3R located on dopamine (DA) 
neurons of the ventral tegmental area (VTA) in the regulation of MAP in 
SHR.   
Experimental approach. SHR (16 weeks) were implanted permanently 
with i.c.v. and/or VTA guide cannulae. Experiments were conducted 24 h 
after catheterization of the abdominal aorta to measure MAP and heart rate 
(HR) in freely behaving rats. Cardiovascular responses to i.c.v. or VTA 
injected NK3R agonist (senktide) and antagonists (SB222200 and R-820) 
were measured before and after systemic administration of selective DA 
antagonists for D1R (SCH23390), D2R (raclopride) or non-selective D2R 
(haloperidol) and after destruction of the VTA with ibotenic acid. 
Key results. I.c.v. or VTA injected SB222200 and R-820 (500 pmol) evoked 
anti-hypertension, which was blocked by raclopride. Senktide (10, 25, 65 
and 100 pmol) elicited greater increases of MAP and HR when injected in 
the VTA and the cardiovascular response was blocked by R-820, SCH23390 
and haloperidol. VTA injected SB222200 prevented the pressor response to 
i.c.v. senktide, and vice versa, i.c.v. senktide prevented the anti-
hypertension to VTA SB222200. Destruction of the VTA prevented the 
pressor response to i.c.v. senktide and the anti-hypertension to i.c.v. R-820. 
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Conclusions and implications. Tachykinin NK3R in the VTA is implicated 
in the maintenance of hypertension by increasing midbrain DA 
transmission in SHR. Hence, this receptor may represent a therapeutic 
target in the treatment of hypertension. 
Keywords. Dopamine, tachykinins, NK3R, senktide, SB222200, R-820, 
ventral tegmental area, hypertension, spontaneously hypertensive rats 
 
Abbreviations.  ANOVA, analysis of variance; aCSF, artificial 
cerebrospinal fluid; BP, blood pressure; DA, dopamine; DMSO, 
dimethylsulphoxide; HR, heart rate; i.c.v., intracerebroventricular(ly);  i.v., 
intravenous(ly); MAP, mean arterial blood pressure; NKA, neurokinin A; 
NKB, neurokinin B; NK1R, tachykinin NK1 receptor; NK2R, tachykinin NK2 
receptor; NK3R, tachykinin NK3 receptor; s.c., subcutaneous(ly); SHR, 
spontaneously hypertensive rats; SP, substance P; WKY, Wistar Kyoto; 
VTA, ventral tegmental area. 
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Introduction 
The ventral tegmental area (VTA), the origin of the mesolimbic and 
mesocortical (A10) dopaminergic (DA) pathways is traditionally known for 
its implication in the regulation of locomotor activity, stress responses, 
reinforcement and reward mechanisms (Le Moal and Simon, 1991; 
Swanson et al., 2000; Hyman and Malenka, 2001). The literature from the 
1990s suggests a role for the VTA and the mesolimbic DA system in 
cardiovascular homeostasis in link with the defence reaction and the 
somatosensory input (van den Buuse, 1998). The mesolimbic DA system is 
involved in diurnal blood pressure (BP) and heart rate (HR) regulation (Sei 
et al., 1999; Sakata et al., 2002). The discharge rate of DA neurons in the VTA 
seems to be regulated by inputs from arterial baroreceptors, likely through 
a relay in the nucleus tractus solitarius (Kirouac and Ciriello, 1997). 
Stimulation of the VTA is also associated with the modulation of the 
circulatory and pressor effects of vasopressin (van den Buuse and 
Catanzariti, 2000). Electrical stimulation of the rat VTA or microinjection of 
a substance P (SP) analogue produces increases of BP and HR through the 
activation of DA-D1 and D2 receptors (R), and vasopressin release (Cornish 
and van den Buuse, 1995). 
In a further recent study, the VTA was proposed as a potential target for 
tachykinin receptors in cardiovascular regulation (Deschamps and Couture 
2005). Increases of BP, HR and stereotypic behaviours are elicited by the 
intra VTA injection of physiological doses (pmol) of tachykinin NK1, NK2 
and NK3 receptor agonists in freely moving rats. These responses are 
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blocked in a selective manner by their respective antagonist and by 
systemic treatment with the DA-D1R antagonist, SCH23390, but not with 
the DA-D2R antagonist, raclopride. Furthermore, the cardiovascular 
response to tachykinin agonists is ascribed to enhanced cardiac output 
following the stimulation of cardiac β1-adrenoceptors. This study is 
consistent with the increased firing rate of A10 dopamine cells induced by 
application of NK1, NK2 and NK3 receptors agonists in the VTA (Overton et 
al., 1992) and the presence of NK1 and NK3 receptors on DA and non-DA 
neurons in the VTA as revealed by confocal and electron microscopy (Chen 
et al., 1998; Lessard et al., 2007; 2009). The VTA is enriched of NK3R binding 
sites (Dam et al., 1990; Stoessl and Hill, 1990; Ding et al., 1996; Langlois et 
al., 2001) and is particularly sensitive to the NK3R agonist senktide 
(Seabrook et al., 1995; Deschamps and Couture, 2005). SP and senktide 
injected into the VTA enhance levels of DA and its metabolite 
dihydroxyphenylacetic acid (DOPAC), DA turnover in the prefrontal 
cortex and nucleus accumbens (Elliott et al., 1986; Cador et al., 1989; 
Overton et al., 1992; Marco et al., 1998), and behaviour consistent with 
mesolimbic DA activation (Eison et al., 1982; Elliott and Iversen, 1986; 
Deschamps and Couture, 2005). SP, neurokinins A and B are found in the 
VTA (Deutch et al., 1985; Kalivas et al., 1985; Warden and Young, 1988) and 
SP immunoreactive axon terminals make direct synaptic contact with DA 
neurons in the VTA (Tamiya et al., 1990). SP projecting fibres in the VTA 
originate from the nucleus accumbens and the habenular nucleus (Cuello et 
al., 1978; Lu et al., 1998).  
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In a recent study, we reported that intracerebroventricular (i.c.v.) injection 
of NK3R antagonists reverse hypertension in spontaneously hypertensive 
rats (SHR) without affecting resting blood pressure in Wistar-Kyoto rats 
(WKY) (Lessard et al., 2004). Conversely, inhibition of brain NK1R and 
NK2R fails to affect blood pressure in SHR and WKY. Whereas these 
findings support a role for brain tachykinin NK3R in the maintenance of 
hypertension in SHR, the underlying mechanism of the anti-hypertensive 
effect of NK3R antagonists remains elusive. We showed that it persists after 
bilateral nephrectomy and is not accompanied of changes in plasma levels 
of vasopressin (Lessard et al., 2004).  
Based on all these revised findings, the VTA may represent a strategic site 
for the central anti-hypertensive effect of NK3R antagonists in SHR. This is 
in keeping with the increased central DA activity which contributes 
substantially to hypertension in SHR (van den Buuse, 1997; Amenta et al., 
2001). An upregulation of D1R and D2R in the nucleus accumbens, one 
major neuronal projection of the VTA, was reported in young SHR 
(Kirouac and Ganguly, 1993; Vaughan et al., 1999; Russell, 2003). 
The present pharmacological study was undertaken to test the hypothesis 
that tachykinin NK3R in the VTA contributes to the maintenance of high 
arterial blood pressure by interacting with the mesocorticolimbic DA 
system in freely behaving SHR. This was achieved by determining the 
cardiovascular response to selective NK3R agonist (senktide) and 
antagonists (SB222200 and R-820) injected i.c.v. or into the VTA before and 
after inhibition of DA-D1R and D2R (with SCH23390 and raclopride, 
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respectively) or after destruction of the VTA with ibotenic acid. Data 
suggest that tachykinin NK3R located in the VTA are subjected to 
persisting tonic activation which increases midbrain DA transmission and 
thereby contributes to hypertension in SHR. 
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Methods 
Animal source and care 
Male SHR (16 weeks) were purchased one week prior to experiments from 
Charles River (St. Constant, Qc, Canada). They were housed two per cage 
under a 12 h light–dark cycle in a room with controlled temperature (22°C) 
and humidity (40%). Food (Charles River Rodent) and tap water were 
available ad libitum. The care of animals and research protocols conformed 
to the guiding principles for animal experimentation as enunciated by the 
Canadian Council on Animal Care and approved by the Animal Care 
Committee of our University. 
Animal preparation 
Before each surgery, rats received the antibiotics Trimethoprim and 
Sulphadiazine (Tribrissen 24%, 30 mgkg-1, s.c., Schering Canada Inc., Pointe 
Claire, Qc, Canada) and the analgesic Ketoprophen (Anafen, 10 mgkg-1, s.c., 
Merial Canada Inc., Baie d’Urfé, Qc, Canada). They were anaesthetized 
with isoflurane (3%) and then positioned in a stereotaxic apparatus (David 
Kopf Instrumentation, Tujunga, CA, U.S.A.) with the incisor bar set at 0.0 
mm the interaural line for i.c.v. and at 3.3 mm below the interaural line for 
VTA implantation. The skull was exposed, cleaned and a hole was drilled 
to implant a 23-gauge stainless-steel guide cannulae into the left 
(contralateral) or right (ipsilateral) lateral brain ventricle (coordinates: 0.6 
mm posterior to the bregma, 1.3 mm lateral to the midline, 3.0 mm ventral 
from the skull surface) and/or 2 mm above the left or right VTA 
(coordinates: 5.3-5.6 mm posterior to the bregma, 0.7 mm lateral to the 
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midline, 7.0 mm ventral from the skull surface) according to Paxinos and 
Watson (1998). The guide cannulae was fixed with two screws and dental 
cement to the skull. Then the skin was replaced and sutured. Finally, stylet 
(31-gauge stainless-steel) was inserted into the guide cannulae to prevent 
loss of cerebrospinal fluid and to avoid its obstruction. Animals were 
housed in individual plastic cages (40 x 23 x 20 cm) in the same controlled 
conditions and allowed to recover.   
Three days later, the animals were re-anaesthetized with isoflurane and 
two siliconized PE-10 catheters (one PE-10 connected to PE-60), filled with 
physiological saline and 100 i.u.ml-1 heparin sodium salt, were inserted into 
the abdominal aorta through the left femoral artery for blood pressure 
recording and into the left femoral vein for drug administration, 
respectively. They were passed subcutaneously to emerge at the back of the 
neck and secured with tape. During the following days, the animals were 
observed closely. Those which lost more than 20% of their body weight or 
had clear signs of cerebral haemorrhage, atypical behaviour or weaknesses 
were killed with CO2 inhalation. Experimental protocols were initiated 24-
48 h after the last vascular surgery in conscious and freely moving rats 
(Deschamps and Couture, 2005). Successful VTA and i.c.v. implantation 
were confirmed in all rats used in the study after post-mortem examination. 
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Measurement of cardiovascular parameters 
During all experiments, continuous direct recordings of arterial blood 
pressure (BP) and heart rate (HR) were made on a high-performance data 
acquisition system PowerLab 8/30 with LabChart Pro ML870P and ML228 
Bridge Amp (ADInstruments Inc, Colorado Springs, CO, USA). Mean 
arterial blood pressure (MAP) was calculated from systolic (S) and diastolic 
(D) blood pressure values ((S – D) ÷ 3 + D = MAP). 
The cardiovascular response was measured 1 h after the rats were 
transported to an isolated and quiet testing room. Rats remained in their 
resident cage, but the top grid containing the food and tap water was 
removed prior to and up to 1h post-injection. When BP and HR were 
stable, a 31-gauge stainless-steel injector connected to a Hamilton 
microsyringe 5 μl via a PE-10 tubing catheter was inserted into the guide 
cannulae which was accessible without handling the rat. Five min later, 
injection was made i.c.v. or directly into the VTA of undisturbed, freely 
behaving rats. All solutions were freshly prepared and injected (volume of 
1 μl i.c.v.; 0.5 μl VTA and 0.1 mlkg-1 i.v.) over a period of 1 min. The injector 
was removed from the guide cannulae 1 min after injection to prevent any 
possible leakage of the injectate. 
 
Experimental Protocols 
Cardiovascular effects of i.c.v. and VTA administered tachykinin NK3R 
antagonists. This series of experiments aimed at determining the anti-
hypertensive effect of centrally administered NK3R antagonists (500 pmol). 
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SHR received by i.c.v. the selective tachykinin NK3R antagonist (SB222200, 
n=8) (Sarau et al., 2000) 1h after the vehicle (artificial cerebrospinal fluid or 
aCSF, n=8). The inactive enantiomer of SB222200 (SB222201, n=10) was also 
injected as control for specificity in a separate group of SHR. The selection 
of this dose of SB222200 was based on a previous dose-response curve 
which established that i.c.v. 500 pmol caused the optimal anti-hypertensive 
effect in SHR (Lessard and Couture, 2004). SHR implanted with a VTA 
cannulae received aCSF and 1h later SB222200 (500 pmol, n=5) for 
comparison purpose. 
In two separate groups of SHR, R-820 (500 pmol) was injected either i.c.v. 
(n=5) or directly into the VTA (n=4) and the anti-hypertensive responses 
were measured for up to 3 days or until they were back to baseline values. 
The dose and duration of recording were based on a previous i.c.v. study 
achieved in SHR (Lessard et al., 2004). 
 
Effects of systemic treatments with dopamine D1 and D2 receptor antagonists 
against SB222200 and R-820. This series of experiments was designed to 
determine the contribution of DA and its receptors in the anti-hypertensive 
effects of NK3R antagonists. SHR that have received SB222200 (500 pmol, 
24h earlier) or R-820 (500 pmol, 72h earlier) by the i.c.v. or the VTA route, 
were given the DA-D1R antagonist SCH23390 (0.2 mgkg-1, i.v.) (Kirouac 
and Ciriello, 1997; Gioanni et al., 1998) or the DA-D2R antagonist raclopride 
(0.16 mgkg-1, i.v.) (Millan et al., 1998) 30 min prior to a second injection of 
NK3R antagonist. SB222200 and R-820 (500 pmol) were re-injected again 
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either 24h (SB222200) or 72h (R-820) later to assess the reversibility of any 
blockade observed in the presence of DA antagonist. A rat received only 
one DA antagonist and one NK3R antagonist either i.c.v or into the VTA.  
Chronic anti-hypertensive effect of i.c.v. R-820. SHR (n=4) received daily an 
i.c.v. injection of R-820 (500 pmol) to see whether its anti-hypertensive 
effect could be maintained for a period of 5 days. MAP and HR were 
measured at the peak time within the 5h post-injection every day. The 
recording was pursued up to two days after the interruption of the 
treatment. 
Dose–response curves with the NK3R agonist senktide after i.c.v. and VTA 
microinjection. Two groups of SHR were used on 4 consecutive days; the 
first group was implanted with an i.c.v. cannulae (n=6) and the second 
group with a VTA cannulae (n=6). They received i.c.v. or directly into the 
VTA a microinjection of aCSF followed by a dose of 10 pmol senktide 60 
min later, and then increasing doses of 25, 65 and 100 pmol were 
administered on the following 3 days at 24 h intervals. This protocol and 
the doses selected were based on our previous studies in which the 
cardiovascular effects of i.c.v. and VTA injected senktide were 
characterized in normotensive rats (Cellier et al., 1997; Deschamps and 
Couture, 2005). 
Blockade of senktide by tachykinin NK3R antagonist in the VTA. In this series of 
experiments, the dose of 25 pmol senktide was selected on the basis of its 
maximal cardiovascular response upon VTA injection. SHR (n=4) received 
a microinjection of aCSF into the VTA followed 60 min later by a single 
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dose of senktide (25 pmol). Twenty-four hours later, senktide was re-
injected again 1h after the VTA injection of the tachykinin NK3R antagonist 
R-820 (500 pmol) (Regoli et al., 1994). The reversibility of the inhibition was 
tested 24 h later.  
Effects of systemic treatments with dopamine D1 and D2 receptor antagonists 
against i.c.v. senktide. In this series of experiments, the dose of 65 pmol 
senktide was selected on the basis of its maximal pressor response upon 
i.c.v. injection. Three groups of SHR were initially injected i.c.v. with a 
single dose of senktide (65 pmol). One hour later, they received 
intravenous (i.v.) or subcutaneous (s.c.) injection of either the DA-D1R 
antagonist SCH23390 (0.2 mgkg-1, i.v. n=6), the DA-D2R antagonist 
raclopride (0.16 mgkg-1, i.v. n=6) or the non-selective DA-D2R antagonist 
haloperidol (10 mgkg-1, s.c. n=4) (Nsimba et al., 1997; Miyamoto et al., 2005), 
followed 30 min later by senktide (65 pmol). The following day (24 h later) 
senktide (65 pmol) was re-injected alone to assess the reversibility of any 
blockade observed in the presence of antagonist on the preceding day. In 
one additional group of SHR (n=4), raclopride and SCH23390 were 
administered alone at 24h apart to assess their direct cardiovascular effects. 
A second group of SHR (n=4) served to evaluate the direct cardiovascular 
effect of haloperidol. Pilot experiments have shown that the cardiovascular 
response to i.c.v. senktide (65 pmol) is reproducible when two injections 
are given at 1h apart. 
Blockade of i.c.v. senktide by SB222200 injected into the VTA of SHR and 
reciprocally blockade of VTA SB222200 by i.c.v. senktide. This experiment 
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aimed at determining, firstly, the contribution of VTA NK3R in the i.c.v. 
pressor response to senktide, and secondly, the possibility that the anti-
hypertensive effect of SB222200 injected into the VTA could be prevented 
by the ipsilateral i.c.v. injection of the agonist senktide. Rats received 
senktide (65 pmol, n=4) by i.c.v (right side). Two hours later, SB222200 (500 
pmol) was injected into the ipsilateral VTA, and senktide was re-injected 
i.c.v. 1 h later to evaluate the inhibition of the pressor response to senktide. 
On the second day, SB222200 (500 pmol, n=4) was injected into the right 
VTA to assess its anti-hypertensive response. On the third day, senktide (65 
pmol) was injected i.c.v. (right side) 1h after injection of SB222200 into the 
right VTA to see if it could block the anti-hypertensive effect of SB222200, 
which starts one-hour post-injection. In another group of rats (n=4), 
senktide was injected i.c.v. on the contralateral side (left side) of VTA 
injection of SB222200 (right side) and the rest of the protocol was similar to 
that described above. 
 
Effect of ipsilateral and contralateral lesions of the VTA with ibotenic acid on the 
cardiovascular response to senktide and R-820. Ibotenic acid is proposed as an 
effective technique for producing circumscribed lesions when local, 
discrete brain lesions are desired. This method works reliably without 
apparent damage to passing or underlying fibers and without causing 
distant lesion effects in the brain in contrast to kainic acid, a similar 
excitatory amino acid toxin (Guldin and Markowitsch, 1981; 1982).  
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Senktide (65 pmol) was given i.c.v. in two groups of sham-operated rats 
(n=4) and in rats subjected to ipsilateral (n=4) or contralateral (n=4) lesions 
of the VTA with ibotenic acid (1 μg in 0.5 μl) injected directly into the VTA, 
5 days earlier. Twenty four h after senktide injection, R-820 (500 pmol) was 
given i.c.v. in the four groups of SHR.   
 
Histology   
At the end of the experimental protocol, the rats were killed with CO2 
inhalation and then received immediately 0.5 μl of Evans Blue dye (Sigma-
Aldrich Canada) in the VTA. The brains were removed  and fixed with 10% 
(vv-1) buffered formalin (Fisher Scientific Inc., ON, Canada) and 20% (wv-1) 
sucrose until the piece was floating (around 2 weeks) on the surface 
(Carson, 1992). Coronal sections (40 μm, cut on a freezing microtome) were 
mounted on glass slides and stained with cresyl violet for histological 
examination of the microinjections site. The injection site was confirmed by 
the presence of a black spot in the VTA with no evidence of haemorrhage 
or necrosis (Figure 1). 
Drugs and solutions 
The drug target nomenclature conforms to BJP's Guide to Receptors and 
Channels (Alexander et al., 2009). aCSF was purchased from Harvard 
Bioscience (MA, U.S.A.). Succinyl-[Asp6,MePhe8]-SP (6–11) (senktide) 
(MW: 842) was purchased from Bachem Bioscience Inc. (King of Prussia, 
PA, U.S.A.). Raclopride, haloperidol, ibotenic acid and heparin were 
purchased from Sigma-Aldrich Canada and SCH23390 from Tocris 
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(Ellisville, MO, U.S.A.). Haloperidol was dissolved in ethanol and 
dimethylsulphoxide (DMSO) and completed in saline (final solution 
contained 3% ethanol and 0.5% DMSO). SCH23390 and raclopride were 
dissolved in DMSO and completed in saline (final solutions contained 3% 
DMSO).  R-820 (3-indolylcarbonyl-Hyp-Phg-N (Me)-Bzl) (MW: 624.6) was a 
kind gift of late Dr. Jean-Luc Fauchère (Research Institute Servier, Paris, 
France) (Regoli et al., 1994). SB222200 [(S)-( )-N-( -ethylbenzyl)-3-methyl-
2-phenylquinoline-4-carboxamide (MW: 686.7) and its inactive enantiomer 
SB222201 were a donation of Dr. Henry M. Sarau (GlaxoSmithKline, PA, 
U.S.A.) (Sarau et al., 2000). They were dissolved in DMSO and aCSF mixed 
with 2-hydroxypropyl-β-cyclodextrin (Sigma-Aldrich Canada) to obtain the 
desired solution (final solutions contained less than 15% DMSO and 20% 2-
hydroxypropyl-β-cyclodextrin).   
 
Statistical analysis of data  
Results are expressed as the means ± s.e.m. of values obtained from (n) 
rats. Statistical analysis of data was performed with Graph-Pad Prism 
software. Time-course effects were analyzed for statistical significance by a 
two-way analysis of variance (ANOVA) followed by a Bonferroni’s test for 
multiple comparisons. A one-way ANOVA followed by a post hoc 
Dunnett’s test was used for multiple comparisons to the same control 
group or by a post hoc Bonferroni’s test for comparison between groups 
(area under the curve (AUC)). Only probability values (P) less than 0.05 
were considered to be statistically significant. 
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Results 
Cardiovascular responses induced by i.c.v. or VTA injected SB222200 
The tachykinin NK3R antagonist SB222200 (500 pmol) injected i.c.v. caused 
a significant anti-hypertensive effect from 5 to 10 h post-injection in 
comparison with vehicle values in SHR. MAP was back to hypertensive 
levels (184.1 ± 3.8 mmHg) 24 h later (Figure 2a). The anti-hypertension 
induced by SB222200 peaked at 8 h (-42 ± 5.5 mmHg, P<0.001) and was 
associated with a significant bradycardia. In contrast, the inactive 
enantiomer of SB222200 (SB222201) did not affect MAP or HR in 
comparison with vehicle values. 
The injection of SB222200 (500 pmol) into the VTA caused a more rapid 
decrease in MAP, which was significant at 1h and peaked at 3 h post-
injection in SHR. This anti-hypertensive effect of the NK3R antagonist was 
resolved at 8h and was associated with a significant increase in HR at 3h 
and during the remaining recording period of 8h (Figure 2b).  
 
Effects of dopamine antagonists on anti-hypertensive responses induced by 
tachykinin NK3R antagonists. 
Raclopride (0.16 mgkg-1, i.v.) prevented the anti-hypertensive effect of i.c.v. 
SB222200 (500 pmol) and reduced the accompanied bradycardia (Figure 
3a). Conversely, SCH23390 (0.2 mgkg-1, i.v.) caused a small reduction of the 
cardiovascular response to SB222200 (Figure 3a). The anti-hypertensive 
effect mediated by i.c.v. SB222200 was completely recovered 24 h later 
when it was re-injected in the absence of DA antagonists (data not shown). 
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Likewise, the longer lasting anti-hypertensive response and bradycardia 
induced by i.c.v. R-820 (500 pmol) were blocked by raclopride (0.16 mgk-1, 
i.v.) (Figure 3b). A similar treatment with raclopride also prevented the 
more rapid although shorter lasting anti-hypertensive response and the 
accompanied tachycardia elicited by R-820 injected into the VTA (Figure 4). 
Chronic anti-hypertensive effect of i.c.v. R-820 
In SHR, daily i.c.v. injection of R-820 (500 pmol) for 5 days led to a 
persistent decrease of both MAP and HR in comparison with the pre-
administration values. MAP and HR values returned gradually to baseline 
hypertensive values within 48h after the interruption of the treatment with 
R-820 (Figure 5).   
Comparison of the cardiovascular effect of i.c.v. and VTA injected senktide 
The i.c.v. injections of the tachykinin NK3R agonist senktide (10-100 pmol) 
increased significantly but not dose-dependently MAP and HR during the 
first 30-60 min post-injection in SHR. The pressor response was maximal at 
65 pmol while the tachycardiac response was greater in intensity and 
duration at 25 pmol (Figure 6a).  
When senktide (10-100 pmol) was injected directly into the VTA of SHR, it 
caused larger increases of MAP and HR than by i.c.v. (Figure 6b). These 
effects were, however, not dose-dependent and reached maximal values at 
25 pmol for both parameters. The initial depressor response to senktide 
contributes to the smaller AUC for the MAP response at 65 pmol and may 
explain the absence of dose-dependent cardiovascular effect. 
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Effect of tachykinin NK3R antagonist, R-820, on the cardiovascular response to 
senktide in the VTA 
The increases of MAP and HR induced by senktide (25 pmol) injected into 
the VTA were completely abolished by the prior administration into the 
VTA of the NK3R antagonist R-820 (500 pmol, 1h earlier) in SHR (Figure 7). 
The cardiovascular response to senktide was fully recovered 24 h later in 
the absence of R-820 (data not shown). When microinjection of senktide (25 
pmol, n = 6) was made outside the VTA, no cardiovascular effect was 
observed.  Also, no changes of blood pressure occurred after microinjection 
of R-820 (500 pmol, n = 8) outside the VTA (data not shown). 
 
Effects of dopamine receptor antagonists on the pressor response induced by i.c.v. 
senktide  
The dopamine D1R antagonist SCH23390 (0.2 mgkg-1, i.v., 30 min earlier) 
blocked the pressor effect mediated by i.c.v. senktide (65 pmol). In contrast, 
the DA-D2R antagonist raclopride (0.16 mgkg-1, i.v., 30 min earlier) had a 
marginal effect on the pressor response induced by senktide (Figure 8 a, c). 
The same treatment with haloperidol (10 mgkg-1, s.c., 30 min earlier), 
abolished the pressor effect caused by senktide (65 pmol) injected i.c.v. in 
SHR (Figure 8 b, c). The MAP response to senktide was completely 
recovered when it was re-injected alone 24 h after treatment with 
dopamine antagonists (data not shown). 
At the dose used, the systemic administration of raclopride (0.16 mgkg-1, 
i.v.) caused a transient increase of MAP, which was significant in 
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comparison with saline between 5 and 15 min post-injection. SCH23390 (0.2 
mgkg-1, i.v.) had no significant effect on MAP during the first hour post-
injection. Conversely, haloperidol (10 mgkg-1, s.c.) caused an anti-
hypertensive effect which reaches significance from 1h up to 6h post-
injection in comparison with saline (Figure 9). The maximal decrease in 
MAP induced by haloperidol at 3 h (-33 ± 5.5 mmHg, P<0.001) was back to 
hypertensive levels 8 h later (184.1 ± 3.8 mmHg). 
 
Interaction between i.c.v. senktide and VTA SB222200 in SHR.The pressor 
response evoked by i.c.v. senktide (65 pmol) was blocked when SB222200 
(500 pmol) was injected into the ipsilateral VTA, 1h prior to a second 
injection of i.c.v. senktide (Figure 10 a,e). In contrast, when SB222200 was 
injected into the VTA under the same conditions, the pressor response to 
senktide injected i.c.v. on the contralateral side was little affected (Figure 10 
b, f). Moreover, the anti-hypertensive effect which occurred from 1 to 5h 
after VTA injection of SB222200 (500 pmol) was blocked when senktide was 
injected i.c.v. on the ipsilateral side (Figure 10 c, e), yet it was only slightly 
reduced when senktide was injected i.c.v. on the contralateral side (Figure 
10 d, f). This suggests that i.c.v. senktide diffused chiefly to the ipsilateral 
VTA to cause its pressor effect and to prevent the anti-hypertensive effect 
of SB222200. This also suggests that microinjected SB222200 into the VTA 
had limited diffusion to the contralateral VTA. 
Effect of ipsilateral and contralateral lesions of the VTA with ibotenic acid on the 
cardiovascular response to senktide and R-820.   
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The pressor response induced by i.c.v. senktide (65 pmol) in sham-
operated SHR was absent in rats subjected to ipsilateral lesion of the VTA 
with ibotenic acid (Figure 11 a, e). One day after the senktide experiment, 
R-820 (500 pmol) was given i.c.v. to both groups of rats. Only the sham-
operated rats displayed the typical anti-hypertensive response to R-820 
(Figure 11 c, e). Conversely, the pressor response induced by i.c.v. senktide 
(65 pmol) in sham-operated SHR was similar to that observed in rats 
subjected to contralatereal lesion of the VTA with ibotenic acid (Figure 11 
b, f). One day after the senktide experiment, the anti-hypertensive effect of 
i.c.v. R-820 (500 pmol) was very little affected by the contralateral lesion of 
the VTA (Figure 11 d, f). 
 
Discussion 
This study extended our earlier work showing that tachykinin NK3R 
antagonists exert dose-dependent and reversible anti-hypertensive effects 
when injected intracerebrally in SHR (Lessard et al., 2004). The present 
findings demonstrate that this anti-hypertension is mediated by the VTA 
and the mesocorticolimbic DA pathway. This statement is based on four 
arguments: 1- the anti-hypertensive effect of NK3R antagonists injected 
i.c.v. was reproduced with a faster onset when drugs were injected directly 
into the VTA; 2- the cardiovascular responses elicited by i.c.v. or VTA 
administration of NK3R agonist and antagonists were blocked by DA 
antagonists; 3- the i.c.v. pressor effect of the NK3R agonist was prevented 
following inhibition of  NK3R in the ipsilateral VTA, and vice versa, the anti-
hypertensive effect of SB222200 injected into the VTA was blocked by 
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ipsilateral i.c.v injection of senktide; 4- chemical destruction of the 
ipsilateral VTA with ibotenic acid eliminated completely the 
cardiovascular response induced by i.c.v. senktide and R-820. Hence, these 
findings suggest that the VTA and its brain DA projections are of primary 
importance in the cardiovascular effects associated to i.c.v. injection of 
NK3R agonist and antagonist. 
I.c.v. injection of senktide increased HR and blood pressure in 
normotensive rat (Cellier et al., 1997) and guinea-pig (Roccon et al., 1996). 
This cardiovascular response was blocked by the prior i.c.v. injection of the 
NK3R antagonist R-820 in normotensive rat (Cellier et al., 1997) and was 
ascribed to the activation of the sympatho-adrenal system (Nagashima et 
al., 1989; Roccon et al., 1996). The cardiovascular response to senktide in the 
VTA, also blocked by R-820 (present study), was mediated by the 
sympathetic nervous system and the subsequent increase of cardiac output 
as it was abolished by i.v. treatment with atenolol, a β1-adrenoceptor 
antagonist (Deschamps and Couture, 2005). The latter study showed that 
the cardiovascular response to senktide in the VTA was similar to that 
caused by glutamic acid, which is consistent with neuronal cell activation. 
Moreover, the cardiovascular response to central injection of senktide in 
SHR is likely mediated by DA release because it was abolished after 
treatment with SCH23390 and haloperidol. The lack of effect of raclopride 
suggests the involvement of DA-D1R rather than DA-D2R, as reported 
previously in normotensive rats (Deschamps and Couture, 2005). This is 
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congruent with the release of DA in the nucleus accumbens following the 
activation of NK3R by senktide in the VTA (Spooren et al., 2005) and with 
the localization of NK3R on DA neurons in the VTA (Chen et al., 1998; 
Lessard et al., 2007; 2009). 
Findings suggest that tonic activation of NK3R in the VTA enhances the 
release of DA in the mesocorticolimbic system and contributes to high 
blood pressure in SHR. This hypothesis is supported by the normalization 
of high blood pressure under blockade of NK3R in the VTA through a 
mechanism sensitive to DA inhibition. The persisting anti-hypertensive 
effect under the 5-day i.c.v. administration of R-820 suggests that NK3R is 
under constant and chronic tonic activation in SHR. By the same token, this 
experiment also substantiates the use of centrally acting NK3R antagonists 
in the treatment of hypertension in this model. Since the anti-hypertensive 
effect of NK3R antagonists was prevented by raclopride and much less by 
SCH23390, it is concluded that this effect is chiefly mediated by DA-D2R. 
The suggestion of a greater basal release of tachykinins in the 
mesocorticolimbic system of SHR is consistent with the existence of 
endogenous tachykinins in the VTA (Kalivas et al., 1985; Warden and 
Young, 1988; Tamiya et al., 1990; Lu et al., 1998) and the increased 
neurokinin B-like immunoreactive contents in the brain of SHR, the 
putative NK3R endogenous ligand (Nagashima et al., 1989). Since D1R and 
D2R are up-regulated in the nucleus accumbens in SHR (Kirouac and 
Ganguly, 1993; Vaughan et al., 1999), it is tempting to suggest that the tonic 
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activation of NK3R by endogenous tachykinins in the VTA is facilitated by 
a hyperactive DA mesolimbic system. Reciprocally, tonic activation of 
NK3R may contribute to the hyperactivity of the VTA DA neuronal 
pathway and thereby in the maintenance of hypertension in SHR. The 
affinity and densities of specific NK3R binding sites measured in the VTA 
and other midbrain nuclei were, however, not significantly different 
between SHR and WKY (Lessard et al., 2003). 
Because i.c.v. injection of NK3R antagonists had no significant effect on 
resting blood pressure in normotensive rats, it was concluded that brain 
NK3R did not exert a tonic autonomic control of blood pressure in 
normotensive rats (Deschamps and Couture, 2005; Couture et al., 1995; 
Cellier et al., 1997; Lessard et al., 2004). Nevertheless, the mesolimbic DA 
system is involved in diurnal BP and HR regulation (Sei et al., 1999; Sakata 
et al., 2002) and therefore, the VTA may represent an important site of 
action for tachykinins in cardiovascular regulation in normotensive subject. 
Whereas SB222200 and R-820 caused a tachycardia when injected into the 
VTA, both antagonists induced a small bradycardia at the peak of the anti-
hypertensive response upon i.c.v. injection. The occurrence of tachycardia 
in response to a fall of blood pressure suggests that the inhibition of NK3R 
in the VTA did not interfere with the activation of baroreceptors contrarily 
to i.c.v. administration of NK3R antagonists and further suggests that 
inhibition of the cardiac output or baroreflex activity is unlikely the 
mechanism of the anti-hypertension. Although the increase of blood 
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pressure and HR induced by i.c.v. and VTA injected senktide was ascribed 
to the activation of the sympathetic nervous system (Roccon et al., 1996; 
Deschamps and Couture, 2005), the decrease of blood pressure induced by 
i.c.v. injected SB222200 was not associated with changes in plasma 
catecholamines levels in SHR (Lessard et al., 2004). One cannot exclude, 
however, that central tachykinin NK3R antagonists may exert inhibitory 
action on neuronal sympathetic vasomotor tone. 
The dissimilar time-course of the anti-hypertensive effect of R-820 and 
SB222200 was also observed in our previous study (Lessard et al., 2004) and 
may be explained by the different physico-chemical features of these two 
compounds. SB222200, a much more lipophilic molecule than R-820, can 
diffuse more easily into the brain after i.c.v. injection. This could explain 
why SB222200 displays a quicker but less prolonged effect than R-820. 
Peripheral administration of these antagonists at 500 pmol in SHR had no 
effect on blood pressure, supporting a central site of action (Lessard et al., 
2004) that has been identified in the present study as the VTA. 
The anti-hypertensive effect of s.c. administered haloperidol in SHR was 
not shared by selective blockade of D1R and D2R, which caused either no 
effect or a transient pressor response. The non-selectivity of haloperidol 
versus SCH23390 and raclopride for DA receptors and the putative 
inhibition of non DA receptors can account for the pronounced anti-
hypertensive response of haloperidol. Although data of the present study 
obtained with haloperidol support the conclusion drawn with the selective 
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DA antagonist SCH23390 on the cardiovascular effect of senktide, they 
must be cautiously interpreted. The reduction of mean arterial blood 
pressure with haloperidol was also observed in angiotensin II-hypertensive 
rats while the same treatment had no effect in normotensive rats (De Brito 
Gariepy et al., 2010). Haloperidol was suggested as treatment of 
hypertensive crises caused by high-dose amphetamine or 
methamphetamine abuse (Angrist et al., 2001). 
Conclusion 
This neuropharmacological study suggests that tachykinin NK3R located in 
the VTA are subjected to persisting tonic activation which increases 
midbrain DA transmission and thereby contributes to hypertension in 
SHR. Hence, these receptors may represent a therapeutic target in the 
treatment of arterial hypertension. Since NK3R antagonists are proposed as 
putative antipsychotics in the treatment of schizophrenia (Spooren et al., 
2005; Meltzer and Prus, 2006), understanding the functional interaction 
between NK3R and the DA system in the central autonomic control of 
blood pressure is of prime importance. 
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Figure Legends: 
Figure 1: Identification of the VTA as microinjection site following post-
mortem histological examination of microinjected Evans’s blue. A rat was 
considered to be correctly injected when a black spot was seen in the VTA 
without any evidence of haemorrhage or necrosis. Diagram was modified 
from the atlas of Paxinos and Watson (1998). Abbreviations: VTA, ventral 
tegmental area; SNR, substantia nigra reticular; ml, medial lemniscus; 
RMC, red nucleus magnocellular; MS, microinjection site. Scale: 0.5 mm. 
 
Figure 2: Time-course effects on changes in mean arterial blood pressure 
(ΔMAP) and heart rate (ΔHR) induced by i.c.v. (a) or VTA (b) injection of 
500 pmol of SB222200 or its inactive enantiomer SB222201. Areas under the 
curves (AUC) were measured for a period of 0-10 h for i.c.v. and 0-8 h for 
VTA (small insets). Values represent the mean ± s.e.m. of n rats.  Statistical 
comparison to aCSF is indicated by *P<0.05; **P<0.01; ***P<0.001. 
 
Figure 3: Time-course effects on changes in mean arterial blood pressure 
(ΔMAP) and heart rate (ΔHR) induced by i.c.v. injection of (a) SB222200 
(500 pmol) and (b) R-820 (500 pmol) before and 30 min after treatment with 
the DA-D2R antagonist raclopride (0.16 mgkg-1, i.v.) or the DA -D1R 
antagonist SCH23390 (0.2 mgkg-1, i.v.). Areas under the curves (AUC) were 
measured for a period of 0-8 h (SB222200) or 0-72 h (R-820) as shown in 
small insets. Values represent the mean ± s.e.m. of n rats.  Statistical 
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comparison to aCSF values (*) or NK3R antagonist alone (†) is indicated by 
* P<0.05, ** ††P<0.01; *** †††P<0.001. 
 
Figure 4: Time-course effects on changes in mean arterial blood pressure (Δ 
MAP) (a) and heart rate (ΔH) (b) induced by R-820 (500 pmol) injected into 
the VTA before and 30 min after treatment with the DA-D2R antagonist 
raclopride (0.16 mgkg-1, i.v.). Areas under the curves (AUC) were 
measured for a period of 0-5 h (small insets). Values represent the mean ± 
s.e.m. of n rats. Statistical comparison to aCSF values (*) or R-820 (†) is 
indicated by * †P<0.05; ** ††P<0.01; *** †††P<0.001. 
 
Figure 5: Time-course effects on changes in mean arterial blood pressure 
(ΔMAP) and heart rate (ΔHR) induced by i.c.v. injection of 500 pmol R-820, 
once daily for a period of 5 days in SHR. Values represent the mean ± 
s.e.m. of 4 rats. Statistical comparison to pre-injection values is indicated by 
*P<0.05; **P<0.01. 
 
Figure 6: Time-course effects on changes in mean arterial blood pressure 
(ΔMAP) and heart rate (ΔHR) following i.c.v. (a) or VTA (b) injection of 
four increasing doses (10, 25, 65 and 100 pmol) of senktide in SHR. Areas 
under the curves (AUC) were measured for a period of 0-1 h (open bars for 
VTA and closed bars for i.c.v.). Values represent the mean ± s.e.m. of 6 rats 
per injection site. Statistical comparison to aCSF values (*) or i.c.v. (†) is 
indicated by ** ††P<0.01; *** †††P<0.001. 
 
Figure 7: Time-course effects on changes in mean arterial blood pressure 
(ΔMAP) and heart rate (ΔHR) produced by senktide (25 pmol) injected into 
the VTA prior to (first day) and 1 h  after VTA injection of R-820 (second 
day). Each point represents the means ± s.e.m. of 4 rats. Statistical 
comparison to aCSF (*) or senktide (†) values is indicated by * †P<0.05; ** 
††P<0.01; *** †††P<0.001. 
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Figure 8: Time-course effects on changes in mean arterial blood pressure 
(ΔMAP) produced by i.c.v. senktide 65 pmol (baseline: 161±5 mmHg) prior 
to and after treatment with (a) the DA-D1R antagonist SCH23390 (0.2 
mgkg-1 i.v.) and the DA-D2R antagonist raclopride (0.16 mgkg-1 i.v.) 
(baseline: 167±4 mmHg); and (b) the non-selective DA-D2R antagonist 
haloperidol (10 mgkg-1 s.c.) (baseline: 164±2.4 mmHg) in SHR. In (c) are 
shown the Areas under the curves (AUC) measured for a period of 0-1 h. 
Values represent the mean ± s.e.m. of n rats. Statistical comparison to aCSF 
(*) or senktide (†) values is indicated by * †P<0.05; ** ††P<0.01; *** †††P<0.001. 
Figure 9: Time-course effects on changes in mean arterial blood pressure 
(ΔMAP) produced by treatments with the DA-D1R antagonist SCH23390 
(0.2 mgkg-1 i.v.), DA-D2R antagonist raclopride (0.16 mgkg-1 i.v.) and the 
non-selective DA-D2R antagonist haloperidol (10 mgkg-1 s.c.) in SHR. 
Different time scales were used: in (a) (min), and (b) (hours).Values 
represent the mean ± s.e.m. of 4 rats. Statistical comparison to saline is 
indicated by *P<0.05; **P<0.01; ***P<0.001. 
Figure 10: Time-course effects on changes in mean arterial blood pressure 
(Δ MAP) produced by senktide injected i.c.v. on the (a) ipsilateral and (b) 
contralateral side before and after SB222200 (500 pmol) injected into the 
VTA. The anti-hypertensive effect elicited by the VTA injection of SB222200 
(500 pmol) was measured before and after i.c.v. injection of senktide (65 
pmol) on the ipsilateral (c) and contralateral (d) side in SHR. Areas under 
the curves (AUC) for MAP are shown in (e and f). Values represent the 
mean ± s.e.m. of n rats.  Statistical comparison to aCSF (*) and senktide 
alone or SB222200 alone (†) is indicated by * † P<0.05; ** ††P<0.01; *** ††† 
P<0.001.  
 
Figure 11: Time-course effects on changes in mean arterial blood pressure 
(Δ MAP) produced by i.c.v. injected 65 pmol senktide (a, b) or 500 pmol R-
820 (c, d) in SHR which underwent an ipsilateral (a, c) and contralateral (b, 
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d) lesion of the VTA with ibotenic acid (IBO), 5 days earlier or a sham-
operation. Areas under the curves (AUC) for MAP are shown in (e, f). Each 
point represents the mean ± s.e.m of n rats. Statistical comparison to aCSF 
(*) or sham-operated rats (†) is indicated by * †P<0.05; ** ††P<0.01; *** 
†††P<0.001. 
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12.2 Article #2 
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revision of the manuscript.   
 
159 
 
  
Contribution of the central dopaminergic system in the anti-
hypertensive effect of kinin B1 receptor antagonists in two rat models of 
hypertension 
 
 
 
H. De Brito Gariepy a, P. Carayon b, B. Ferrari b, R. Couture a,* 
 
 
 
a Département de Physiologie, Faculté de médecine, Université de 
Montréal, C.P. 6128 Succursale Centre-ville, Montréal, QC, Canada - H3C 
3J7 
b Sanofi-Aventis R&D, 371 Rue du Professeur Blayac, Montpellier, France - 
34184 
 
 
 
Article published in Neuropeptides Vol 44, Issue 2, pages 191 to 198, 2010. 
 
 
 
 
*Corresponding author: 
Tel.: +1 514 343 7060 
Fax: +1 514 343 2111 
 
160 
 
  
Abstract  
 
Kinins are neuroactive peptides that could play a role in central autonomic 
control of blood pressure. Whereas kinin B1R binding sites were increased 
in specific brain areas of spontaneously hypertensive rats (SHR) and 
Angiotensin II (AngII)-hypertensive rats, the contribution of kinin B1R in 
hypertension remains controversial. The aims of the study were to 
determine: a) the effects on mean arterial blood pressure (MAP) of centrally 
and peripherally administered B1R antagonists in SHR (16 weeks) and 
AngII-hypertensive rats (200 ng/kg/min x 2 weeks, s.c.); b) the 
contribution of central dopamine in the effects of SSR240612. The rationale 
is based on the overactivity of the dopaminergic system in hypertension. In 
both models, SSR240612 (1, 5, 10 mg/kg, gavage) reduced dose-
dependently MAP (≥ -75 mmHg at least up to 6-8 h) and this therapeutic 
effect was resolved after 24 h. At the dose of 5 mg/kg, SSR240612-induced 
anti-hypertension was prevented by two dopamine receptor blockers, 
namely raclopride (0.16 mg/kg i.v.) and haloperidol (10 mg/kg s.c.). I.c.v. 
SSR240612 (1μg) decreased rapidly MAP in both models (1-6h) via a 
raclopride sensitive mechanism. In comparison, peripherally acting B1R 
antagonists (R-715 and R-954, 2 mg/kg s.c.) caused shorter and very 
modest decreases of MAP (-20 to -30 mmHg). Centrally or peripherally 
administered B1R antagonists had no effect on MAP in control Wistar-
Kyoto rats. Data provide the first pharmacological evidence that the 
upregulated brain kinin B1R contributes through a central dopaminergic 
mechanism (DA-D2R) to the maintenance of arterial hypertension in 
genetic and experimental animal models of hypertension.  
 
Keywords: Kinin B1R antagonist, blood pressure, dopamine, cardiovascular 
effect. 
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1. Introduction 
Kinins which refer to bradykinin (BK) and kallidin (Lys-BK) are vasoactive 
peptides regulating the vasomotor tone and putative mediators involved in 
the central autonomic control of blood pressure (BP) (Couture and Lindsey, 
2000). These 9-10 amino acid peptides exert their effect through the 
activation of two transmembrane G-protein-coupled receptors denoted as 
B1 and B2. The genes encoding the two receptors (R) have been cloned in 
several animal species and the organisation of the mammalian B1B2 
receptor gene locus was identified (Cayla et al., 2002). The B2R is 
constitutive and mediates most of the biological effects of BK and kallidin. 
However, the B1R has a low level of expression in normal physiological 
conditions, yet it is readily expressed and induced following inflammation, 
tissue injury or in conditions of hyperglycemia/diabetes associated with 
the oxidative stress (Couture and Girolami, 2004; Lungu et al., 2007; Ismael 
et al., 2008). The preferential agonists of the B1R are the C-terminal 
fragments des-Arg9-BK and Lys-des-Arg9-BK (Regoli et al., 2001). This 
receptor is a potential pharmacological target for chronic inflammation and 
various cardiovascular and neurological diseases (Bader et al., 2000; Rodi et 
al., 2005; Leeb-Lundberg et al., 2005). 
 
Recently, we reported that two non-peptide kinin B1R antagonists (LF22-
0542, SSR240612) reversed dose- and time-dependently high systolic BP 
when given acutely while SSR240612 caused a persistent normalization of 
high BP when given chronically to glucose-fed rats, a model of insulin 
resistance (Lungu et al., 2007; Dias et al., 2009). The anti-hypertensive effect 
of these antagonists was most likely centrally mediated because R-715 
(AcLys [D-ßNal7, Ile8] des-Arg9-BK), a peptide B1R antagonist, which does 
not pass the blood-brain barrier, did not alter BP (Lungu et al., 2007). 
Nevertheless, the role of B1R in hypertension remains controversial. 
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Martins et al. (1991) reported that neither the B1R agonist des-Arg9-BK nor 
the B1R antagonist Leu8-des-Arg9-BK injected into the fourth ventricle 
altered BP in spontaneously hypertensive rat (SHR) or Wistar-Kyoto rat 
(WKY). In contrast, Alvarez et al. (1992) reported that the same antagonist 
injected into the lateral ventricle (i.c.v.) caused a long lasting reduction in 
BP and heart rate (HR) in SHR but not in WKY. Emanueli et al. (1999) 
reported that i.c.v. activation of B1R in SHR and WKY evokes increases in 
BP, while i.c.v. injection of R-715 causes a mild decrease of BP (-14 mmHg) 
within 15 min in SHR. The latest findings were, however, not reproduced 
with the same peptide B1R agonist and antagonist in SHR (Cloutier et al., 
2004).  
 
Studies by autoradiography showed elevated densities of B1R binding sites 
in cortical areas, thalamic regions, amygdala and hippocampus, and in 
some pressor-related hypothalamic areas of 16-week-old SHR, such as 
dorsal hypothalamic area and ventromedial hypothalamic nucleus (de 
Wardener, 2001; Cloutier et al., 2004). Densities of B1R binding sites were 
very low in all examined brain structures in young SHR, and only small 
differences were found between SHR and WKY at the age of 8 weeks 
(Cloutier et al., 2004). This is consistent with increased B1R mRNA 
expression in the hypothalamus of 12- to 13-week-old SHR (Qadri et al., 
2002).  
 
In the model of hypertension induced by a 2-week treatment with 
Angiotensin II (AngII), B1R binding sites were markedly increased in the 
spinal cord (Petcu et al., 2005) and in some specific brain regions (SN, 
septum, posterodorsal tegmental nucleus and temporal cortex) (De Brito 
Pereira et al., 2008). The inhibition of the oxidative stress with a diet 
supplemented with alpha-lipoic acid reversed the up-regulation of B1R, 
arterial hypertension and the increased production of vascular superoxide 
anion, suggesting that B1R is induced by the oxidative stress and 
contributes to hypertension in this model (Petcu et al., 2005). 
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The present study was undertaken to determine whether or not the anti-
hypertensive effect of the B1R antagonist SSR240612 seen in glucose-fed 
rats could also be reproduced in SHR and AngII-treated rats, two classical 
models of hypertension. In order to determine whether the anti-
hypertension is centrally or peripherally mediated, BP effects of SSR240612 
administered by gavage and i.c.v. were compared, and two peptide 
antagonists (R-715 and R-954), which do not pass the blood brain barrier 
(Regoli et al., 2001), were tested. It was recently found that brain dopamine 
D2 receptor (DA-D2R) is involved in the anti-hypertensive effect of 
tachykinin NK-3R antagonists in SHR and AngII-hypertensive rats (De 
Brito Pereira and Couture 2007). This is congruent with the increased 
central dopaminergic activity reported in SHR (Amenta et al., 2001). Hence, 
the contribution of central DA in the anti-hypertensive effect of SSR240612 
was examined as a putative mechanism. 
 
2. Materials and methods 
2.1. Animal source and care 
Male SHR (15-16 weeks) and age-matched WKY (200-225g) were 
purchased one week prior to experiments from Charles River (St Constant, 
Québec, Canada). They were housed two per cage under a 12 h light-dark 
cycle in a room with controlled temperature (22°C) and humidity (40%) 
with food (Charles River Rodent) and tap water available ad libitum. The 
care of animals and research protocols conformed to the guiding principles 
for animal experimentation as enunciated by the Canadian Council on 
Animal Care and approved by the Animal Care Committee of our 
University. 
 
2.2. Surgery 
Under isoflurane anesthesia, WKY was implanted subcutaneously with an 
osmotic mini pump (Alzet 2002, Alza Corporation, Palo Alto, CA, USA) to 
deliver AngII (200 ng/kg/min) for 14 days as described previously 
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(Laplante et al., 2003). Control rats were sham-operated WKY having no 
implanted mini pump. Ten days later, rats were anesthetized with 
isoflurane and an i.c.v. guide cannula was implanted into the left lateral 
brain ventricle as described earlier (Lessard et al., 2004). Four days later, 
rats were reanesthetised and a catheter (PE-10 connected to PE-60) was 
inserting into the abdominal aorta through the femoral artery for direct BP 
recording and exteriorized at the back of the neck. Under similar 
procedures, i.c.v. and vascular catheters were implanted in SHR and 
control WKY. Before each surgery, the animals received the antibiotics 
trimethoprime and sulphadiazine (Tribissen 24%, 30 mg/kg, s.c., Schering 
Canada Inc., Pointe Claire, Québec, Canada) and an analgesic drug 
(Anafen, 10 mg/kg, s.c., Merial Canada Inc., Baie d’Urfé, Québec, Canada). 
Thereafter, the rats were allowed to recover in individual plastic cages (40 
cm X 23 cm X 20 cm) and housed in the same controlled conditions. 
Experimental protocols were initiated 24 after the intravascular surgery, in 
freely behaving rats. 
 
2.3. Measurement of blood pressure and i.c.v. injections 
Rats were transported to an isolated and quiet testing room where only the 
experimenter had access. They remained in their resident cage and had free 
access to food and water. One hour after their transportation to the testing 
room, BP was recorded on a high-performance data acquisition system 
PowerLab 8/30 with LabChart Pro ML870P and ML228 Bridge Amp 
(ADInstruments Inc, Colorado Springs, CO, USA). Mean arterial blood 
pressure (MAP) was calculated from systolic (S) and diastolic (D) blood 
pressure values ((S – D)/3 + D = MAP). 
 
I.c.v. injections were made when BP was stable; a 31 G stainless-steel 
injector connected to a Standard Syringe 5 μl (Fisher Scientific Ltd, 
Montréal, Québec, Canada) with PE-10 tubing was inserted into the 
cannula-guide without handling the rat. The injector was removed from 
the guide cannula 1 min after injection to prevent any possible leakage of 
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the injectate (Cloutier et al., 2004). The correct position of the i.c.v. catheter 
was verified by post-mortem examination at the end of experiment. 
 
2.4. Experimental protocols  
2.4.1. Experiment 1: effect of orally administered SSR240612   
AngII-treated rats and SHR received by gavage the B1R antagonist 
SSR240612 (1, 5 and 10 mg/kg) and BP was measured for up to 6-8 h. Rats 
were reconnected 24 h later to see if BP was back to baseline values. They 
received first a single dose of 5 mg/kg and 24-48h later, the dose of 10 
mg/kg.  The dose of 1 mg/kg was given to a separate group of AngII-
treated rats and SHR. Comparison was made to vehicle values (similar 
volume of SSR240612 vehicle given by gavage) and to control WKY that 
received by gavage 5 mg/kg SSR240612. 
2.4.2. Experiment 2: effects of SSR240612 in the presence of dopamine receptor 
antagonists   
Groups of AngII-treated rats and SHR received by gavage SSR240612 (5 
mg/kg) and the effect on BP was recorded continuously for a period of 8h.  
The reversibility of the B1R antagonist effect on BP was assessed 24h later. 
Then rats received an i.v. injection of the DA-D2R antagonist raclopride 
(0.16mg/kg), 30 min prior to assessing again the effect of SSR240612 (5 
mg/kg) on BP. Raclopride was injected alone 24 h later to assess its direct 
effect on BP.  Control WKY rats received only raclopride at the same dose. 
Groups of AngII-treated rats and SHR received by gavage SSR240612 (5 
mg/kg) and the effect on BP was measured continuously for a period of 6-
8h. The reversibility of the B1R antagonist effect on BP was assessed 24h 
later. Then rats were treated subcutaneously (s.c.) with the dopamine 
antagonist haloperidol (10 mg/kg) 30 min prior to assessing again the 
effect of SSR240612 (5 mg/kg) on BP. On the subsequent day, SSR240612 (5 
mg/kg) was re-administered to confirm the reversibility of any blockade 
observed in the presence of haloperidol on the previous day. The 
dopamine antagonist haloperidol (10 mg/kg) was injected alone 24 h later 
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to assess its direct cardiovascular effect. The same treatment with 
haloperidol was given to control WKY. 
 
2.4.3. Experiment 3: effect of i.c.v. administered SSR240612   
I.c.v. injections in AngII-treated rats, SHR and control WKY were initiated 
with an injection of aCSF; this was followed 60 min later by a single dose of 
kinin B1R antagonist SSR240612 (1μg/μl) followed by 4 μl volume of aCSF, 
which corresponds to the void volume of the catheter. BP was measured 
continuously for a period of 6h post-injection. The following day, rats 
received an i.v. injection of the DA-D2R antagonist raclopride (0.16mg/kg), 
30 min prior to assessing the effect of SSR240612 (5 mg/kg) on BP. Baseline 
BP was recorded 24h later. Rats which received i.c.v. injection did not 
receive SSR240612 by gavage. 
 
2.4.4. Experiment 4: peripheral effects of R-715 and R-954  
AngII-treated rats, SHR and their control WKY received the peptide B1R 
antagonist R-954 (2 mg/kg, s.c.) and the effect on BP was measured for up 
to 10-12 h post-injection. On the following day, the same rats received R-
715 (2 mg/kg, s.c.) and the BP was recorded for up to 10-12 h post-
injection. 
 
2.5. Drugs and solutions 
aCSF was purchased from Harvard Bioscience (Massachusetts, U.S.A.) and 
Angiotensin II from Sigma-Aldrich Canada. SSR240612 [(2R)-2-[((3R)-3-
(1,3-benzodioxol-5-yl)-3-{[(6-methoxy-2- 
naphthyl)sulfonyl]amino}propanoyl)amino]-3-(4-{[2R,6S)-2,6 
dimethylpiperidinyl]methyl}phenyl)-N-isopropyl-N-methylpropanamide 
hydrochloride] (Gougat et al., 2004) was synthesized by Sanofi-Aventis 
(Montpellier, France). It was dissolved in dimethylsulphoxide (0.5%), and 
then ethanol (5%) and Tween-80 (5%) were added in this sequence and 
completed with distilled water (30mg/kg) (Dias et al., 2007).  R-715 
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(AcLys[D-ßNal7,Ile8] des-Arg9-BK and R-954 (Ac-Orn-[Oic2, α-MePhe5, D-
βNal7, Ile8]-desArg9-BK) were provided by Dr. Fernand Gobeil 
(Department of Pharmacology, Faculty of Medicine, Université de 
Sherbrooke, Sherbrooke, Québec, Canada) and dissolved in saline. 
Raclopride (selective DA-D2R antagonist) used at 0.16 mg/kg (Millan et 
al., 1998) and haloperidol (non selective DA-D2R antagonist) used at 
10mg/kg (Backhouse et al., 1982) were purchased from Sigma-Aldrich 
Canada. Raclopride was dissolved in DMSO and completed in saline (final 
solution contains 3% DMSO) while haloperidol was dissolved in ethanol 
and DMSO and completed in saline (final solution contains 3% ethanol and 
0.5% DMSO). Haloperidol has high affinity for the DA-D2R (Miyamoto et 
al., 2005) and for sigma 1 and sigma 2 receptors (Hashimoto and Ishiwata 
2006) whereas it shows lower affinity for DA-D1, D3 or D4 receptors, 
serotonin 2A receptor, and α1 adrenergic receptor (Miyamoto et al., 2005). 
 
2.6. Statistical analysis of data 
Results are expressed as means ± s.e.m. of values obtained from (n) rats. 
Statistical analysis of data was performed with Graph-Pad Prism software. 
Time course effects were analyzed for statistical significance by a two-way 
analysis of variance (ANOVA) followed by a Bonferroni test for multiple 
comparisons. A one-way ANOVA followed by a post hoc Dunnett's test was 
used for multiple comparisons to the same control group (maximal values 
and area under the curve (AUC). Only probability values (P) less than 0.05 
was considered to be statistically significant. 
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3. Results 
 
3.1. Anti-hypertensive effect caused by SSR240612 in AngII-treated rats 
AngII-induced hypertension (MAP = 187.9 ± 6.4 mmHg, n=17) was 
significantly reversed to hypotensive values (77.2 ± 4.8 mmHg) by the kinin 
B1R antagonist SSR240612 (5 and 10 mg/kg) at 3 and 6 h post-gavage. The 
response was resolved at 24 h. When the AUC was taken into account, the 
dose of 1mg/kg SSR240612 produced a small but significant depressor 
effect when compared to vehicle (Fig. 1a, c). In contrast, SSR240612 
(5mg/kg) failed to cause significant changes in MAP in control WKY.  
3.2. Anti-hypertensive effect caused by SSR240612 in SHR 
SSR240612 (1, 5 and 10 mg/kg) dose-dependently decreased MAP between 
1 and 6h post-gavage in SHR when compared to vehicle (Fig 2a,c). High 
MAP in SHR (187.2 ± 4.8 mmHg, n = 5) was reduced by 1 mg/kg (167.2 ± 
4.6 mmHg) at 3h and normalized by 5 mg/kg (115.7 ± 7.6 mmHg) between 
3 and 6h post-gavage.  
 
3.3. Blockade of the anti-hypertensive effect caused by SSR240612 in both animal 
models 
The anti-hypertensive effect of SSR240612 (5mg/kg) from 1 to 8h post-
gavage was significantly blocked by the DA-D2R antagonist raclopride 
(0.16mg/kg, i.v.) administered 30 min earlier in both AngII-treated rats 
(Fig. 1b,d) and SHR (Fig. 2b,d). Whereas raclopride had no significant 
effect on MAP in AngII-treated rats and control WKY (Fig. 1b, d), the DA-
D2R antagonist enhanced significantly MAP in SHR (Fig. 2b, d) during the 
recording period of 6h. 
The anti-hypertensive response to SSR240612 (5 mg/kg) was significantly 
reduced by haloperidol (10 mg/kg, s.c.) administered 30 min earlier in 
AngII-treated rats (Fig. 3 a, c) and SHR (Fig. 3b, d). When SSR240612 was 
re-administered alone 24h after haloperidol treatment, the anti-
hypertensive effect of SSR240612 was similar to that measured on the first 
day in the absence of haloperidol (data not shown). Haloperidol (10 
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mg/kg, s.c.) had a direct inhibitory effect on MAP in both AngII-treated 
rats and SHR (Fig. 3). However, the same treatment with haloperidol in 
control WKY had no significant effect on MAP.  
 
3.4. Anti-hypertensive effect induced by i.c.v. injection of SSR240612 
When SSR240612 was injected directly into the left cerebral ventricle at a 
dose of 1μg, it caused a significant reduction of MAP in both AngII-treated 
rats and SHR (Fig. 4). The effect was significant at 1 h post-injection and 
lasted during the whole recording period of 6 h; all rats had returned to 
their hypertensive state 24h later. The anti-hypertensive response induced 
by i.c.v. SSR240612 was significantly reduced by raclopride (0.16 mg/kg, 
i.v.) given 30 min earlier in both models of hypertension (Fig. 4).   
 
3.5. Changes of MAP induced by R-715 and R-954 
In AngII-treated rats (Fig. 5a, c) and SHR (Fig. 5 b, d) both B1R antagonists 
R-954 and R-715 (2mg/kg, s.c.) evoked a modest (-20 to -30 mmHg) but 
significant decrease in MAP when AUC values were compared to vehicle. 
This effect was seen between 1 and 6-8h post-injection. The same 
treatments with R-954 and R-715 in control WKY had no significant effect 
on MAP.   
 
4. Discussion 
The present findings show that SSR240612 caused a pronounced anti-
hypertensive effect in SHR and AngII-treated rats through a central 
mechanism involving DA-D2R. This hypothesis is supported by the 
following observations: 1- the blockade of peripheral B1R with R-954 and 
R-715 caused a less striking decrease of MAP; 2- the anti-hypertensive 
effect of SSR240612 is reproduced when injected directly in the brain 
ventricles; 3- both the systemic and i.c.v. anti-hypertensive effects of 
SSR240612 are prevented by raclopride or haloperidol. Hence, our data 
suggest that B1R may contribute to the overactivity of the DA system 
reported in SHR (van den Buuse, 1997). This conclusion can be extended to 
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the model of AngII-induced hypertension in which raclopride and 
haloperidol reversed the anti-hypertensive effect of SSR240612. Therefore, 
the anti-hypertensive effect of B1R antagonists is not restricted to the 
model of insulin resistance induced by high glucose feeding (Lungu et al., 
2007; Dias et al., 2009) and can be generalised to classical models of 
hypertension. 
SSR240612 is a highly potent, selective non-peptide antagonist of the B1R 
in all species tested (rat, mouse, rabbit and human) and is orally active. The 
selectivity for B1R versus B2R was in the range of 500- to 1000-fold and was 
found inactive when tested over 100 receptor-binding, ion channel-binding, 
and enzyme assays including dopamine DA-D1R and DA-D2R (Gougat et 
al., 2004). Therefore the anti-hypertensive effect of SSR240612 in SHR and 
AngII-treated rats is unlikely a direct interaction with central DA receptors. 
SSR240612 was inactive on blood pressure in normotensive control WKY 
rats which do not express a significant level of B1R. This is a strong 
indication that SSR240612 interacts only with B1R when sufficiently 
expressed as in the present models of hypertension. Since the anti-
hypertensive effect of SSR240612 is lost when DA-D2R is blocked with 
raclopride or haloperidol, it is reasonable to suggest that SSR240612 
reverses hypertension by reducing the overactivation of central DA-D2R 
mediated by B1R. The tonic activation of DA neurons through B1R can be 
direct or indirect through the release of other central neuromediators. 
Electrophysiological studies in addition to immunocytochemical co-
localization of B1R on DA neurons (terminals, dendrites and/or perikarya) 
are compelling to define the exact mechanism by which SSR240612 acts as 
anti-hypertensive drug.  
Although B1R is up-regulated in specific brain areas of SHR and AngII-
induced hypertension (see Introduction), the possibility that endogenous 
B1R ligands are increased in hypertension is still unknown. Nevertheless, 
higher levels of kallikrein activity were detected in the cerebrospinal fluid 
of SHR and desoxycorticosterone-acetate-salt hypertensive rats in 
comparison with their normotensive controls (Khan et al., 1993; 1995). 
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Similarly, kininogen was found significantly increased in CSF of SHR 
(Alvarez et al., 1992). In young and adult SHR, most studies showed that 
kinin concentrations in CSF and in specific areas (hypothalamus and 
septum) are significantly larger than those of age-matched normotensive 
WKY (reviewed by Couture and Lindsey, 2000). The expression of B2R is 
also significantly enhanced in the brain and spinal cord of SHR and 
contributes to the hypersensitivity of the cardiovascular response to BK 
(Cloutier et al., 2002; Ongali et al., 2003; Cloutier et al., 2004). Taken 
together, data suggest that the activity of the central kallikrein-kinin system 
is increased in hypertension. 
 
To investigate the importance of kinin B1R in central regulation of BP, we 
used a pharmacological approach. Discrepancy between earlier studies 
regarding the central anti-hypertensive effect of B1R antagonists in SHR 
(see Introduction) can be related to various factors and experimental 
conditions, including the recording period of BP and the physico-chemical 
features of the antagonists. For instance, the lipophilic non-peptide 
SSR240612 is expected to have a greater brain tissue diffusion and 
distribution than the previously used peptide antagonists (Leu8-des-Arg9-
BK and R-715) whose effect might be limited to B1R located around the 
circumventricular regions upon i.c.v. administration. The reduction of BP 
induced by i.c.v. SSR240612 displayed a slow onset and occurred after 30 
min post-injection and was no longer seen when rats were recorded again 
24h later. Thus the 1 to 6h post-injection window might have been missed 
in our earlier study using R-715 as we expected to see an acute effect within 
30 min on baseline BP (Cloutier et al., 2004). Indeed, the mild anti-
hypertensive effect reported earlier with R-715 by Emanueli et al., (1999) 
was seen within the first minute post-i.c.v. injection and was maximal at 15 
min. 
 
Central DA activity is altered in SHR in comparison with WKY and the role 
of central DA in the development of hypertension has been highlighted 
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(van den Buuse, 1991; 1997). An up-regulation of dopamine D1R and D2R 
in the caudate-putamen and nucleus accumbens, one major neuronal 
projection of the ventral tegmental area, was reported in young SHR 
(Kirouac and Ganguly, 1993; Vaughan et al., 1999). Furthermore, D2R 
mRNA expression was found enhanced in the SN of young and old SHR 
(Vaughan et al., 1999), a region of the nigrostriatal system where B1R 
binding sites were significantly increased in comparison with WKY (De 
Brito Pereira et al., 2008). Lesion of the nigrostriatal DA pathway attenuates 
the development of hypertension in young SHR (van den Buuse et al., 
1991; Linthorst et al., 1994) and electrical or chemical stimulation of pars 
compacta of SN leads to increases of heart rate, BP and striatal DA levels in 
anesthetized rats (Lin and Yang, 1994). Whereas activation of the brain pre-
synaptic DA-D2R decreased BP, stimulation of post-synaptic DA-D2R 
increased BP (Jose et al., 1999).Thus the mesolimbic and nigrostriatal 
dopaminergic systems may represent strategic sites for the anti-
hypertensive effects of B1R antagonist. This would be reminiscent of the 
role played by tachykinins on these systems in the autonomic control of BP 
and in the maintenance of hypertension in SHR (Lessard et al., 2003; 
Deschamps and Couture, 2005).  
 
Whereas the selective blockade of DA-D2R with raclopride produced a 
slight vasopressor response that reached significance only in SHR, 
haloperidol was effective in reversing high blood pressure in SHR and 
AngII-treated rats. The non-selectivity of haloperidol versus raclopride for 
DA receptors is likely to exert a more complete blockade of DA action 
which can account for its pronounced anti-hypertensive response. This 
supports the overactivity of the DA system in hypertension as both DA 
antagonists were inactive in normotensive control WKY. 
 
In conclusion, data provide the first pharmacological evidence that the 
upregulated cerebral kinin B1R contributes through a central dopaminergic 
mechanism (DA-D2R) to the maintenance of arterial hypertension in 
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genetic and experimental animal models of hypertension. The findings 
with R-715 and R-954 which unlikely cross the blood-brain barrier point to 
a small contribution of peripheral B1R in hypertension. Hence, centrally 
active non-peptide B1R antagonists with oral bioavailability could be of 
therapeutic value in the treatment of arterial hypertension. 
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Figures Legends 
Fig. 1: Time-course effects on change in mean arterial blood pressure 
(ΔMAP) induced by three doses of SSR240612 (1, 5 and 10 mg/kg, gavage) 
in AngII-treated rats (a). Raclopride (0.16 mg/kg, i.v.) was injected alone or 
30 min prior to 5 mg/kg SSR240612 to assess the participation of DA-D2R 
in the anti-hypertensive effect of SSR240612 (b). Control WKY also received 
5 mg/kg SSR240612 (a) or 0.16 mg/kg raclopride (b). Area under the 
curves (AUC) was measured for a period of 0-6 h (c) or 0-8h (d). Data are 
means ± s.e.m. of values obtained from (n) rats. Statistical comparison with 
vehicle values (*) or SSR240612 (†) is indicated by **P<0.01; ***, †††P<0.001.  
 
Fig. 2: Time-course effects on change in mean arterial blood pressure 
(ΔMAP) induced by three doses of SSR240612 (1, 5 and 10 mg/kg, gavage) 
in SHR (a). Raclopride (0.16 mg/kg, i.v.) was injected alone or 30 min prior 
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to 5 mg/kg SSR240612 to assess the participation of DA-D2R in the anti-
hypertensive effect of SSR240612 (b). Control WKY also received 5 mg/kg 
SSR240612 (see Fig 1a) or 0.16 mg/kg raclopride (b). Area under the curves 
(AUC) was measured for a period of 0-6 h (c,d). Data are means ± s.e.m. of 
values obtained from (n) rats. Statistical comparison with vehicle values (*) 
or SSR240612 (†) is indicated by *P<0.05; **P<0.01; ***, †††P<0.001. 
 
Fig. 3: Time-course effects on change in mean arterial blood pressure 
(ΔMAP) induced by SSR240612 (5mg/kg, gavage) in AngII-treated rats (a) 
and SHR (b) before and 30 min after administration of the dopamine 
antagonist haloperidol (10 mg/kg, s.c). Hypertensive rats and control WKY 
also received 10 mg/kg haloperidol alone. Area under the curves (AUC) 
was measured for a period of 0-8 h (c) or 0-6 h (d). Data are means ± s.e.m. 
of values obtained from (n) rats. Statistical comparison with vehicle values 
(*) or SSR240612 (†) is indicated by *P<0.05;    **, ††P<0.01; ***, †††P<0.001.  
 
Fig. 4: Time-course effects on change in mean arterial blood pressure 
(ΔMAP) induced by SSR240612 (1μg, i.c.v.) in AngII-treated rats (a) and 
SHR (b) before and 30 min after administration of the DA-D2R antagonist 
raclopride (0.16 mg/kg, i.v.). Control WKY also received i.c.v. SSR240612. 
Raclopride alone was assessed in previous figures. Area under the curves 
(AUC) was measured for a period of 0-6 h (c, d). Data are means ± s.e.m. of 
values obtained from (n) rats. Statistical comparison with aCSF values (*) or 
SSR240612 (†) is indicated by *, †P<0.05; **, ††P<0.01; ***, †††P<0.001.  
 
Fig.5: Time-course effects on change in mean arterial blood pressure 
(ΔMAP) induced by R-715 and R-954 (2mg/kg, s.c.) in AngII-treated rats 
(a) and SHR (b). Effects of both B1R antagonists were also tested in control 
WKY (a). Area under the curves (AUC) was measured for a period of 0-10 
h (c) or 0-12 h (d). Data are means ± s.e.m. of values obtained from (n) rats. 
Statistical comparison with vehicle values (*) is indicated by **P<0.01; 
***P<0.001.
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Summary  
Background and purpose. Our laboratory recently reported a role for brain 
kinin B1 receptor (B1R) in the maintenance of hypertension in 
spontaneously hypertensive rat (SHR) and experimental hypertension 
induced by Angiotensin II (Ang II). This study aims at determining 
whether activation of B1R can enhance behavioural activity in these two rat 
models of hypertension and at identifying the mechanism. 
 
Experimental approach. SHR (16 weeks) and Ang II-hypertensive rats (200 
ng∙kg-1 min-1 x 2 weeks, s.c.) were i.c.v. injected with the selective B1R 
agonist Sar[DPhe8][des-Arg9]BK (1 μg) before and after treatment with 
antagonists (10 μg i.c.v. or otherwise stated) for B1 (SSR240612), tachykinin 
NK1 (RP67580), glutamate NMDA (DL-AP5), dopamine D1 (SCH23390, 0.2 
mg∙kg-1 s.c.) and D2 (Raclopride, 0.16 mg∙kg-1 s.c.) receptors or inhibitors 
(10 μg) of NOS (L-NNA) and iNOS (1400W). B1R was also measured in 
selected brain areas by qRT-PCR. Wistar Kyoto rats (WKY) served as 
controls.  
 
Key results. Whereas the B1R agonist had no effect in WKY, it induced 
behavioural manifestations in both models of hypertension (face washing, 
sniffing, head scratching, rearing, teeth chattering, grooming, digging, 
licking, wet dog shake). These responses were prevented by all 
antagonists/inhibitors tested, while 1400W had a less inhibitory effect on 
most behaviors. Compared with controls, B1R mRNA levels were 
markedly enhanced in hypothalamus, ventral tegmental area and nucleus 
accumbens of SHR and Ang II-treated rats.  
 
Conclusion and implications: Activation of the upregulated cerebral kinin 
B1R enhanced nocifensive behaviors in hypertensive rats through the 
release of several mediators, notably substance P, glutamate, dopamine 
and NO.  
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area; WKY, Wistar Kyoto rat 
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Introduction 
Kinins are vaso- and neuro- active regulatory peptides which exert central 
and peripheral effects through the activation of two G-protein-coupled 
receptors (R) denoted as B1 and B2  (Regoli et al., 1998). Bradykinin (BK) and 
Lys-BK are the preferential agonists at the B2R which is widely and 
constitutively expressed in various cell types. The C-terminal kininase I 
metabolites des-Arg9-BK and Lys-des-Arg9-BK are the active endogenous 
agonists at B1R which is virtually absent or weakly expressed in healthy 
tissues. The B1R is de novo synthesised under pathological situations 
(Calixto et al., 2004; Rodi et al., 2005). Several authors have reported that 
Angiotensin II (Ang II) enhances the expression of B1R in cardiovascular 
tissues and in cultured vascular smooth muscle cells   (Ceravolo et al., 2007; 
Fernandes et al., 2006; Kintsurashvili et al., 2001). The induction of B1R in 
vascular smooth muscle cells was ascribed to the activation of AT1 receptor 
that enhances the production of reactive oxygen species and the 
subsequent activation of phosphatidyinositol-3 kinase and the 
transcriptional nuclear factor-kappa B (NF-κB) (Morand-Contant et al., 
2010). NF-κB is the transcription factor that allows the increased expression 
of B1R (Leeb-Lundberg et al., 2005). The induction of B1R by Ang II is 
reminiscent of the increased B1R mRNA levels observed in the heart and 
renal tissues of mice in renin/angiotensin-dependent renovascular 
hypertension (Duka et al., 2001). Autoradiography studies have also 
documented elevated densities of B1R binding sites in the spinal cord 
(Petcu et al., 2005) and specific brain areas (substantia nigra, septum, 
posterodorsal tegmental nucleus and temporal cortex) (De Brito Pereira et 
al., 2008) in the rat model of hypertension induced by a 2-week treatment 
with Ang II. Enhanced densities of B1R binding sites were also reported by 
autoradiography in cortex, thalamus, amygdala, hippocampus and 
hypothalamus of 16-week old SHR (Cloutier et al., 2004; de Wardener, 
2001). This is consistent with the increased B1R mRNA level in the 
hypothalamus of 12- to 13-week old SHR (Qadri et al., 2002). 
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The present study was undertaken to determine whether the increased 
expression of B1R binding sites are functional receptors in the brain of SHR 
and Ang II-hypertensive rats. This question was addressed by the 
measurement of changes of behavior induced by intracerebroventricular 
(i.c.v.) injection of Sar[DPhe8][des-Arg9]BK, a stable and selective B1R 
agonist (Drapeau et al., 1991). The putative contribution of DA and other 
central mediators (substance P (SP), glutamate, nitric oxide (NO)) in B1R-
induced behavioural activity was determined using a pharmacologic 
approach with selective receptor antagonists and enzymatic inhibitors. The 
increased expression of B1R at mRNA level was also ascertained in selected 
brain regions related to behavior and the mesolimbic dopaminergic system. 
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Materials and Methods 
Animal source and care 
Male SHR (16 weeks) and age-matched Wistar Kyoto rats (WKY) were 
purchased one week prior to experiments from Charles River (St. Constant, 
Québec, Canada) and housed two per cage under pathogen-free conditions 
on a 12:12-h light-dark cycle in a room maintained at 22°C and 40% 
humidity. Food (Charles River Rodent) and tap water were accessible ad 
libitum. All research procedures and the care of the animals were in 
compliance with the guiding principles for animal experimentation as 
enunciated by the Canadian Council on Animal Care and were approved 
by the Animal Care Committee of our University. 
 
Animal models and surgery  
Under isoflurane anesthesia, WKY were implanted subcutaneously with a 
micro-osmotic pump (Alzet 2002, Alza Corporation, Palo Alto, CA, USA) to 
deliver Ang II (200 ng∙kg-1 min-1 in saline) for 14 days as described 
previously (Petcu et al., 2005). Control rats were sham-operated WKY. An 
i.c.v. guide cannula was implanted into the left lateral brain ventricle in 
isoflurane anesthetised WKY, SHR and 10-day Ang II-treated rats as 
described earlier (Cloutier et al., 2004). During surgery, the animals 
received the antibiotics Trimethoprim and Sulphadiazine (Tribrissen 24%, 
0.05 ml∙kg-1, s.c., Schering Canada Inc., Pointe Claire, Québec, Canada) and 
the analgesic Ketoprophen (Anafen, 10 mg∙kg-1, s.c., Merial Canada Inc., 
Baie d’Urfé, Québec, Canada). Thereafter, the rats were placed in custom-
made plastic cages (L x W x H, 40 x 23 x 20 cm) and housed in the same 
controlled conditions. Experimental protocols were initiated 4-5 days after 
i.c.v. implantation in freely behaving rats. I.c.v. implantations were 
confirmed in all rats used in the study after post-mortem examination.  
 
Measurement of behavior and i.c.v. injections  
The behavioural activity was measured as previously reported in a quiet 
testing room where only the experimenter had access (Deschamps and 
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Couture, 2005; Picard et al., 1994). Rats remained in their resident cage and 
the food and water were removed during the protocol. Briefly, during 
every consecutive period of 15 s, a score of 1 or 0 was given depending on 
whether the animal showed the specific type of behavior or not, whatever 
its frequency, intensity or duration during that period. Summation of 
scores for the first 30 min period following the i.c.v. injection provided the 
behavioural scores for face washing, sniffing, head scratching, digging, 
grooming, rearing, licking and teeth chattering. The maximal theoretical 
score was 120 (15 s intervals x 30 min). The wet dog shake was measured 
according to the number of episodes or frequency during the first 30 min 
period, whatever the intensity. 
For i.c.v. injection, a 31GA stainless-steel injector was connected to the 
guide cannula. The other end was connected to a Hamilton microsyringe 
5μl (Fisher Scientific Ltd, Montréal, Québec, Canada) with a PE-10 tubing. 
Injection was made i.c.v. in undisturbed freely behaving rats. The injector 
was removed from the guide cannula 1 min after injection to prevent any 
possible leakage of the injectate. All solutions were freshly prepared and 
injected in a volume of 1 μl over a period of 1 min.  
 
Experimental protocols 
In a first series of experiments, SHR, Ang II-treated rats and age-matched 
sham-operated rats received by i.c.v. a microinjection of artificial 
cerebrospinal fluid (aCSF) followed 60 min later by a single dose of 
Sar[DPhe8][des-Arg9]BK (1 μg or 10 μg). This protocol served at 
determining the behavioural effects of 1 and 10 μg of B1R agonist in the two 
models of hypertension and their normotensive counterpart.  
In a second series of experiments, SHR and Ang II-treated rats were 
separated in 8 groups of 6 rats treated as follows: Group 1, B1R antagonist 
SSR240612 (10 μg i.c.v.); Group 2, SSR240612 (10 mg∙kg-1 per gavage); 
Group 3, tachykinin NK1R antagonist RP67580 (10 μg i.c.v.); Group 4, 
glutamate NMDA receptor antagonist DL-AP5 (10 μg i.c.v.); Group 5, nitric 
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oxide synthase inhibitor L-NNA (10 μg i.c.v.); Group 6, inducible nitric 
oxide synthase inhibitor 1400W (10 μg i.c.v.); Group 7, dopamine D1R 
antagonist SCH23390 (0.2 mg∙kg-1 s.c.); Group 8, dopamine D2R antagonist 
Raclopride (0.16 mg∙kg-1 s.c.). These treatments were given 30 min prior to 
Sar[DPhe8][des-Arg9]BK (1 μg) or 3 h earlier (B1R antagonist i.c.v. and 
gavage). The behavioural responses induced by Sar[DPhe8][des-Arg9]BK (1 
μg) were compared in the absence (2h prior to treatments) and presence of 
antagonists or inhibitors. 
 
Determination of brain B1R mRNA levels by SYBR green-based quantitative RT-
PCR 
SHR, Ang II-treated and age-matched sham-operated rats not implanted 
with an i.c.v. cannula were decapitated after anesthesia under CO2 
inhalation. Brains were removed from the skull and rinsed in saline to 
remove any surface blood and placed in a glass plate. With the use of a 
surgical microscope, the hypothalamus, VTA and nucleus accumbens were 
micro-dissected as described by Palkovits et al., (1998). About 10 mg of 
tissue were put in RNAlater stabilization reagent (QIAGEN, Valencia, CA, 
USA). RNA extraction and real-time PCR were performed as described 
elsewhere (Talbot et al., 2009). For standardization and quantification, rat 
18S was amplified simultaneously. The real-time PCR primer pairs used in 
this study were designed by Vector NTI software and presented in Table 1.  
 
Drugs and solutions 
The aCSF was purchased from Harvard Bioscience (Massachusetts, U.S.A.). 
Sar[DPhe8][des-Arg9]BK was synthesised at the Research Institute of 
Biotechnology, National Research Council of Canada and dissolved in 
aCSF. The B1R antagonist SSR240612 [(2R)-2-[((3R)-3-(1,3-benzodioxol-5-
yl)-3-[[(6-methoxy-2-naphthyl)sulfonyl]amino]propanoyl)amino]-3-(4-
[[2R,6S)-2,6- dimethylpiperidinyl]methyl]phenyl)-N-isopropyl-N-
methylpropanamide hydrochloride] (Gougat et al., 2004) was kindly 
provided by Dr. Pierre Carayon from Sanofi-Aventis R&D (Montpellier, 
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France). It was dissolved in dimethylsulphoxide (DMSO 0.5%), and then 
ethanol (5%) and Tween-80 (5%) were added in this sequence and 
completed with distilled water for gavage (10 mg∙kg-1 in a volume of 1 ml 
by 100 g of body weight) (Dias et al., 2007). SSR240612 was dissolved in 
DMSO (0.5%) and ethanol (5%) in this sequence and completed with aCSF 
for i.c.v. administration. Tachykinin NK1R antagonist, RP67580 [Imiro-1 
(methoxy-2 phenyl)-2ethyl]-2 diphenyl-7.7 perhydroisoindolone-4-(3aR, 
7aR) (Garret et al., 1991) was purchased from Tocris Bioscience (Ellisville, 
MO, USA). Ang II, NOS inhibitor L-NNA (Nω-Nitro-L-arginine) (Furfine et 
al., 1993), iNOS inhibitor 1400W (Babu and Griffith, 1998), NMDA receptor 
antagonist DL-AP5 (DL-2-Amino-5-phosphonopentanoic acid) (Kent et al., 
1996), dopamine D2R antagonist raclopride and dopamine D1R antagonist 
SCH23390 (Millan et al., 1998) were purchased from Sigma-Aldrich Canada 
Ltd (Oakville, ON, Canada). Raclopride and SCH23390 were dissolved in 
DMSO and completed in saline (final solution contains 3% DMSO). All the 
other reagents were dissolved in aCSF. Drug and receptors nomenclature 
were cited conforms to BJP's Guide to Receptors and Channels (Alexander 
et al., 2008).  
Statistical analysis of data 
Results are expressed as the means ± s.e. mean of values obtained from (n) 
rats. Statistical analysis of data was performed with Graph-Pad Prism 
software. B1R mRNA levels were analyzed for statistical significance with 
Student’s t-test for unpaired samples. Data of behaviors were analyzed 
with the non-parametric Kruskal-Wallis test (Figure 2) or the non-
parametric Wilcoxon-Mann-Whitney test (Figures 3-4). Only probability 
values (P) less than 0.05 were considered to be statistically significant. 
 
Results 
Brain B1R mRNA levels in SHR and Ang II-treated rats 
Using quantitative real-time PCR, the overexpression of B1R was confirmed 
in the brain of SHR and Ang II-treated rats (Fig. 1). B1R mRNA levels were 
markedly increased in the hypothalamus, VTA and nucleus accumbens 
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isolated from both rat models of hypertension in comparison with age-
matched WKY. The upregulation of B1R in SHR was greater in intensity in 
the hypothalamus and VTA while in Ang II-treated rats the expression was 
greater in the VTA and nucleus accumbens. 
 
Behavioural effects induced by kinin B1R agonist in SHR and Ang II-treated rats 
The first series of experiments showed that 1 and 10 μg Sar[DPhe8][des-
Arg9]BK injected i.c.v. in SHR and Ang II-treated rats caused several 
behavioural manifestations while the same treatments in WKY had no 
significant effect when compared to aCSF (data not shown). In Fig. 2 the 
B1R agonist have been injected into the i.c.v. in control WKY rats, which 
caused no behavioural activity when compared with B1R injected into the 
i.c.v. in SHR. Doses of 1 μg and 10 μg Sar[DPhe8][des-Arg9]BK caused 
comparable effects and therefore the dose of 1 μg was selected for the 
remainder of the study. In SHR, 1 μg (i.c.v.) of the B1R agonist caused 
significant increases of behavioural activity when compared to aCSF (face 
washing > sniffing = head scratching = rearing = teeth chattering >> 
grooming = digging > licking = wet dog shake) (Fig. 3a and c). In Ang II-
treated rats, Sar[DPhe8][des-Arg9]BK (1 μg) injected i.c.v. also enhanced 
significantly behavioural activity but with a somewhat different pattern 
(sniffing ≥ teeth chattering > head scratching = grooming = rearing ≥ face 
washing > digging = licking = wet dog shake) (Fig. 3b and d).  
 
Blockade of behavioural effects induced by kinin B1R agonist in SHR 
In SHR, the behavioural responses induced by 1 μg Sar[DPhe8][des-
Arg9]BK were significantly blocked by the B1R antagonist SSR240612 
administered either i.c.v. (10 μg) or by gavage (10 mg∙kg-1) 3 h earlier (Fig. 
3a and c). Teeth chattering and wet dog shake were reduced only when the 
B1R antagonist was given i.c.v., suggesting that systemic SSR240612 
reached less efficiently the brain area involved in these behaviors. 
Moreover, most stereotypic behaviors induced by 1 μg Sar[DPhe8][des-
Arg9]BK in SHR were significantly blocked by the prior i.c.v. injection (10 
197 
 
 
μg, 30 min earlier) of the tachykinin NK1R antagonist RP67580 (Fig. 4a), the 
glutamate NMDA receptor antagonist DL-AP5 (Fig. 4b), the NOS inhibitor 
L-NNA (Fig. 4c), the dopamine D1R antagonist SCH23390 (Fig. 4e) and the 
dopamine D2R antagonist Raclopride (Fig. 3f). Conversely, pre-treatment 
with the iNOS inhibitor 1400W (10 μg i.c.v. 30 min earlier) had a small 
inhibitory effect on most behaviors while digging and wet dog shake were 
not significantly affected (Fig. 3d). Whereas the level of inhibition achieved 
with 1400W was much less than that seen with the other treatments, face 
washing was almost abolished. When the B1R agonist was re-injected alone 
24h later, the behavioural manifestations were back to responses elicited in 
the absence of antagonists or inhibitors (data not shown). None of the 
antagonists or inhibitors caused behavioural changes per their own (data 
not shown). 
Blockade of behavioural effects induced by kinin B1R agonist in AngII-treated rats 
In Ang II-treated rats, all behavioural manifestations evoked by 1 μg 
Sar[DPhe8][des-Arg9]BK were significantly blocked by SSR240612 
administered either i.c.v. (Fig. 3b) or by gavage (Fig. 3d), 3 h earlier. 
Similarly to SHR, SSR240612 was more effective in inhibiting teeth 
chattering when injected i.c.v. As shown in Figure 5, behavioural activities 
elicited by Sar[DPhe8][des-Arg9]BK were significantly blocked by the 
tachykinin NK1R antagonist RP67580, the glutamate NMDA receptor 
antagonist DL-AP5, the NOS inhibitor L-NNA, the dopamine D1 and D2 
receptors antagonists SCH23390 and Raclopride. Similarly to SHR, 
behavioural responses to the B1R agonist were less reduced by the iNOS 
inhibitor 1400W (Fig. 4d). Behavioural activities caused by Sar[DPhe8][des-
Arg9]BK were completely recovered 24h later and all antagonists and 
inhibitors tested had no direct effect on behavior in Ang II-treated rats 
(data not shown).  
 
Discussion   
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The present study provides the first pharmacological evidence that central 
kinin B1R stimulation can enhance behavioural and locomotor activity 
through a mechanism involving SP, DA, glutamate and NO. This was 
shown in SHR and Ang II-treated rats, two rat models of hypertension that 
overexpressed B1R in the hypothalamus, VTA and nucleus accumbens. In 
contrast, the B1R is weakly expressed and physiologically inert in control 
WKY. These findings and particularly those obtained with SP and DA 
antagonists suggest that the mesolimbic dopaminergic system could be a 
strategic site for the behavioural manifestations induced by the B1R 
agonist.  
It is known that i.c.v. injection of SP increases locomotor activity, 
awareness, face washing, sniffing and grooming that are typical behaviors 
observed during the defence reaction (Tschöpe et al., 1992; Unger et al., 
1988). They are also similar to behavioural arousal reaction induced by 
endogenous release of SP in the response to morphine withdrawal 
(Michaud and Couture, 2003) and physiological stress (Culman et al., 1997). 
The centrally mediated behavioural effects of SP were blocked by the NK1R 
antagonist RP67580 (Cellier et al., 1999; Culman et al., 1995; Picard et al., 
1994).  
The implication of SP and NO in B1R-induced behavioural manifestations 
is reminiscent of B1R-induced thermal hyperalgesia which was associated 
with the release of sensory SP and the subsequent production of NO 
following NK1R activation in the spinal dorsal horn of type 1 diabetic rats 
(Couture et al., 2001). The activation of NK1R in the rat spinal cord with 
endogenous and exogenous SP also evoked hyperalgesia in the tail-flick 
test through glutamate release and the subsequent activation of the NMDA 
receptor and NO production (Radhakrishnan et al., 1995; Sun et al., 2003; 
Yashpal et al., 1991). Pharmacological blockade of NOS prevented the 
responses to NMDA, SP and noxious cutaneous stimuli in cat dorsal horn 
(Radhakrishnan et al., 1993).  
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Hence, one can suggest that a similar event occurs in the brain of SHR and 
Ang II-treated rats where the release of SP following B1R activation triggers 
the release of glutamate and the activation of NMDA receptor. In this 
scenario, NO would be located downstream to mediate the final effect of 
the B1R agonist on behavior. Data suggest that iNOS is not the primary 
source of NO for most behaviours elicited by the B1R agonist. 
In vitro studies have raised the possibility that cerebrovascular NO systems 
were altered in hypertensive rats (Miyata et al., 1990; Malinski et al., 1993). 
Moreover, perturbations in endothelium-dependent relaxation have been 
identified in pial arteries, which were examined in situ studies (Yang et al., 
1991; Mayhan, 1992). In contrast, in vivo studies showed that the 
cerebrovascular sensitivity to NO inhibition was conserved (Izuta et al., 
1995). Furthermore, basal local cerebral blood flow appears to be 
unaffected by hypertension (Wei et al., 1992). Moreover, i.c.v. injections of 
high doses of NG-monomethyl-L-arginine (L-NMMA), a non selective 
NOS inhibitor, which can block eNOS, caused marked insulin resistance, 
hyperglycemia, defective insulin secretion, and hypertension (Skankar et 
al., 1998). However, acute systemic induction of hypertension with L-
NMMA may cause increased insulin resistance (Baron et al., 1995). NO 
derived from eNOS located in endothelial cells of the brain may diffuse to 
nearby neurons and influence their activity. This notion is supported by 
data demonstrating the importance of NO derived from eNOS in the 
control of inhibitory neurotransmitter release in mouse cerebral cortex 
(Kano et al., 1998). 
Studies in aggressive behavior were analyzed using knockout mice, which 
are extremely aggressive, because of the disruption of the gene of nNOS. 
The results showed that nNOS is a major mediator of the aggressive 
behavior. The administration of nNOS inhibitor in wild-type mice 
increased the aggression behavior, suggesting that nNOS activators may 
have therapeutic roles in inflammatory, cardiovascular, and neurologic 
diseases (Demas et al., 1997). However, the mechanism for the regulation of 
behavior by NOS in the brain is still unknown. 
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Behavioural activity induced by SP was also related to midbrain DA 
release (Stoessl et al., 1991) which may suggest that the release of SP 
following B1R activation can affect DA neurotransmission and account for 
the inhibitory effect of D1R and D2R antagonists on centrally mediated 
behavioural effects of B1R agonist. This is keeping with the involvement of 
DA in the anti-hypertensive effect of B1R antagonist in SHR and Ang II-
treated rats (De Brito Gariépy et al., 2010) and with the increased central 
dopaminergic activity reported in SHR (van den Buuse, 1991; Amenta et al., 
2001). Thus the activation of DA neurons through B1R can be direct or 
indirect through the release of other central mediators such as SP. This is 
feasible because SP immunoreactive axon terminals make direct synaptic 
contact with DA neurons in the VTA (Tamiya et al., 1990) on which NK1R 
was localized by electron microscopy (Lessard et al., 2009). Furthermore, 
the application of SP and NK1R agonists into the VTA increased firing rate 
of A10 dopamine cells, the levels of DA and its metabolite 
dihydroxyphenylacetic acid (DOPAC) and DA turnover in the prefrontal 
cortex and nucleus accumbens (Cador et al., 1989; Elliott et al., 1986; 
Overton et al., 1992). This was accompanied by increased behavioural 
activity consistent with mesolimbic DA activation (Deschamps and 
Couture, 2005; Eison et al., 1982; Elliott et al., 1986). 
Since the mesolimbic dopaminergic pathway and SP are both involved in 
the defence reaction to physiological stress and peripheral noxious 
stimulation (Culman et al., 2010; Culman et al., 1997; Le Moal and Simon, 
1991; van den Buuse, 1998), it is tempting to suggest that kinin B1R may 
exert a central regulatory function in the coordination of nocifensive 
behavior and locomotor activity in response to stress and noxious 
stimulation. Although this hypothesis remains to be proven, it would be in 
line with the pro-nociceptive effect of B1R in the periphery (Calixto et al., 
2004: Couture et al., 2001). 
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Conclusion  
The cerebral injection of a kinin B1R agonist induces stereotyped behaviors 
and locomotor activity in SHR and Ang II-treated rats, two models of 
hypertension associated with a marked induction of B1R in the 
hypothalamus, VTA and nucleus accumbens. The B1R-induced behavioural 
responses are mediated by several central mediators, notably SP (NK1 
receptor), dopamine (D1 and D2 receptors), glutamate (NMDA receptor) 
and nitric oxide. Hence, cerebral activation of B1R reproduced the 
nocifensive defence reaction induced by these mediators in the mesolimbic 
system. 
 
Conflict of interested 
The authors have declared that no competing interests exist. 
 
Acknowledgements 
This work was supported by a Grant-in-aid from the Canadian Institutes of 
Health Research (CIHR) (MOP-79471). H. De Brito Gariépy held a 
Studentship from the National Council of Technological and Scientific 
Development (CNPq) (proc. 201428/2003-2) Brazil. S. Talbot holds a 
Frederick Banting and Charles Best Canada Graduate Scholarships-
Doctoral Award from CIHR. Authors are thankful to Mr Julien Saint-Denis 
for his technical assistance in qRT-PCR. 
 
Table 1: PCR primer pairs used in this study 
 
18S  forward 5' 3' 363 - 386
18S  reverse 5' 3' 470 - 447
B1 receptor forward 5' 3' 367 - 391
B1 receptor reverse 5' 3' 478 - 454
Sequences Position Gen Bank
GCA GCG CTT AAC CAT AGC GGA AAT
NM_030851
CCA GTT GAA ACG GTT CCC GAT GTT
TCA ACT TTC GAT GGT AGT CGC CGT
X01117
TCC TTG GAT GTG GTA GCC GTT TCT
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Figure legends 
Figure 1. B1R gene expression in hypothalamus, ventral tegmental area 
(VTA) and nucleus accumbens of SHR and Ang II-treated rats. B1R mRNA 
levels were measured relative to 18S level. Data represent the mean ± 
s.e.mean of values obtained in groups of 4 rats. Statistical comparison to 
control WKY is indicated by * P < 0.05; ** P < 0.01 or ***P < 0.01.  
 
Figure 2.  Behavioural responses to 1 μg Sar[DPhe8][des-Arg9]BK injected 
i.c.v. in SHR and WKY. Each bar represents the mean ± s.e.mean of values 
obtained in 4 rats per group. Comparison to WKY is indicated by ***P < 
0.001. 
 
Figure 3. Inhibition of the behavioural responses to 1 μg Sar[DPhe8][des-
Arg9]BK injected i.c.v. in SHR (a, c) and Ang II-treated rats (b, d) before 
and 3h after treatment with the kinin B1R antagonist SSR240612 
administered either i.c.v. (10 μg) or by gavage (10 mg∙kg−1). Each bar 
represents the mean ± s.e.mean of values obtained in 4 groups of 6 rats. 
Comparison to aCSF (*) and to the B1R agonist (†) is indicated by *† P < 
0.05; **†† P < 0.01; ***P < 0.001. 
 
Figure 4. Inhibition of the behavioural responses to 1 μg Sar[DPhe8][des-
Arg9]BK injected i.c.v. in SHR before and 30 min after treatment with the 
tachykinin NK1R antagonist RP 67580 (a), the NMDA receptor antagonist 
DL-AP5 (b), the NOS inhibitor L-NNA (c), the iNOS inhibitor 1400W (d), 
the dopamine D1R antagonist SCH23390 (e), the dopamine D2R antagonist 
Raclopride (f). Each bar represents the mean ± s.e.mean of values obtained 
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in 6 groups of 6 rats. Comparison to the B1R agonist before treatment is 
indicated by *P < 0.05, **P < 0.01. 
 
Figure 5. Inhibition of the behavioural responses to 1 μg Sar[DPhe8][des-
Arg9]BK injected i.c.v. in Ang II-treated rats before and 30 min after 
treatment with the tachykinin NK1R antagonist RP 67580 (a), the NMDA 
receptor antagonist DL-AP5 (b), the NOS inhibitor L-NNA (c), the iNOS 
inhibitor 1400W (d), the dopamine D1R antagonist SCH23390 (e), the 
dopamine D2R antagonist Raclopride (f). Each bar represents the mean ± 
s.e.mean of values obtained in 6 groups of 6 rats. Comparison to the B1R 
agonist before treatment is indicated by *P < 0.05, **P < 0.01. 
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13. General Discussion 
13.1 Central tachykinin NK-3R in hypertension 
The first study described in the Chapter I was a continuation of a previous 
study from our laboratory showing that tachykinin NK-3R antagonists 
exert dose-dependent and reversible anti-hypertensive effects when 
injected i.c.v. in SHR (Lessard et al., 2004). The objective of this thesis was 
to further define the site of action and the mechanism responsible for this 
central anti-hypertensive effect in SHR and to determine whether the 
blockade of kinin B1R can reproduce this effect based on the finding that 
this receptor is induced and overexpressed in the CNS of hypertensive rats. 
The dopaminergic pathway in the VTA was studied as a putative target for 
tachykinin NK-3R and kinin B1R antagonists based on the previous review 
of the literature. 
The thesis shows firstly the effect of the tachykinin NK-3R agonist senktide 
when injected either i.c.v. or directly into the VTA in SHR (Figure 12). 
Previous studies have documented the effects of i.c.v. and VTA injected 
senktide in normotensive control rats (Cellier et al., 1997; Deschamps and 
Couture, 2005). In SHR, senktide caused maximal increases of BP and HR 
at the dose of 25 pmol when injected into the VTA as reported previously 
in Wistar rats (Deschamps and Couture, 2005), while the maximal effect of 
senktide injected i.c.v. was achieved at the dose of 65 pmol in SHR and at 1 
nmol in Wistar rats (Cellier et al., 1997). Senktide-induced increases of BP 
and HR were also observed in guinea-pig (Roccon et al., 1996). 
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Figure 12. Schematic representation showing tachykinin NK-3R 
agonist/antagonists injected i.c.v. (A) and VTA (B) in rats. 
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The cardiovascular response to central injection of senktide in SHR is likely 
mediated by DA release, since it was abolished after treatment with 
SCH23390 and haloperidol. The lack of effect of raclopride suggests the 
involvement of DA-D1R rather than DA-D2R, as reported previously in 
normotensive rats (Deschamps and Couture, 2005). Blocking the NK-3R led 
to a reduction of dopamine activity on DA-D2R (Spooren et al., 2005), 
which is consistent with the prevention of the anti-hypertensive effects of 
tachykinin NK-3R antagonists (i.c.v. and VTA) by raclopride, the DA-D2R 
antagonist. 
Studies by in situ hybridization showed significant higher levels of DA-
D2R mRNA in the caudate-putamen, nucleus accumbens, olfactory 
tubercle, and SN of SHR in comparison with control WKY rats (Vaughan et 
al., 1999). The increased levels of DA-D2R gene expression displayed in 
SHR suggest an enhanced central dopaminergic activity in the 
pathogenesis of hypertension, which might also be partly due to increased 
tonic activation of the NK-3R making input on this system.   
The anti-hypertensive effects of NK-3R antagonists (SB222200 and R-820) 
injected directly into the VTA were faster in onset than by i.c.v. injection, 
which is consistent with a site of action in this brain area. 
The cardiovascular response caused by senktide in the VTA of SHR was 
blocked by the prior i.c.v. injection of the NK-3R antagonist R-820, 
suggesting that i.c.v. injected NK-3R antagonist diffuse to the VTA. 
Reciprocally, the cardiovascular effect of i.c.v. senktide was prevented by 
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blockade of NK-3R in the VTA. Moreover, the anti-hypertensive effect of 
SB222200 injected into the VTA was blocked after i.c.v injection of senktide. 
Finally, chemical lesion of VTA with ibotenic acid inhibited the 
cardiovascular effects caused by senktide and R-820 injected i.c.v. 
Consequently, these findings suggest that the VTA and its brain DA 
projections are of primary importance in the cardiovascular effects 
associated with i.c.v. injection of NK-3R agonist and antagonist. 
When the NK-3R antagonists (R-820 and SB2222200) were injected into the 
VTA of SHR, a tachycardia was observed. The same dose of antagonists 
(500 pmol) caused a small bradycardia when injected i.c.v., coinciding with 
the peak of the anti-hypertensive effect. Hence, the inhibition of NK-3R in 
the VTA did not interfere with the activation of baroreceptors contrary to 
i.c.v. injection of NK-3R antagonists. This also suggests that the mechanism 
of anti-hypertension associated with NK-3R antagonists in the VTA was 
unlikely due to the inhibition of the cardiac output. 
I.c.v. injections of R-820 in SHR for five consecutive days caused a 
significant decrease in BP accompanied by bradycardia, suggesting that the 
NK-3R is under constant and chronic tonic activation in SHR. Since the 
anti-hypertensive effect of NK-3R antagonists was prevented by raclopride, 
it is concluded that this effect is mainly mediated by DA-D2R. This is 
consistent with the existence of endogenous tachykinins in the VTA 
(Kalivas et al., 1985; Warden and Young, 1988; Tamiya et al., 1990; Lu et al., 
1998) and the NK-3R on dopaminergic neurons in the VTA (Chen et al., 
1998; Lessard et al., 2007) (Figure 13).  
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Figure 13. Schematic representation of the NK-3R agonist and 
antagonists in the CNS. In A, upper panel shows that NKB is released 
and caused high occupancy of NK-3R. DA neurons are excited by NKB, 
resulting in an increase of DA release in the nucleus accumbens and a 
high level of DA-D2R occupancy post-synaptically. In B, lower panel 
illustrates the inhibition of NKB effect by NK-3R antagonist. As 
consequence, the DA neurons are less excited and the release of DA in 
the nucleus accumbens is strikingly decreased. Adapted from Spooren et al., 
2005. 
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13.2 Central kinin B1 receptors in hypertension and behavioural activity  
The second objective of this thesis was to assess, for the first time, the 
relative contribution of central B1R in hypertension. The first animal model 
used was SHR and the second was the rat treated with chronic infusion of 
Ang II for two weeks, which corresponds to an appropriate experimental 
model of arterial hypertension associated with increased vascular oxidative 
stress (Laplante et al., 2003). The B1R antagonist SSR240612 injected i.c.v. 
produced a significant anti-hypertensive effect in both animal models of 
hypertension. SSR240612 is expected to spread within the brain through 
the CSF pathways (Figure 14). In contrast, systemic treatments with R-954 
and R-715 caused a small decrease in blood pressure. These later two 
peptide antagonists do not penetrate into the CNS. SSR240612 crosses the 
blood-brain barrier and its anti-hypertensive effect produced by systemic 
or i.c.v. administration was prevented by the DA-D2R antagonists 
raclopride and haloperidol. Thus, our data suggest that B1R might 
contribute to the over-activity of the DA system reported in SHR (van den 
Buuse, 1997). Our results are supported by the increased density of B1R 
binding sites in the CNS, including the spinal cord (Petcu et al., 2005) and 
several brain regions (SN, septum, posterodorsal tegmental nucleus and 
temporal cortex) in Ang II-hypertensive rats (De Brito Pereira et al., 2008). 
In SHR, autoradiography studies also showed high densities of B1R 
binding sites in cortical areas, thalamic regions, amygdala and 
hippocampus, and in some pressor-related hypothalamic areas, such as the 
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dorsal hypothalamic area and ventromedial hypothalamic nucleus (de 
Wardener, 2001; Cloutier et al., 2004).   
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Figure 14. Schematic representation showing the CSF circulation 
of kinin B1R agonist and antagonists injected i.c.v. in rats. 
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The inhibition of the oxidative stress with a diet supplemented with alpha-
lipoic acid reversed the upregulation of B1R, arterial hypertension and the 
increased production of vascular superoxide anion, suggesting that B1R is 
induced by the oxidative stress and contributes to hypertension in the 
model of Ang II-treated rats (Petcu et al., 2005). 
The third objective of this thesis was to assess the contribution of central 
B1R on behavioural activity. This was to provide further evidence that the 
increased expression of B1R binding sites in the brain of hypertensive rats 
corresponds to functional receptors. The objective was not to link 
hypertension to behavioural activity but to use this paradigm as model of 
functional B1R activity in the brain. The stimulation of B1R by the agonist 
Sar[DPhe8][des-Arg9]BK injected i.c.v. in SHR and Ang II-treated rats 
enhanced behavioural and locomotor activity through a mechanism 
involving SP, DA, glutamate and NO. Both hypertensive rat models 
showed an over-expression of B1R mRNA in the hypothalamus, VTA and 
nucleus accumbens. However, in control WKY rats, B1R was weakly 
expressed in the same brain areas and its stimulation did not cause any 
behavioural effects. These results as well as those obtained with SP and DA 
antagonists suggest that the mesolimbic dopaminergic system could be a 
strategic site for the behavioural manifestations induced by the B1R 
agonist.  
Amongst the originalities of this thesis are the demonstration that: 1- 
similarities occur between NK-3R and B1R in CNS function; and 2- the 
blockade of either receptor decreases high blood pressure by a central 
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dopaminergic mechanism. However, future experiments are needed to 
determine whether the B1R are located on dopamine neurons as already 
documented for NK-3R (Deschamps and Couture, 2005; Spooren et al., 
2005; Lessard et al., 2007; De Brito Gariepy et al., 2010).  
B1R are over-expressed in pathological conditions such as diabetes and 
hypertension (Petcu et al., 2005; Lungu et al., 2007; Dias et al., 2007; present 
study). It is still unknown, however, whether or not kininase I activity is 
enhanced. This carboxypeptidase is involved in the formation of des-Arg9-
BK, the preferred B1R agonist. Studies are therefore needed to measure the 
activity and the expression of kininase I in the brain of SHR and Ang II-
treated rats. Likewise, studies are needed to determine whether BK and its 
active metabolite des-Arg9-BK are increased in specific brain areas of 
hypertensive rats. This could help our understanding of the anti-
hypertensive effect of B1R antagonists. This has to be keeping with the 
possibility that des-Arg9-BK can also upregulate its own B1R (Schanstra et 
al., 1998). In parallel studies, the endogenous levels of SP and other 
tachykinins (NKB as a preferred agonist of NK-3R) deserve to be measured 
to confirm their involvement in hypertension.  
Our results on B1R-induced behavioural manifestation highlight the 
involvement of SP and NO. This is similar to B1R-induced thermal 
hyperalgesia, which depends on the release of sensory SP and the 
subsequent production of NO following NK-1R activation in the spinal 
dorsal horn of type 1 diabetic rats (Couture et al., 2001). One can suggest, 
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however, that NO is also directly produced after direct activation of B1R 
through the inducible NO synthase (Ignjatovic et al., 2004; Zhang et al., 
2007; Kuhr et al., 2010). The behavioural responses to the B1R agonist were, 
however, little affected by 1400W, the specific inhibitor of iNOS, suggesting 
that B1R is not operating primarily via the iNOS pathway.  
Interestingly, the profile of NO output generated by B2R-mediated 
activation of eNOS and B1R-mediated activation of iNOS is extremely 
different in human lung microvascular endothelial cells (Kuhr et al., 2010). 
Thus, while B2R activation results in a peak output of NO that lasts for 
about 5 min, B1R-mediated iNOS activation results in a much more 
profound and prolonged response, lasting almost 90 min. The specific B1R 
antagonist, des-Arg10-Leu9-KD, inhibited this response as did the iNOS 
specific inhibitor 1400W but L-NNA, the eNOS inhibitor, had no effect 
(Ignjatovic et al., 2004). 
 
According to Zhang et al. (2007) iNOS could be acutely activated in a 
receptor-dependent process. iNOS activity is not regulated by a change in 
intracellular Ca2+ and the phosphorylation sites on eNOS are not conserved 
in iNOS nor do kinases activating eNOS phosphorylation could activate 
iNOS (Fulton et al., 1999; Zhang et al., 2007). Further investigation revealed 
that B1R and iNOS-mediated NO output is dependent on MAPK 
activation, which results in phosphorylation of iNOS at Ser745 (Zhang et al., 
2007).  
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The neuronal NOS (nNOS) produce NO in the central and peripheral 
nervous system. nNOS also plays a role in cell communication and is 
associated with plasma membrane. Although, nNOS and eNOS have 
similar characteristics (Regoli, 2004), the relative contribution of nNOS in 
behavioural activity induced by brain B1R activation is still unknown. 
Further studies using specific nNOS inhibitor is compelling to address this 
issue. 
The i.c.v. activation of NK-1R with SP caused characteristic behaviours 
similar to the defense reaction (Unger et al., 1988; Tschöpe et al., 1992). 
Those behaviours mimic the behavioural reaction induced by endogenous 
release of SP in response to morphine withdrawal (Michaud and Couture, 
2003) and physiological stress (Culman et al., 1997). Moreover, central SP 
produced behavioural activities which were blocked by the NK-1R 
antagonist RP67580 (Picard et al., 1994; Culman et al., 1995; Cellier et al., 
1999). The behavioural activity induced by SP was associated with 
midbrain DA release (Stoessl et al., 1991) which suggests that the release of 
SP following B1R activation may involve DA neurotransmission and 
account for the inhibitory effect of D1R and D2R antagonists on centrally 
mediated behavioural effects of B1R agonist. This is consistent with the 
participation of DA in the anti-hypertensive effect of B1R antagonist in 
SHR and Ang II-treated rats (De Brito Gariepy et al., 2010) and with the 
increased central DA activity described in SHR (Amenta et al., 2001). 
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Our study focused on the role of the inducible B1R in CNS autonomic and 
behavioural functions in hypertensive rats. The putative role of brain B2R 
was not further investigated because it was reported that two-week i.c.v. 
infusion of B2R antagonist (HOE 140) did not alter systolic BP in 
comparison to vehicle in SHR (Maddedu et al., 1994). This supports the 
hypothesis that brain kinin B2R are unlikely involved in the central 
regulation of blood pressure and hypertension. Nevertheless, B2R may 
participate in the modulation of baroreceptor reflex sensitivity in SHR 
(Madeddu et al., 1994). 
High concentration of BK in the presence of Ang I-converting enzyme 
inhibitors (ACEI) and Ang AT2 receptor stimulation (under angiotensin 
AT1 receptor blockade) provides cardioprotective and nephroprotective 
effects. Selective kinin B2R agonists also show potential as therapeutic 
agents in the treatment of several cardiovascular disorders and diabetes 
mellitus. Ang AT2 receptor activation and Ang (1–7) facilitate the release of 
BK and NO (via eNOS) in the periphery. Hence, BK in the periphery has a 
beneficial function by causing vasodilatation, anti-proliferative and anti-
fibrotic effects (for review, see Couture and Girolami, 2004). 
13.3 Other drugs with central effects 
CNS stimulation of α-adrenoceptors leads to bradycardia and a fall in 
systemic arterial blood pressure. Decrease of blood pressure was induced 
by i.c.v. administration of L-DOPA in dogs (McCubbin et al., 1960) and 
with methyldopa in cats and rats (Henning and Van Zwieten, 1968; Day et 
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al., 1972; 1973). In 1972, Heise and Kroneberg showed that the decrease in 
blood pressure produced by peripheral injection of methyldopa in 
anaesthetized cats could be prevented by prior treatment with α-
adrenoceptor blocking agents. Likewise, the anti-hypertensive effects of 
clonidine may also be mediated via central α-adrenoceptor stimulation 
since its action in anesthetized dogs and cats is also inhibited by α-
adrenoceptor antagonists (Schmitt and Fenard, 1971). Clonidine has been 
shown to decrease vasopressin secretion when administered either i.v. or 
i.c.v. (Reid et al., 1979; Kimura et al., 1981). Inhibition of noradrenaline 
release following the activation of α-adrenoceptors on noradrenergic 
sympathetic terminals may also contribute to the anti-hypertensive effect of 
clonidine (Reid, 1986). 
Contrarily to the results with NK-3R and B1R antagonists, CNS stimulation 
of α-adrenoceptors with clonidine and other agents did not seem to recruit 
the dopaminergic system. To the best of our knowledge, we do not know 
any drugs with anti-hypertensive properties which are acting on central 
dopamine. Most of centrally acting drugs were found to interfere with 
noradrenergic activity.  Clonidine decreases blood pressure by reducing 
cardiac output and peripheral vascular resistance in addition to causing 
unwanted depression of the respiratory system (Shen, 2008; Kaczynska and 
Szereda-Przestaszewska, 2006). This latter side effect of clonidine and those 
previously described in the Introduction are the mean reasons why these 
drugs were abandoned in the treatment of hypertension. Currently, the 
anti-hypertensive therapy relies on drugs (calcium antagonists, ACEI, AT1 
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antagonists, beta and alpha blockers, diuretic) acting chiefly in the 
periphery (vasculature, kidneys, sympathetic nervous system).  
Although the pharmaceutical industry wants to stay away from the CNS in 
the development of new medication for the treatment of cardiovascular 
diseases, a better understanding of the mechanism involved in the use of 
kinin and tachykinin receptor antagonists (NK-3R and B1R) is compelling 
since these drugs offer great potential for the treatment of psychiatric 
diseases (schizophrenia and anxiety for NK-3R) and central neuronal 
diseases (epilepsy, Alzheimer and pain for B1R).  
 
14. Perspectives 
The neuropharmacological studies on B1R suggest that this kinin receptor 
interacts either directly or indirectly with the mesocorticolimbic DA 
system. Further experiments are needed to confirm the presence of B1R on 
DA, SP or glutamatergic fibers. This can be addressed by 
immunocytochemistry using confocal or electron microscopy on the brain 
of SHR and Ang II-treated rats. Moreover, the anti-hypertensive effect of 
NK-3R and B1R antagonists are alike, showing a possible cross-talk 
involving the DA system as the downstream mechanism. Two questions 
should be addressed: (i) does NK-3R antagonist block the anti-hypertensive 
effect of B1R antagonist? (ii) does B1R antagonist block the anti-
hypertensive effect of NK-3R antagonist? To answer these questions, NK-
3R antagonists (R-820 and SB222200) and B1R antagonist (SSR240612) have 
to be co-administrated i.c.v. in SHR and Ang II-treated rats. If both 
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receptors interact, no changes in high blood pressure should occur (loss of 
the anti-hypertensive response). At this time, no evidence suggests a 
putative interaction at the level of the receptor. It is more likely that NK-3R 
and B1R increase DA neurotransmission by a redundant or a synergistic 
mechanism located either on terminals, cells bodies or dendrites of DA 
neurons. 
Several studies have shown in SHR behavioural manifestations 
(hyperactivity, impulsiveness, poorly sustained attention) similar to the 
behavioural disturbances occurring in children with attention deficit 
hyperactivity disorder (ADHD) (for review, see Russell et al., 2005). In 
SHR, hyperactivity is observed at three to four weeks of age before they 
enter puberty (De Jong et al., 1995). DOPA decarboxylase activity was 
found to be enhanced in the midbrain of children and reduced in the 
prefrontal cortex of adults with ADHD in comparison to controls (Ernst et 
al., 1998). SHR is also a model exhibiting alterations in the central DA 
system (Russell et al., 2005). Although the exact mechanism by which 
altered brain DA affects ADHD is still unknown, SHR may represent a 
suitable model for studying ADHD. This may or may not relate to B1R, 
NK-3R or both receptors function. This possibility, however, is supported 
by my observation that tachykinin NK-3R antagonist injected i.c.v. caused 
a sedative-type response in SHR and the same treatment with kinin B1R 
antagonist, SSR240612, decreased the hyper-locomotor activity. Thus, the 
anxiolytic, anti-depressor or both effects of these drugs deserve to be 
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examined. The putative role of B1R in anxiety warrants further 
investigation. 
As the VTA is believed to be the site of action of tachykinin NK-3R agonist 
and antagonist, it would be interesting to investigate the VTA as a putative 
target for i.c.v. B1R agonists and antagonists. This should also further our 
understanding of the similar anti-hypertensive effects observed with B1R 
and NK-3R antagonists. 
The next challenge will be to study the induction of B1R linked to the 
oxidative stress in hypertension. The oxidative stress and the amount of the 
two pro-oxidative peptides (Ang II and endothelin-1 (ET-1)) increased in 
hypertension. Also, Ang II and ET-1 enhanced kinin B1R expression in 
vascular smooth muscle cells (VSMC) (Kintsurashvili et al., 2001; Fernandes 
et al., 2006; Morand-Contant et al., 2010). As Ang II increased B1R 
expression through ET-1 release in VSMC, it would be interesting to 
explore the effect of ET-1 receptor blockade on B1R expression and 
function in rat models of hypertension (SHR and Ang II-treated rats). 
In the same experimental rat models of hypertension, we found that kinin 
receptor antagonists (SSR240612, R-715 and R-954) given i.c.v. or in the 
periphery caused a decrease in body temperature for several hours (De 
Brito Pereira et al., 2008) (Figure 15, unpublished results). However, 
SSR240612 was inactive in control WKY. This finding suggests that 
peripheral and central kinin B1R are also involved in the control of core 
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temperature. Experiments are under way to investigate the mechanism of 
action of kinin B1R on body temperature. 
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15. General conclusion 
 
Salient findings of this thesis are: 
I. Our neuropharmacological studies suggest that the tachykinin NK-
3R located in the VTA is submitted to persisting tonic activation 
which increases midbrain DA transmission and thereby contributes 
to hypertension in SHR. The VTA may represent a central 
cardiovascular regulatory site for tachykinin NK-3R in hypertensive 
rat. 
II. Brain kinin B1R contributes through a central dopaminergic 
mechanism (DA-D2R) to the maintenance of arterial hypertension 
in SHR and Ang II-treated rats.  
III. I.c.v. injection of kinin B1R agonist induces stereotypic behaviours 
and locomotor activity in both animal models of hypertension; SHR 
and Ang II-treated rats. This was associated with a marked 
induction of B1R in the hypothalamus, VTA and nucleus 
accumbens. The B1R-induced behavioural responses are mediated 
by several central mediators, particularly SP (NK-1R), DA (D1R and 
D2R), glutamate (NMDA receptor) and nitric oxide. 
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